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“Nothing in the world can take the place of persistence. Talent will not; 
nothing is more common than unsuccessful men with talent. Genius will 
not; unrewarded genius is almost a proverb. Education will not; the world 
is full of educated derelicts. Persistence and determination alone are 
omnipotent. The slogan Press On! has solved and always will solve the 
problems of the human race.”  





Objective: Brugada Syndrome is an autosomal dominant congenital heart disease that 
is responsible for 20% of sudden deaths of patients with structurally normal hearts. 
The majority of mutations involve the cardiac sodium channel gene SCN5A and give 
rise to classical symptoms, which include an abnormal electrocardiogram with 
ST segment elevation and a predisposition to ventricular fibrillation. To date, the 
implantation of a cardioverter defibrillator is the only proven effective treatment of 
the disease. The ability to reprogram dermal fibroblasts to induced pluripotent stem 
(iPS) cells and to differentiate these into cardiomyocytes with the same genetic 
background provides a novel approach to studying inherited cardiac channelopathies 
with advantages over existing model systems. Whilst this technique has enormous 
potential to model inherited channelopathies, such as Brugada Syndrome, the derived 
cells have not been fully characterised and compared to foetal and adult 
cardiomyocytes.  
 
Methods: Dermal fibroblasts from a patient with Brugada syndrome (SCN5A; 
c.1100G>A - pARG367HIS) and an age- and sex-matched control were 
reprogrammed using episomal vectors. All newly derived iPS cell lines were fully 
characterised using immunocytochemistry, flow cytometry, real-time quantitative 
reverse transcription PCR and single nucleotide polymorphism analysis and were 
compared to established human embryonic stem (hES) cell and in-house derived 
healthy control iPS cell lines. The same control cell lines were used to compare the 
efficiencies of several cardiac differentiation media. Spontaneously contracting areas, 
derived from control as well as patient iPS cell lines, were disaggregated and single 
cardiomyocytes were compared to foetal and adult cardiomyocytes isolated from 
primary human tissue using immunocytochemistry, transmission electron 






Results: Comparison of cardiac differentiation protocols using healthy control hES 
and iPS cell lines found that despite significant inter-line variability with regard to 
efficiency of cardiac formation guided differentiation protocols could be used to 
reliably and efficiently generate beating bodies. Spontaneous contraction was 
observed in stem cell-derived cardiomyocytes and human foetal cardiomyocytes. 
Pluripotent stem cell-derived cardiomyocytes stained for markers of the cardiac 
contractile apparatus such as α-actinin, cardiac troponin I and cardiac troponin T. 
They also expressed functional voltage-activated sodium channels and exhibited 
action potential triggered calcium-induced calcium release. Stem cell-derived 
cardiomyocytes showed organisation of myofibrils, ultrastructure and calcium 
handling more similar to foetal than adult cardiomyocytes. Brugada Syndrome 
patient-specific cardiomyocytes were structurally indistinguishable from healthy 
control iPS cell line-derived cardiomyocytes. Electrophysiological analysis of 
sodium current density confirmed a ~50% reduction in patient-derived compared to 
healthy control-derived cardiomyocytes. 
 
Conclusion: Although iPS cells give rise to a mixture of immature and more mature 
cardiomyocytes, they all express typical cardiac proteins and have functional cardiac 
sodium channels. Results illustrate the ability of patient-specific iPS cell technology 
to model the abnormal functional phenotype of an inherited channelopathy that is 
independent of structural abnormalities and that the relative immaturity of iPS 
cell-derived cardiomyocytes does not prevent their use as an accurate model system 
for channelopathies affecting the cardiac sodium channel Nav1.5. This iPS cell based 
model system for classical Brugada Syndrome allows for the first time to study the 
mutation in its native environment and holds promise for further studies to 
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1.1 Brugada Syndrome 
Brugada Syndrome is an autosomal dominant congenital heart disorder that is 
responsible for 20% of sudden deaths of patients with structurally normal hearts1. 
First described by the Brugada brothers in 19922 it is characterised by an abnormal 
electrocardiogram (ECG) with ST segment elevation in the right precordial leads 
V1-V3 (Figure 1) and right bundle-branch block frequently leading to ventricular 
fibrillation (VF) and sudden cardiac death in patients with structurally normal hearts. 
Patients often present with symptoms of ventricular tachycardia (VT), bradycardia, 
and atrial ventricular (AV) node conduction disorder, and more males than females 
present with symptoms of Brugada Syndrome. The most important criterion for 
diagnosis of Brugada Syndrome is a spontaneous or drug inducible ST segment 
elevation in the 12-lead ECG. Patient ECGs are subject to fluctuations are more 
likely to exhibit spontaneous classical Brugada Syndrome patterns between 12 am 
and 6 am3. This has important implications since spontaneous ST segment elevation 
is considered a risk factor. For the definitive diagnosis one of five possible clinical 
characteristics has to be met1: a family history of sudden cardiac death, a family 
history of ST segment elevation, agonal respiration during sleep, a history of VT/VF 
or inducibility of VT/VF during electrophysiological study. To date, the implantation 










Figure 1: Normal vs Brugada Syndrome ECG 




Some patients can be asymptomatic for life, some present with syncope and some 
suffer from sudden cardiac death caused by ventricular fibrillation without prior 
symptoms. Men are not only more likely than women to develop Brugada Syndrome 
but also carry a 5.5-fold increased risk of sudden cardiac death. While the mean age 
of patients with VF episodes is 41±15 years1, arrhythmic events may occur from the 
age of 2 causing sudden cardiac death in infants and young children6, 7. The 
prevalence of Brugada Syndrome is low in the general population but higher in Asia 
than in the United States and Europe which has been thoroughly reviewed 
elsewhere8. Fever frequently induces ECG changes and VF in both adults and 
children1, 6, 10. Generally, frequency of abnormal ECGs with a classical Brugada 
Syndrome phenotype is also much higher in adults compared to children9. Patients 
are more likely to suffer an arrhythmic event at night11, which might be attributed to 
activity of the vagus nerve12, 13, and atrial fibrillation is commonly observed in 
11-14% of Brugada Syndrome patients14.  
 
Even though Brugada Syndrome has been associated with mutations in 17 genes15, 
its main identified genetic cause is a mutation in SCN5A16. This gene encodes the 
alpha-subunit of the cardiac sodium channel Nav1.5 responsible for sodium inward 
current (INa) and is located in the membrane of cardiomyocytes. In order to 
understand the underlying mechanisms of the Brugada phenotype, different model 
systems have been utilized. These models include transgenic mice17, canine heart 
preparations18 and expression of mutant SCN5A in different expression systems16. 
This literature review aims to analyse the most commonly used systems to model 
Brugada Syndrome to show their major accomplishments as well as their advantages 
and disadvantages. In addition to model systems, Brugada Syndrome patients have 
been studied extensively both to understand the underlying mechanism as well as to 
improve treatment19-21. These clinical studies combined with experimental models 
have led to the proposal of several mechanisms. The two most prominent hypotheses 
propose conduction delay in the right ventricle (depolarisation hypothesis) and 
transmural dispersion of repolarisation between the endo- and epicardium of the right 
ventricular outflow tract (repolarization hypothesis) as the mechanism underlying 
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Brugada Syndrome. Arguments for and against either hypothesis have been 




SCN5A, located on chromosome 3p21, is the gene that encodes the alpha-subunit of 
cardiac sodium channel Nav1.5 (Figure 2). It is made up of four homologues 
transmembrane domains (DI-DIV) each consisting of 6 transmembrane segments 
(1-6) and neighbouring homologues domains are connected through linker loops. The 
positively charged transmembrane segment 4 has been associated with 
voltage-dependent activation of Nav1.5
24, 25, while inactivation of the channel has 
been attributed to intracellular loops III and IV. The transmembrane segments 6 and 
the loops between 5 and 6 in each domain form the Na+-conducting channel pore26. 
Although the alpha-subunit of Nav1.5 by itself is sufficient to act as a voltage-
dependent sodium channel, it is part of a large multi-protein complex. The alpha-
subunit interacts with four beta-subunits that are encoded by SCN1B, SCN2B, SCN3B 
and SCN4B27, 24. Each 30-35 kDa protein contains a transmembrane alpha-helix with 
an extracellular N-terminus and an intracellular C-terminus and while beta-subunits 1 
and 3 bind to the alpha-subunit through non-covalent bonds, subunits 2 and 4 bind 
through disulphide bonds.   
 
Beta-subunits play a potential role in Nav1.5 cell surface expression and have been 
shown to modulate Ina density and /or gating characteristics27. Other binding 
partners include cytoskeletal, regulatory, trafficking, cell adhesion and gap junction 
proteins (Table 1) that have recently been reviewed in detail by Willis et al.28. Not all 
Nav1.5-protein interaction sites have been identified but it has been shown that some 
binding partners interact with Nav1.5 between loops II and III or at its C-terminus 
which contains a PDZ domain. The PDZ domain consists of postsynaptic density 


















Figure 2: Nav1.5 channel scheme showing the location of mutations in SCN5A identified in patients with the Brugada Syndrome  
Of the >400 SCN5A mutations linked to Brugada Syndrome only missense mutations that have been functionally characterized using expression systems are displayed. 
Nonsense and insertion or deletion mutations are not shown. Mutations described to cause a complete loss of INa are dark grey, those reported to alter Nav1.5 properties 
are light grey, and white indicates no changes in channel properties. Mutations for which 2 different types of alterations have been reported are displayed in both 
colors. The mutation investigated in this study is indicated by a black arrow.  
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Table 1: Known Nav1.5 binding partners 
Protein Protein function Nav1.5 Interaction Site Ref. 





Desmoglein-2 Desmosome structure ? 31 




FHF Growth factor COOH-terminus 33 
GPD1-L Enzyme, modulator ? 34 
MOG-1 Intranuclear traffic Domain II and III loop 35 










FHF – fibroblast growth factor homologous factors; GPD1-L – glycerol-3-phosphate dehydrogenase-
like protein; MOG1 – multicopy suppressor of gsp-1; SAP97 – synapse-associated protein 97 
 
 
Mutations in SCN5A can lead to a number of clinical phenotypes depending on 
whether they cause a gain or loss of function. A mutation that causes a gain of 
function can result in increased late INa, leading to Long QT Syndrome type 3 
(LQT3). A loss-of-function mutation on the other hand can lead to decreased peak 
INa, which is associated with Brugada syndrome, sick sinus syndrome and cardiac 
conduction diseases. In cases where a mutation causes both a gain in late INa and a 
loss of peak INa can lead to overlap syndromes (e.g. Brugada syndrome/LQT3). 






1.1.2 Murine model of Brugada Syndrome 
Two approaches are conceivable, one knocking out the mouse equivalent of the 
human SCN5A (Scn5a) to simulate a generic Brugada Syndrome phenotype, the 
other one introducing a specific mutation found in Brugada Syndrome patients and 
replicating its associated phenotype. 
 
 
1.1.2.1 Scn5a heterozygous knock-out mice 
In 2002 Papadatos et al.17 generated a mouse model for arrhythmias through targeted 
disruption of Scn5a (Figure 3). Homozygous knock-out mice exhibited embryonic 
lethality caused by their structurally abnormal hearts. Heterozygous knock-out mice 
(Scn5a+/-) were indistinguishable from their wild type (WT) littermates regarding 
weight, heart/body weight ratio, heart morphology and mortality. ECGs of Scn5a+/- 
mice revealed a slow conduction compared to WT mice but a normal QT interval. 
These findings were affirmed with whole cell patch-clamp recordings showing a 
~50% reduction in sodium conductance causing impaired action potential 
propagation, conduction block, re-entrant arrhythmias and ventricular tachycardia. 
Scn5a+/- mice exhibited several cardiac phenotypes however not one strictly 
representative of the Brugada Syndrome. Phenotypic heterogeneity, even resulting in 
some symptom-free mutation carriers, in Scn5a+/- mice as well as in patients carrying 
a SCN5A mutation, could at least in part be explained by varying levels of Nav1.5 
protein expression, with severity of the phenotype correlating with the expression 






















Figure 3: Overview of model systems of Brugada Syndrome 
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The mouse model described in this initial report was subsequently used by different 
groups to investigate in how far it recapitulates phenotypes observed in Brugada 
Syndrome patients, drug response and to examine the underlying causes of those 
phenotypes observed. Age- and sex-related factors in disease progression such as an 
increased risk of cardiac related mortality, and developing AV node conduction 
disorder and bradycardia in old males have successfully been replicated41, 42, 43. All 
these studies verified the Scn5a heterozygous knock out mouse as a suitable system 
to model Brugada Syndrome.  
 
Studies looking to recapitulate the response of Brugada Syndrome patients to pro- 
and anti-arrhythmic drugs showed that, compared to WT, flecainide-treated Scn5a+/- 
Langendorff perfused hearts indeed reiterated the pro-arrhythmic effects of this 
Nav1.5 blocker on Brugada patients
44. ECGs from anesthetized WT and Scn5a+/- 
mice, recorded by Martin and co-workers45, showed that the ventricular arrhythmias, 
ST segment elevation, increased transmural repolarisation gradients and abnormal 
conduction was accentuated in Scn5a+/- mice by treatment with flecainide but not 
quinidine, a class Ia anti-arrhythmic agent. Surprisingly both flecainide and quinidine 
suppressed spontaneous and induced atrial arrhythmias, suggesting a different 
mechanism for ventricular and atrial arrhythmias46. These studies verified the 
Scn5a+/- mouse as a suitable model system for Brugada Syndrome by replicating the 
effects of flecainide and quinidine on Brugada Syndrome patients. 
 
So far only one aspect of the advantages provided by a model system has been 
considered, namely the ability to replicate the disease phenotypes observed in 
patients. Another possible application of model systems is the in-depth analysis of 
the underlying physiological mechanisms of individual symptoms. Attempts to find 
the physiological basis of ventricular tachycardia, one of the main symptoms leading 
to sudden cardiac death, have led to two hypotheses, namely altered conduction 





To test these hypotheses, monophasic action potentials (MAP) were recorded from 
Langendorff-perfused WT and Scn5a+/- hearts before and after administration of 
flecainide and quinidine47, 48. MAP recordings of neighbouring epi- and endocardium 
from the right and left ventricle and activation latencies suggested a key role of 
transmural gradients rather than altered conduction times in arrhythmogenicity 
associated with Brugada Syndrome. Transmural gradients were accentuated in the 
right but not left ventricle. 
 
The Scn5a+/- mouse models Brugada Syndrome quite accurately concerning the 
impact of age and sex on the progression of the disease and drug response. 
Scn5a+/-mice show an increased risk of AV node conduction disorder, bradycardia 
and cardiac related death in old males as well as an accentuation of the Brugada 
Syndrome phenotype after administration of flecainide. Using this model system, 
researchers have also been able to link atrial arrhythmias to Brugada Syndrome and 
to determine transmural gradients as the major contributor to development of VT. 
 
 
1.1.2.2 Scn5a-1798insD knock-in mice 
In addition to knocking out Scn5a, creating a system that models a generic Brugada 
Syndrome phenotype, investigators also generated a mouse strain carrying the 
murine equivalent of the human SCN5A-1795insD mutation, enabling them to 
investigate the effects of a specific mutation and compare them to observations made 
in patients. Members of a Dutch family carrying a SCN5A-1795insD mutation 
display overlap symptoms of LQT3, Brugada Syndrome and progressive cardiac 
conduction defects. LQT3 and Brugada Syndrome are usually associated with gain 
and loss-of-function mutations in SCN5A respectively49. Mice carrying a 
Scn5a-1798insD mutation indeed show a similar phenotype demonstrating 
bradycardia, right ventricular conduction slowing and QT prolongation, confirming 





1.1.2.3 Scn1b knock-out mice 
It is important not to forget that every model system has its restrictions. Phenotypes 
observed in models do not necessarily reflect those examined in patients as the 
example of the Scn1b knock-out mouse illustrated51. The knock-out of Scn1b, the 
gene encoding the beta subunit of the cardiac sodium channel Nav1.5, triggered 
ventricular repolarisation which is not present in Brugada Syndrome patients with a 
SCN1B loss-of-function mutation. The inconsistency could either be due to 
differences between loss-of-function mutation and knock-out or fundamental 
differences in physiology relating to the species.     
 
The heterozygous knock-out of Scn5a in mice generated a mouse model that 
accurately replicates most of the phenotypes associated with the Brugada Syndrome 
including sex-dependent disease progression and drug response. It also proved 
valuable as a tool for exploring transmural gradients as the underlying cause of VT in 
patients. Mice carrying the equivalent of the human SCN5A-1795insD mutation 
exhibited a phenotype similar to the human phenotype, confirming that a single 
mutation is sufficient to cause an overlap of Brugada Syndrome and LQT3.  
 
 
1.1.2.4 Strengths and limitations of the murine model 
The advantage of using a model organism rather than a single cell expression system 
is that a mutation of interest can be investigated in its physiological environment and 
during different developmental stages. The effect of Nav1.5 depletion on the 
morphology of ventricles for example would not have become apparent in an 
expression system. However, despite giving valuable insight into the Brugada 
phenotype, the cardiac electrophysiological characteristics of mice and humans are 
markedly different as exemplified by studies using the Scn1b knock-out mice. In 
addition to being expensive, two major limitations of this model system remain. 
Firstly, research at the molecular level is restricted by the limited life-span of isolated 
cardiomyocytes in culture. Secondly, the murine model only allows for 
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investigations of known genetic causes and has this far been restricted to SCN5A 
mutations which make up for only 11-28% of all Brugada Syndrome cases52.  
 
 
1.1.3 Porcine model 
Recently, a large-animal porcine model was developed to model SCN5A mutations. 
Pigs carrying the porcine equivalent of the human nonsense mutation 
SCN5A-E555X, previously identified in a patient with Brugada Syndrome, were 
generated and their hearts Langendorff perfused and investigated53. Their hearts are 
similar to those of humans in terms of structure and function, and in this model 
showed no structural abnormalities, but conduction slowing and an increased 
susceptibility to ventricular arrhythmias accurately modelling aspects of the human 
disease phenotype.  
 
 
1.1.4 Canine Model of Brugada Syndrome 
Almost all experiments utilizing the canine model for Brugada Syndrome are based 
on arterially perfused wedges of canine left or right ventricles rather than a whole 
heart. These are then treated with drugs to induce the Brugada phenotype18. Over the 
years and depending on the group different drugs have been used to cause the 
Brugada phenotype, all of which are either sodium channel blockers 
(e.g. pilsicainide54), calcium channel blockers (e.g. verapamil55) or potassium 
channel openers (e.g. pinacidil56) and are administered either alone or in combination 
(Figure 3). These induced systems are then exploited in order to investigate the 
underlying electrophysiological cause of the abnormalities observed on the 
electrocardiogram in Brugada Syndrome. 
 
 
1.1.4.1 J-wave/Osborne wave 
The J-wave, also called Osborne wave, is a positive deflection located between the 
QRS and ST segment in an ECG (Figure 1) and is, among others, found in patients at 
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risk of developing ventricular fibrillation, such as Brugada Syndrome patients. The 
drug induced canine heart preparation was first suggested as a suitable model system 
for the Brugada Syndrome in 1996, when Yan and Antzelevitch investigated the 
underlying cause of the J-wave18. Transmembrane action potential (AP) recordings 
suggested a voltage gradient across the ventricular wall as the underlying cause of 
the J-wave. Similar results could be achieved by cooling of the right ventricular 
outflow tract (RVOT) in test-subjects57, providing a possible in vivo model. 
 
 
1.1.4.2 ST segment elevation 
In an ECG of a Brugada patient the ST segment elevation is the most striking feature 
and is one of the criteria used for diagnosis of Brugada Syndrome (Figure 1). Several 
groups have pursued investigations to find the electrophysiological alterations that 
lead to ST segment elevation. The ST segment of an ECG represents the time 
between depolarisation and repolarisation of the ventricles.  
 
Yan and Antzelevitch used flecainide and acetylcholine to induce Brugada Syndrome 
in a canine model,  proposing that ST segment elevations are caused by the same 
transmural voltage gradient across the epicardial RV wall that causes the J-wave18, 58. 
The transmural voltage gradient across the epicardial RV wall is caused by a 
depression of the AP dome. Their results also indicated that phase 2 re-entry (P2R) 
could cause extrasystolic activity in the RV wall which could serve as a substrate for 
VF/VT. ST segment elevation had previously been linked to electrical heterogeneity 
in the recovery phase, a substrate for P2R54. Further experiments have shown that 
repolarisation abnormalities associated with ST segment elevation are more precisely 
located in the RVOT in both patients and model system59, 60.  
 
In conclusion, while transmural dispersion of repolarisation leads to ST segment 
elevation in the ECG, dispersion of repolarisation in the epicardium of the RV causes 
P2R with extrasystoles that can degenerate to VF/VT, the main cause of sudden 




1.1.4.3 T-Wave alternans and VF/VT 
Another feature of the Brugada phenotype associated with loss of the action potential 
dome, besides J-waves and ST segment elevation, is T-wave alternans (TWA). TWA 
is a beat to beat variation in amplitude, polarity and morphology of the T-wave in an 
ECG which in patients has been associated with an increased risk of ventricular 
arrhythmias. Morita et al. were the first to describe its electrophysiological 
foundation and showed that it is at least in part caused by the same increased 
dispersion of repolarisation that causes ST segment elevation61. Recently Fish and 
Antzelevitch showed that TWA shares another feature with ST segment elevation.  
The results from an arterially perfused RV wedge preparation induced with 
verapamil, a sodium and calcium channel blocker, indicate that TWA could be 
caused not only by an AP dome loss but also a concealed P2R which both lead to 
transmural dispersion of repolarisation which could trigger VF/VT62. This study used 
verapamil to induce Brugada Syndrome by blocking calcium and sodium channels, 
but this drug is only recognized for its calcium channel blocking properties. Even 
though both the heterozygous loss of either the cardiac sodium  or calcium channel 
causes Brugada Syndrome, there are phenotypic differences between them63.  This 
questions the applicability of the data gathered from model systems using a 
combined sodium/calcium channel block approach. 
 
To sum up, T-wave alternans is a feature of the Brugada Syndrome that appears to 
have the same electrophysiological basis as ST segment elevation, namely P2R and 
loss of AP dome, leading to an increased risk of VF/VT. In addition, the probability 
of developing ventricular arrhythmias at certain heart rates is not only influenced by 
mutations in different channels but there is also a notable temperature component. 
Following the observation that ventricular arrhythmias are promoted by fever in BrS 
patients Morita and co-workers conducted experiments looking at the effects of 
hyperthermia and hypothermia on functional dynamics and spatial heterogeneity of 
RV electrophysiological activity. AP recordings of the hypothermia model showed 
spontaneous activation triggered by prolongation and increased dispersion of AP 
duration. Recordings of the hyperthermic system, modelling fever, exhibited shorter 
AP durations causing premature ventricular activations and reentrant VT64. 
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1.1.4.4 Sex differences 
One curious aspect about Brugada Syndrome is that even though mutations causing 
the disorder are equally inherited by males and females, males are 8-10 times more 
likely to develop symptoms65. Canine epicardium preparations have shown a smaller 
transient outward potassium current (Ito) density in females compared to males, 
which could protect them from developing Brugada Syndrome but make them more 
prone to progressive conduction problems when inward currents like INa are 
compromised66. Another study showed that INa amplitude in the LV epicardium of 
females is smaller compared to males and that testosterone modulates this 
amplitude67. This could put females at a higher risk of developing arrhythmias in the 
LV, a feature found in LQTS, and explain why the incidence of arrhythmias related 
to LQTS is lower in males than females. 
 
 
1.1.4.5 Prediction of high risk patients and treatment 
Even though discovering the mechanisms which lead to ventricular arrhythmias is 
important, the ultimate goal remains to apply the gathered knowledge to improve 
methods for diagnosis, prediction of high risk patients and treatment. 
 
Investigations of conduction abnormalities, such as right bundle branch block, led to 
the discovery of fragmented QRS (f-QRS) as a new marker for Brugada patients with 
a high risk of syncope and developing spontaneous VF68. Fragmented QRS are 
conduction abnormalities within the QRS complex and can manifest as multiple 
spikes in the QRS complex of an ECG. In terms of treatment, most strategies aim at 
preventing sudden death caused by ventricular arrhythmias rather than treating the 
underlying cause, loss of sodium channel function. Recently, using the canine model, 
researchers were able to show that a more focused application of radiofrequency 
catheter ablation (RFCA) to the epicardium might be more efficient in eradicating 




These examples illustrate how the canine model system could help not only to find 
new, easy to measure, markers for high risk patients, but also suggest possible 
improvements for established treatments. 
 
Canine preparations have proven to be a useful system for modelling Brugada 
Syndrome. Not only have they linked J-waves, ST segment elevation and T-wave 
alternans to a depression of the action potential dome, they were also instrumental in 
determining that a lower Ito density in females compared to males, could protect them 
from developing Brugada Syndrome. In addition, the canine model helped reveal 
f-QRS as a new marker for high risk patients and suggested an improved method of 
using RFCA to treat VT in Brugada Syndrome patients. 
 
 
1.1.4.6 Strengths and limitations of the canine model 
The main advantages of having a heart preparation are that cells in epi- and 
endocardium can be investigated, and that they remain in their natural environment.  
The most obvious limitation of this system is that the Brugada Syndrome phenotype 
is drug induced. Combinations of sodium and calcium channel blockers and/or 
potassium channel openers have been used, even though the majority of patients only 
carry one mutation and experiments have shown subtle differences in phenotypes 
depending on which channel is bearing the mutation. Because the Brugada Syndrome 
phenotype is drug induced, drug screening is limited not only due to possible 
interactions with the channel blocking agent but also because mutations underlying 
Brugada Syndrome may be more complex than simple loss-of-function modelled by 
a drug induced Brugada Syndrome phenotype. Unfortunately, it also does not allow 
for investigations of either atypical Brugada Syndrome patients with no mutation but 





1.1.5 Expression systems modelling Brugada Syndrome 
Experiments using expression systems aim at deciphering the biophysical properties 
of single cells, which can give clues to understand the underlying molecular 
mechanisms of Brugada Syndrome. Plasmids carrying mutations identified in 
Brugada Syndrome patients are mainly transfected into either tsA201 cells or 
Xenopus oocytes. Xenopus laevis (frog) oocytes are rather large, about 1mm, and 
cheap to maintain and manipulate; both of which make them a desirable tool for 
electrophysiological experiments. tsA201 cells are immortalised Human Embryonic 
Kidney (HEK) 293 cells. Comparative experiments quickly showed that results from 
both expression systems were, depending on the mutation, contradictory. Employing 
expression systems, investigators have been able to study biophysical consequences 
of Brugada Syndrome associated mutations, which generally lead to reduced net 
sodium current, due to altered Nav1.5 properties or complete loss of INa. Expression 
systems have also been used to study double mutants and mutations in genes other 
than SCN5A that have been associated with the Brugada Syndrome phenotype. Since 
the focus of this literature review is to discuss the strengths and limitations of model 
systems, only a few selected studies will be used to highlight the main identified 
mechanisms through which mutations can cause Brugada Syndrome.  
 
 
1.1.5.1 Altered Nav1.5 properties 
Three mechanisms have been proposed to explain how the channel’s altered function 
can lead to the cardiac dysfunction. The first mechanism, a shift in steady-state 
activation and/or inactivation curve, was suggested after studying 1795insD. The 
insertion of an aspartic acid after position 1795 (1795insD) was discovered after 
screening a large family with members exhibiting symptoms of both Brugada and 
LQT3 syndrome. Indeed, altered Nav1.5 function can lead to other cardiovascular 
disorders besides Brugada Syndrome, as well as overlap syndromes70. Expression of 
1795insD in Xenopus oocytes and tsA201 cells revealed a negative shift of the 
steady-state inactivation curve and positive shift of the steady-state activation 
curve71, 72. Studies on other mutations revealed that the shift of activation and 
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inactivation curves can be towards more negative or positive voltages, and can occur 
together or separately. These alterations in channel properties would result in a 
reduction of action potential amplitude, which is in accordance with the 
heterogeneity of repolarisation across the ventricular wall observed in the canine 
model of Brugada Syndrome. A residual sodium current, only detected in tsA201 
cells but not Xenopus oocytes, was hypothesised to cause long QT intervals and 
explain symptoms of LQTS in individuals carrying this insertion72. Examination of 
other mutations found to cause both LQT3 and Brugada Syndrome in carriers 
revealed the same biophysical mechanism73. Observing that two mutations, A735V 
and R1192Q74, found in families with sudden unexplained nocturnal death syndrome 
(SUNDS) resulted in the same shift in activation and inactivation curve led to the 
conclusion that Brugada Syndrome and SUNDS are the same disorder74.  
 
After studying 1795insD in tsA201 cells, Veldkamp at al. proposed a second 
mechanism75 in addition to the change of voltage dependence of activation and 
inaction described above. They suggested that some mutant channels enter an 
intermediate state of inactivation from which they recover relatively slower than WT 
channels. Prolonged recovery from inactivation that could lead to arrhythmias in 
Brugada patients76 was also described as the underlying mechanism for Nav1.5 
carrying the T1620M mutation. These results were however restricted to expression 
in tsA201 cells whereas Xenopus oocytes transfected with the same mutation showed 
the opposite phenotype77.  
 
Lastly, mutations can alter the time-dependence of steady-state inactivation resulting 
in accelerated or decelerated inactivation78, 79. Whereas a faster current decay reduces 
the net sodium current, a feature linked to Brugada Syndrome, slower current decay 
is generally associated with LQT3 and appears in Brugada Syndrome patients in 
combination with reduced peak current or current window due to shifts in activation 
and/or inactivation curves78, 80. 
 
In summary, these investigations showed that there are three mechanisms by which 
altered properties of mutant Nav1.5 cause Brugada Syndrome. The first mechanism, a 
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shift of the activation and/or inactivation curves, is consistent with reduced action 
potential durations. This generates transmural heterogeneity of repolarisation 
between the epicardium and endocardium across the ventricular wall causing 
ST segment elevations in the ECG. The second mechanism, enhanced 
intermediate/slow inactivation, results in reduced INa. The third mechanism, 
accelerated inactivation, reduces the net sodium current.  
 
 
1.1.5.2 Complete loss of INa 
Rather than altering channel properties, mutations can also result in a complete loss 
of current. Both trafficking defects and truncated proteins have been linked to loss of 
function of Nav1.5 in Brugada Syndrome patients, and again, depending on the 
mutation, expression in Xenopus oocytes and tsA201 cells gives rise to contradictory 
observations. 
 
One such example is R1432G, which lead to completely abolished functional 
expression in tsA201 cells while producing reduced sodium current when expressed 
in Xenopus oocytes. Mutant channels in tSA201 cells were shown to be localised in 
the endoplasmic reticulum81 exposing disrupted cell-surface localisation of Nav1.5 as 
one of the mechanisms underlying Brugada Syndrome. 
 
Besides disruption of protein transport to the cell membrane, Brugada Syndrome has 
also been linked to expression defects. Some mutations found in Brugada patients, 
such as E473X and N1774+12X, produce truncated proteins and hence no detectable 
sodium current82. When these mutant channels were heterozygously expressed with 
WT channels, a 50% reduction of sodium current was detected. However, unlike 
channels whose function has been altered by a mutation, no effects on activation or 





1.1.5.3 Induced Brugada Syndrome 
Expression systems have been also used to study the effects of external factors on the 
behaviour of mutant Nav1.5. For example, functional expression of Nav1.5 carrying 
the G1740R mutation appears to depend on the temperature at which the currents are 
recorded. Expression in tsA201 generated no currents at 37°C, whereas at 22°C 
macroscopic sodium currents could be detected82.    
 
Beside temperature sensitivity, mutations in SCN5A have also been shown to cause 
drug induced Brugada Syndrome. In rare cases, a mutation in SCN5A can cause a 
Type 1 Brugada Syndrome phenotype with ST segment elevation after 
administration of lidocaine. A double mutation, V232I+L1308F, was identified in a 
patient exhibiting lidocaine induced Brugada Syndrome84. WT and mutant channels 
expressed in tsA201 exhibited similar current-voltage relationships but the maximum 
current was reduced in cells expressing the double mutation after lidocaine 
administration. A slower recovery from inactivation and a shift of steady-state 
inactivation towards more negative voltages after lidocaine treatment was also 
observed, resulting in manifestation of the Brugada phenotype84. The additive effects 
of both mutations appear to sensitize the sodium channel to lidocaine. This study 
therefore suggests that caution should be exerted when treating patients carrying said 
mutation with Class I anti-arrhythmic drugs. 
 
Certain drugs can also not only trigger symptoms in people with an unidentified 
mutation but cause a non-genetic form of Brugada Syndrome. These drugs include 
medication used to treat some forms of arrhythmia, angina, high blood pressure, 
depression, and other mental illnesses. Hypercalcemia, hyperkalaemia as well as 






1.1.5.4 Other genes associated with Brugada Syndrome 
Mutations in SCN5A account for the majority (11-28%) of Brugada Syndrome cases 
with a defined genetic cause52. Nonetheless, mutations in other channels, or channel 
regulatory proteins, have also been linked to the Brugada Syndrome albeit at smaller 
percentages. Thus far, mutations in 16 other genes have been found through 
screenings of patients15. These include genes encoding for the L-type calcium 
channels Cav1.2 (CACNA1c) and Cavß2b (CACNB2b)
85, 86, glycerol-3-phophate 
dehydrogenase 1-like enzyme (GPD1L)87, beta-subunits of the sodium channel 
(SCN1B88, SCN2B89 , SCN3B90) and MiRP2 (KCNE3)91, among others. However, 
only a few have been functionally studied. Mutations in SCN2B, SCN3B, SCN1B and 
GPD1L have been shown to cause a reduction in sodium current, in some cases due 
to disruption in trafficking of Nav1.5 to the cells surface
92. Also, a mutated MiRP2 
has been reported to trigger an increased Ito intensity
91. Two mechanisms have been 
associated with mutated CACNA1c or CACNB2b found in Brugada patients, and 
while both result in loss of function, one is caused by reduction of L-type calcium 
current, the other one triggers accelerated inactivation of calcium current85. Table 2 
gives an overview of some of the mutations in genes other than SCN5A that have 
been found in patients with Brugada Syndrome. A more detailed description of the 
various Brugada Syndrome subtypes can be found in the Nielsen et al. review15.  
 
Mutations associated with Brugada Syndrome are found in ion channels and proteins 
that regulate ion channel function. Gain- or loss-of-function mutations in these genes 
can affect the resting membrane potential, or can directly or indirectly lead to 
changes in depolarisation or repolarisation dynamics during action potential 
propagation. Like loss-of-function mutations in SCN5A these alterations lead to 
decreased action potential domes or action potential durations resulting in the 
characteristic electrophysiological Brugada Syndrome phenotype. In affected people 
without an identified gene mutation, the cause of Brugada syndrome is often 





To sum up, investigators found four mechanisms by which mutations in SCN5A 
cause Brugada Syndrome. They can alter biophysical properties of Nav1.5 by firstly 
causing shifts of steady-state activation and/or inactivation curves, secondly 
enhancing intermediate/slow inactivation or thirdly accelerate inactivation. Lastly, 
mutations can result in a complete loss of function by producing truncated proteins or 
disrupting trafficking to the cell surface. Expression systems have also been utilized 
to examine the functional effects of a double mutant that puts its carriers at risk of 
developing VF if treated with lidocaine due to altered Nav1.5-lidocaine binding, as 






































2 GPD1-L G3PD1L INa A280V ↓ 34 










































6 KCNE3 MiRP2 Ito/IKs R99H ↑ 91 














9 KCNJ8 Kir6.1 IKATP S422L ↑ 94 








11 RANGRF MOG1 INa E83D ↓ 35 












14 HCN4 HCN4 If S841L N/A 98 






















17 SCN2B Navβ2 INa D211G ↓ 101 
↓ – Loss-of-function; ↑ – Gain-of-function; N/A – not available 
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1.1.5.5 Strengths and limitations of expression systems 
Of all three presented model systems, expression systems are the only ones 
investigating the molecular mechanism of mutations found in patients rather than 
looking at manifestations of generic SCN5A knock-out or drug induced Nav1.5 block. 
Cell-based model systems are inexpensive and relatively easy to maintain and 
manipulate. Although 17 genes have been associated with Brugada Syndrome, the 
genetic cause for two thirds of all patients remains unidentified. That limits this 
model system to examination of known genetic causes and it also gives no insight 
into the heterogeneity of phenotypes between family members carrying the same 
mutation, some developing Brugada Syndrome and others not. One major issue 
remaining is the contradictory results from expression of mutant channels in different 
cell lines. Even though tsa201 cells expressing Nav1.5 generate sodium currents, 
these cells are morphologically and functionally very different from cardiomyocytes. 
 
Despite the fact that all three model systems have helped understand the molecular 
basis for certain features they have obvious limitations. The main restriction for all 
model systems so far remains, that they can only model cases in which the 
underlying genetic alteration is identified. However, only approximately one third of 
all Brugada patients carry a known mutation102. These model systems also fail to 
deliver explanations for or a way to investigate mutation carriers who show no 
symptoms. 
 
A new model system based on the generation of induced pluripotent stem 
cell-derived cardiomyocytes offers a unique chance to overcome the above stated 





1.2 Induced pluripotent stem cell-derived cardiomyocytes 
1.2.1 Induced pluripotent stem cells 
The ground breaking work that led to the discovery of iPS cells was based on 
decades of research into ES cells, nuclear fusion and cloning. When in 1958 the 
transplantation of a somatic Xenopus nucleus into an unfertilised Xenopus oocyte led 
to the development of a sexually mature individual103 it provided the first evidence 
that fully differentiated nuclei contained the same genetic information as ES cells 
and that if exposed to appropriate stimuli it can be reprogrammed to an 
undifferentiated ES-like state. Based on this and according observations in 
mammalian cells104 Takahashi and Yamanaka hypothesised that the reprogramming 
effects of oocyte and ES cell cytoplasm could me mimicked by the expression of a 
small number of ES cell-specific genes. The initial experiments identified 24 
candidate genes that, when delivered using retroviral vectors, were able to 
reprogramme mouse fibroblasts to induced pluripotent stem (iPS) cells105. Further 
investigations limited the number of factors essential for reprogramming to the so 
called 4 Yamanaka factors: Oct-4, Klf4, Sox2 and c-Myc. The resulting iPS cells 
expressed pluripotency markers and gave rise to teratomas containing all three germ 
layers when transplanted into immunodeficient mice. Even after loss of transgene 
expression through gene silencing the reprogrammed cells maintained their 
pluripotency, indicating that transient over-expression of exogenous factors was 
sufficient to activate endogenous expression of pluripotency genes. Although 
retroviral vectors are an efficient delivery system for the reprogramming factors 
concerns were raised about the long-term effects of random genetic integration and 
possible re-activation of transgenes. Genetic alteration could influence differentiation 
into specific cell lineages106 and re-activation in particular of oncogenes Klf4 and 
c-Myc led to tumour formation in 20% of the offspring of adult chimeras107. Only a 
year after the first reported generation of murine iPS cells it was demonstrated that 
human fibroblasts could be reprogrammed to iPS cells at a relatively high efficiency 
(0.1%) using retroviral vectors carrying the original 4 factors108, 109. Like murine iPS 
cells human iPS cells expressed markers of pluripotency and were able to form all 
three germ layers in vitro as well as in vivo.  
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1.2.2 Improvements of retroviral reprogramming efficiency 
Having demonstrated that human somatic cells can be reprogrammed to iPS cells, 
investigators quickly began researching non-integrating delivery systems and 
non-oncogenic transcription factors to not only make iPS cell lines more stable but 
eventually clinically relevant. It was shown that mouse and human fibroblast could 
be reprogrammed using only three of the original four factors (Oct-4, Sox2 and Klf4) 
although the process took longer in the absence of c-Myc110. Alternatively, 
transcription factors for oncogenes Klf4 and c-Myc could be completely replaced by 
transcription factors for non-oncogenic Lin28 and Nanog with no negative impact on 
reprogramming efficiency or outcome106. 
 
One approach to increase reprogramming efficiency was to combine the original 
4 Yamanaka factors with additional factors such as human telomerase (hTERT) and 
SV40 large T antigen111 or p53 siRNA and Undifferentiated embryonic cell 
transcription factor 1 (UTF1)112. The addition of the latter two increased efficiency 
100-fold even in absence of c-Myc. Another approach was the use of small 
molecules that could not only improve efficiency but also replace certain 
transcription factors113. Indeed, recent reports showed that small molecules alone are 
sufficient to generate murine iPS cells114 and only require addition of Oct-4 to 
successfully reprogramme human fibroblasts to iPS cells115. Although the 
mechanisms by which small molecules such as valproic acid116 support 
reprogramming are not always understood it appears that most are associated with 
chromatin remodelling.  
 
 
1.2.3 Alternative reprogramming techniques 
To overcome the obstacle of potentially gene-disrupting integration of transgenes 
into the host genome associated with retroviruses several other reprogramming 
methods were explored including non-integrating viruses, excisable transposons and 




An example of a non-integrating viral reprogramming system is the adenovirus 
which has been used to derive both murine117 and human118 iPS cells. In spite of 
having the advantage of targeting dividing as well as non-dividing cells the 
adenoviral delivery system was associated with very low reprogramming efficiency. 
Similarly inefficient was a completely virus-free reprogramming technique 
employing transient transfection with non-integrating plasmids derived from the 
Epstein-Barr virus and was originally only able to generate murine iPS cells119. It 
became a tool for reprogramming of human fibroblasts after changing the delivery 
system to non-integrating episomal vectors encoding for Lin28, Nanog and SV40 
large T antigen in addition to the Yamanaka factors120 but even after these 
modifications efficiency remained very low. 
 
Instead of preventing integration of transgenes altogether they can be transiently 
integrated for the duration of reprogramming. Excisable transposons are delivered 
with the PiggyBac technique, a gene delivery system that allows for temporary 
integration into the host genome with subsequent excision121, 122.  The PiggyBac 
transposon vector encodes for a cassette of all 4 Yamanaka factors linked by 2A 
peptides and is flanked by inverted terminal repeat sequences. PiggyBac transposase, 
co-transfected with the transposon vector, recognises these sequences and mediates 
the relatively random integration of the transposon into the host genome. Once target 
cells have been reprogrammed transposons can be excised by simply re-transfecting 
generated iPS cells with the transposase expression vector.  
 
In 2009 an entirely transgene-free technique was developed wherein human 
fibroblasts were reprogrammed using recombinant proteins123. Cell extracts from 
4 HEK293 cell lines, each expressing one of the 4 Yamanaka factors fused to a 
cell-penetrating peptide, were applied to target cells once a week for 6 weeks. 
Although a promising transgene alternative, the very low reprogramming efficiency 
and technical challenges suggested that further optimisation might be necessary.  
 
A different and more efficient transgene-free technique was developed a short time 
later wherein human fibroblasts were reprogrammed using synthetic mRNAs124. 
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Oct-4, Sox2, Klf4, c-Myc and Lin28 mRNAs were synthesised and modified in vitro 
to counteract their relative instability and susceptibility to degradation. Successful 
reprogramming still required daily transfections for up to 17 days with colonies 
usually appearing around day 20 with an efficiency of 0.0001%. 
 
 
1.2.4 iPS cell-based model systems 
Cutting edge research by Yamanaka and colleagues provided an alternative for 
ethically difficult hES cell work and has already proven its utility in disease 
modelling. The great advantage of this technique is that skin cells carrying the 
desired genetic profile can be obtained directly from the patient, reprogrammed and 
differentiated to the specific tissue that is affected by the disease. This technique 
allows investigators to study the mutant proteins in their native environment 
including all modifier proteins independent of whether the genetic alteration is 
known or not. The earliest proof of principle generation of patient-specific iPS cell 
lines, including Duchenne muscular dystrophy, Parkinson disease and Huntington 
disease, was reported by Park et al. in 2008125. This study did however not include 
any disease modelling characterisation of specific cell lineages involved in disease 
progression. To date several cardiac disorders including LQT1126, LQT2127 and 
Timothy syndrome128 have been modelled using the iPS cell approach (Figure 4). 
Although there are no studies looking at classical Brugada Syndrome phenotypes, 
Davis et al. recently derived cardiomyocytes from patients carrying the 
SCN5A-1795insD mutation129. SCN5A-1795insD causes Brugada Syndrome/LQT3 
overlap symptoms and, as described above, had previously been studied in both 
mouse model and expression systems. The patient-specific iPS cell-derived 
cardiomyocytes recapitulated the decreased INa peak and persistent INa associated 






















Figure 4: Schematic of an iPS cell based model system to model an inherited cardiac disease 
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1.2.5 Cardiac differentiation of iPS cells 
Before the development of reliable in vitro cardiac differentiation protocols, 
researchers transplanted undifferentiated mouse ES cells directly into the 
myocardium of infarcted and healthy control mice to test their regenerative 
capabilities. Their hypothesis was that the cardiac environment such as the 
extracellular matrix and factors released by cardiomyocytes would be sufficient for 
cardiac differentiation and maturation of those ES cells. What they found however 
was that transplanted ES cells quickly and consistently formed cardiac teratomas that 
contained no more cardiomyocytes than teratomas formed in the hind-limb 
control130. These findings suggested that transplantation of in vitro differentiated 
cardiomyocytes might be required to prevent teratoma formation and for cardiac 
repair to be successful. Other important aspects to consider, if attempting to make 
pluripotent stem cell-derived cardiomyocytes clinically relevant, were developing a 
differentiation protocol that was not only scalable but also modifiable to be Good 
manufacturing practice (GMP) compliant.  
 
Over the years a variety of cardiac differentiation protocols have been published 
using first hES cells and later also iPS cells. All protocols can be clustered into three 




1.2.5.1 Unguided differentiation 
Unguided cardiac differentiation is the technically easiest and most inexpensive of 
the three protocols requiring no additional supplements in form of growth factors or 
small molecules to be added to the culture medium. Undifferentiated pluripotent stem 
cells are simply lifted and transferred into ultra-low attachment plates with 
differentiation medium containing serum. Ultra-low attachment plates prevent 
adherence in response to which hES and iPS cells form three dimensional aggregates 
called embryoid bodies (EBs) and this aggregation process itself initiates 
differentiation. After several days in suspension, EBs are plated onto a matrix such as 
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gelatine or poly-L-lysine that promotes attachment and further differentiation. 
Spontaneous differentiation of EBs into contractile cardiac muscle was first observed 
during investigations into the general differentiation potential of hES cells in vitro131 
and was subsequently shown to also occur in EBs derived from iPS cells132. Cells 
within these contracting clusters exhibited structural and functional properties of 
cardiomyocytes133. Like in embryogenesis cardiac cells are among the first cells to be 
formed and contracting EBs or beating bodies appear as early as a few days after 
plating. Cells within an embryoid body spontaneously differentiate into cells from all 
three germ layers and cell-to-cell interactions with cells differentiating towards 
endoderm appear to be sufficient to drive differentiation of adjacent cells towards 
mesoderm and further towards a cardiac commitment134. In the original protocol, 
EBs were generated by simple mechanical disruption of undifferentiated pluripotent 
stem cells, resulting in beating bodies that differed in size as well as the percentage 
of cardiomyocytes they contained. Because in this setting the composition of cells 
within an EB is not externally guided differentiation is random and therefore the 
number of beating bodies generated is subject to great variability. In addition to 
relatively low efficiency of overall <10% beating bodies and <1% cardiomyocytes133, 
unguided differentiation shows great inter-line variability. Efforts to make EB 
formation more consistent with regard to size and morphology were successful using 
hanging-drop135, forced aggregation136, 137 or micro-contact printing138 methods but 
had only limited effect on differentiation efficiency or variability137. Some of the 
initial difficulties with these techniques are likely attributable to the fact that the size 
of forced aggregates was originally optimised for haematopoietic rather than cardiac 
differentiation which might differ with respect to optimal aggregation size. 
Comparison of EBs from 4 hES cell lines generated through forced aggregation 
showed inter-line variability not only with respect to cardiac differentiation potential 
(1%-10%) but also EB growth. The idea of forced aggregation as a means to limit 
variability and increase efficiency was taken up again years later in connection with a 
guided cardiac differentiation protocol139. Over time, media supplements as well as 
external culture conditions were altered to improve efficiency. Regular foetal calf 
serum (FCS) was substituted for HyClone FCS and 5-azacytidine, a known 
cardiogenic factor in differentiation of murine cell lines140, was added in a 
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time-dependent manner141. These changes increased efficiency to up to 70% in 
hES cells but did not succeed in reducing variability141. Culturing EBs under 
dynamic conditions (stirred suspension) was shown to almost double beating body 
formation efficiency to 50% when comparing EBs generated through mechanical 
disruption to micro-contact printing138. Hypoxia (4% compared to 20% oxygen 
tension) tested in the same study had no significant effect on efficiency. Electrical 
stimulation resulting in an increase in reactive oxygen species has also been 
hypothesised to play a role in cardiac differentiation of hES cells142. Despite its great 
inter-line variability and relatively low efficiency, unguided differentiation is still 
widely used owing to its simplicity and low costs. 
 
 
1.2.5.2 Co-culture differentiation 
As established above, spontaneous cardiac differentiation is not very efficient as well 
as highly cell line-dependent. In order to reduce variability and to induce cardiac 
differentiation in cell lines seemingly incapable of spontaneously differentiating 
towards cardiac lineages, a protocol inspired by embryogenesis was developed. 
During embryogenesis, proximity of visceral endoderm is sufficient to induce cardiac 
lineage specification of adjacent mesoderm143, 144. Simulating these conditions 
in vitro, both mouse embryonic carcinoma and mouse ES cells formed spontaneously 
contracting cardiac muscle when co-cultured with a mouse visceral-endoderm-like 
cell line (END-2)145. Later, END-2 cells were shown to have similar cardiogenic 
effects on both hES and iPS cells146, 147. Undifferentiated pluripotent stem cells were 
plated onto growth-arrested END-2 cell replacing mouse embryonic fibroblasts 
(MEFs) as feeders and cultured for up to 6 weeks in medium containing serum. 
Under these conditions beating areas formed even from cell lines that did not 
spontaneously undergo cardiac differentiation using the unguided protocols. 
Efficiency however was difficult to compare to previous protocols since it was 
presented as the percentage of wells of a 12-well plate containing beating areas. The 
total number of cardiomyocytes in a 12-well plate on day 12 of differentiation was 
increased almost 40-fold when hES and END-2 cells were co-cultured in serum-free 
conditions with 10–4 M ascorbic acid added to differentiation medium148. The 
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inhibitory effect of serum was shown to be concentration dependent and similar 
using either serum or serum-replacement.  
 
Further improvement of the protocol was driven by efforts to make it easier scalable 
as well as more efficient. Graichen et al. showed that the cardiogenic potential of 
END-2 cells was co-culture independent and likely stemmed from a soluble factor 
released by the cells into the medium149. EBs were generated from three hES cell 
lines in serum-free medium overnight and subsequently cultured in suspension in 
serum-free END-2 conditioned medium (END-2 CM). When assessed on day 12 of 
differentiation suspension culture in END-2 CM resulted in 50% beating bodies. 
Analysis of gene expression of EBs throughout differentiation showed rapid 
up-regulation of mesodermal genes normally expressed in the primitive streak. A 
small molecule screen identified two p38 MAPK inhibitors (SB203580, SB202190) 
that significantly increased differentiation efficiency when added at concentrations 
<10µM from the beginning of differentiation. The mechanism by which they act is 
not well understood but p38 MAPK signalling has been shown to be activated during 
neuroectoderm formation149. It appears as if SB203580 enhances mesoderm 
induction but it has no inhibitory effects even if present for the entire period of 
differentiation. Addition of SB203580 to END-2 CM increased beating body 
formation from ~50% to ~71% and total cardiomyocyte numbers from 10% to 20%. 
Although on average more efficient, the protocol still showed considerable 
variability in efficiency between cell lines and technical replicates. 
 
The final change to the co-culture protocol was made with the aim of developing a 
xeno-free alternative, thereby making it compatible with the GMP and possibly 
clinically relevant. Comparative gene expression analysis of END-2 and a related but 
non-cardiogenic cell line showed up-regulation of two key enzymes of the 
prostaglandin I2 (PGI2) synthesis pathway in END-2 cells
150. In accordance with 
that, END-2 CM contained PGI2 at levels 6-10 fold higher than control CM. EBs 
from two hES cell lines were formed in serum-free medium overnight and 
transferred into serum-free medium supplemented with PGI2 the next day. After 
12 days of suspension culture ~20% of EBs were contracting. Addition of SB203580 
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led to a further slight increase of efficiency yielding >10% cardiomyocytes. Another 
parameter tested at the same time was whether insulin had inhibitory effects on 
cardiac differentiation. Insulin supports long-term cell growth by facilitating uptake 
of glucose and amino acids from the medium and is a common additive in cell 
culture151. Removal of insulin from medium had no evident negative effects on cell 
survival but presence of insulin, especially during the early stages of differentiation, 
significantly inhibited formation of endoderm and mesoderm while at the same time 
promoting neuroectoderm development. Although the exact mechanisms are not 
understood it was hypothesised that insulin removal and addition of PGI2 and 
SB203580 might, at least in part, be inducing cardiac differentiation indirectly 
through endoderm formation. This was suggested based on the up-regulation of 
endoderm markers, especially those of visceral endoderm, preceding cardiac 
development in this system. It was further suggested that inhibitory effects of insulin 
were mediated through activation of the PI3K/Akt pathway. 
 
Overall, serum-free medium supplemented with PGI2 and SB203580 induced cardiac 
differentiation at levels similar to END-2 CM alone but less than END-2 CM 
supplemented with SB203580. Unlike END-2 CM however, the newly developed 
chemically defined differentiation medium was compatible with GMP and offered 
opportunities to act as a platform for additional screens for cardiogenic small 
molecules. While subsequently this co-culture protocol was not further improved 
with regards to differentiation efficiency, it was slightly altered with respect to 
maintenance of derived cardiomyocytes. After initial differentiation cardiomyocytes 
were re-plated onto new END-2 cells followed by short-term culture in three 
dimensional aggregates152. Cardiomyocytes maintained under these conditions for up 
to one year showed enhanced electrophysiological maturation, an aspect particularly 







1.2.5.3 Guided differentiation 
Co-culture with endoderm-like END-2 cells had shown that even in vitro, cues from 
endodermal cells can be sufficient to direct undifferentiated cells towards cardiac 
commitment, suggesting that developmental cues might be recapitulated in a dish to 
initiate cardiomyocyte differentiation via mesoderm and subsequently cardiac 
mesoderm development. Employing members of the three major families of growth 
factors associated with cardiac induction (BMP, activin, Wnt)153, guided cardiac 
differentiation was developed as an in vitro adaptation of in vivo cardiogenesis 
during embryonic development. Both EB and monolayer based protocols were 
developed independently by two groups and although the composition of 
differentiation media changed over time, the principal of stepwise induction of 
mesoderm followed by cardiac mesoderm and finally cardiomyocyte commitment 
remained. Initially, induction of mesoderm was achieved through media 
supplemented with growth factors of the transforming growth factor beta (TGF-β) 
family before the role of canonical Wnt signalling was fully appreciated and while in 
the beginning protocols were developed using hES cells and recombinant proteins, in 
time they were complimented or replaced by iPS cells and small molecules. 
 
 
Mesoderm induction through growth factors 
The first published guided differentiation protocols employed factors that had been 
shown in species like Xenopus154, chicken155 and mice156 to induce mesoderm 
formation and cardiac linage commitment. In 2007 Laflamme et al. showed that a 
high density monolayer of H7 hES cells could be differentiated to spontaneously 
contracting cells using activin A and bone morphogenetic protein 4 (BMP4)157. 
1x105 undifferentiated single hES cells were seeded per cm2 and were culture 
feeder-free in MEF-conditioned medium for 6 days. Differentiation was initiated 
with RPMI/B27 medium supplemented with 100 ng/mL human recombinant 
activin A for 24 hours, followed by 10 ng/mL human recombinant BMP4 for 4 days. 
Spontaneous contractions were observed after 7 additional days in RPMI/B27 
medium supplemented with knockout serum replacement (KOSR) with yields 
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consistently >30% cardiomyocytes. A serum-free version of this protocol achieved 
similar efficiencies158.  
 
At the same time a similar protocol was developed focusing not only on mesoderm 
induction through activin A and BMP4 media supplements but also investigated the 
role of canonical Wnt signalling in human cardiac differentiation159. Stage-specific 
inhibition of the canonical Wnt pathway had previously been shown to be a 
requirement for cardiac development in other species160-162. The 3-stage protocol they 
developed used vascular endothelial growth factor (VEGF), human basic fibroblast 
growth factor (bFGF) and Dickkopf-related protein 1 (DKK1), a canonical Wnt 
inhibitor, in addition to BMP4 and activin A. During the first stage, formation of a 
primitive-streak-like population and mesoderm is induced in EBs with 0.5 ng/mL 
BMP4 for 24 hours and 10 ng/mL BMP4, 5 ng/mL bFGF and 3 ng/mL activin A for 
4 days. Stage 2, cardiac mesoderm induction through 150 ng/mL DKK1 and 
10 ng/mL VEGF for 4 days, is followed by stage 3, expansion of cardiovascular 
lineages, during which EBs are treated with 10 ng/mL VEGF, 150 ng/mL DKK1 and 
5 ng/mL bFGF for 6 days. For the first 10-12 days EBs are cultured under hypoxic 
(5% O2) conditions, which was then followed by normoxia. In their hands activing A 
and BMP4 alone were sufficient to induce mesoderm and cardiac linage formation 
but addition of FGF increased differentiation efficiency from 20% to 40% 
cardiomyocytes. Although supplementation of differentiation medium with 
Wnt inhibitor DKK1 increased overall efficiency only slightly 
(~45% cardiomyocytes), experiments indicated that stage-specific inhibition of 
canonical Wnt signalling is crucial for cardiac differentiation. While Wnt3a increased 
cardiac differentiation when added during mesoderm specification (day 0-4), it 
completely inhibited it when added afterwards (day 4). Conversely, DKK1 had the 
opposite effect by completely inhibiting cardiac linage formation when added during 







The role of canonical Wnt signalling in cardiac differentiation 
A subsequent study further investigated the mechanisms by which this biphasic 
stage-specific activation and inhibition of canonical Wnt signalling regulates cardiac 
differentiation134. EBs derived from 3 hES cell lines were treated with Wnt3a for 
48 hours in serum-supplemented medium, followed by a further 4 days in suspension 
without Wnt3a before being plated onto gelatine coated dishes in serum-reduced 
medium. Finally, on day 8 after EB formation medium was changed to serum-free 
medium. This protocol was optimised by varying serum concentrations at every stage 
and supplementing medium with several compounds including different Wnt 
isoforms for the first 48 hours. Alternatively, instead of EBs undifferentiated 
monolayers were used but showed drastically reduced expression of cardiac markers. 
Lack of serum at the beginning decreased EB size and although it resulted in the 
highest expression of mesoderm markers, EBs showed low expression of cardiac 
genes. High serum and insulin levels throughout differentiation on the other hand, 
drastically reduced cardiac formation. As observed previously by other groups, EB 
size had a significant influence on differentiation efficiency137. Comparison of the 
different compounds showed that cardiogenic effects were restricted to Wnt3a. 
Wnt3a alone was sufficient to induce mesoderm and cardiac lineage formation by 
activating β-catenin through stabilisation and nuclear translocation. 
 
In hES cell differentiation, activin A and BMP4 were shown to induce endogenous 
canonical Wnt expression and low expression in some cell lines was linked to 
reduced cardiogenic potential163 which could explain some of the variability seen 
between cell lines. Cardiac differentiation efficacy of these cell lines could be 
increased by addition of exogenous Wnt3a throughout early stages of differentiation. 
Alternatively, efficient cardiac differentiation (>60% cardiomyocytes) was achieved 
in a number of hES and iPS cell lines through optimisation of exogenous activin A 
and BMP4 concentrations, activin and/or BMP antagonists and differentiation 






Moving forward after better understanding the mechanisms controlling mesoderm 
induction, efforts were made to further reduce inter-line variability of differentiation 
efficiency and finding small molecules to compliment or replace recombinant 
proteins.  
 
Addressing the former, Burridge et al. developed a protocol that combined 
knowledge of chemically defined medium to induce mesoderm with that of the 
impact of EB size on successful cardiac differentiation139. It was developed through 
step-by-step optimisation of >45 parameters grouped in 4 phases that included 
pluripotent stem cell culture prior to differentiation, mesoderm induction, cardiac 
specification and finally cardiomyocyte development. For the final protocol, 
undifferentiated cells were grown feeder-free in monolayers for a minimum of 
3 passages before differentiation, creating a uniform pluripotent stem cell population. 
Forced aggregates, each containing 5000 of these cells, were formed with RPMI and 
polyvinyl alcohol in uncoated 96 well V-bottom plates and mesoderm formation was 
induced with 25 ng/mL of BMP4 and 5 ng/mL of FGF2 for the first 48 hours. For 
cardiac specification, medium was replaced with RPMI supplemented with 20% 
serum on day 2.  Maturation and final cardiomyocyte development was achieved 
through attachment of forced aggregates to a tissue culture surface when transferred 
to coated 96 well U-bottom plates in serum-free medium on day 4. This protocol, 
derived using one hES cell line and subsequently tested with a further 3 hES and 7 
iPS cell lines, consistently yielded 95% beating bodies, making it faster, more 
efficient and more reliable than previous guided differentiation protocols. On the 
other hand continued culture of pluripotent stem cells as single cells and forced 
aggregation make it also technically more challenging. 
 
 
Growth factor-free cardiac differentiation 
Concerning the identification of cardiogenic small molecules, two approaches have 
been taken: unbiased screens that might reveal new previously unknown pathways by 
which cardiomyogenesis is controlled, and biased screening, with a clear function 
and target pathway in mind. The first approach identified several compounds 
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including but not limited to DMSO165, ascorbic acid166, cardiogenols167 and 
sulfonyl-hydrazones168 and while some have a wide range of effects on cells (DMSO, 
ascorbic acid), others are specific to pathways involved in cardiogenesis 
(sulfonyl-hydrazones). However, not every compound identified this way can been 
linked to a definitive pathway and the mechanisms by which they promote cardiac 
differentiation remain poorly understood (SB203580)149.  
 
The second approach usually employs molecules previously identified to act on a 
certain pathway and are used to replace recombinant proteins making protocols 
cheaper, more easily scalable and bringing them closer to GMP standards for 
possible future clinical applications. One such example is the completely growth 
factor-free protocol developed by Lian et al. guiding cardiac differentiation solely by 
manipulating canonical Wnt signalling169. Using genetically engineered cell lines 
with dox-inducible knock-down of β-catenin they confirmed that knock-down of 
β-catenin during the first days of differentiation completely inhibits cardiac 
differentiation while doing the same after mesoderm induction increases 
differentiation efficiency. Unlike other protocols described thus far, mesoderm 
induction was achieved through use of glycogen synthase kinase 3 (GSK-3) 
inhibitors in place of activin A or BMP4. GSK-3 is a serine/threonine protein kinase 
that, among many other things, phosphorylates β-catenin thereby marking it for 
degradation. By inhibiting GSK-3, phosphorylation and degradation of β-catenin are 
prevented and activation of the canonical Wnt pathway leads to mesoderm induction. 
GSK-3 inhibition increased cardiac differentiation efficiencies drastically in both EB 
and monolayer systems. In their final protocol feeder-free pluripotent stem cells were 
seeded in a high-density monolayer and cultured for 5 days. Differentiation was 
initiated with RPMI/B27-insulin supplemented with a small molecule 
GSK-3 inhibitor (BIO or CHIR99021) for 24 hours followed by 2 days in 
RPMI/B27-insulin. After mesoderm induction, the canonical Wnt pathway was 
inhibited for 2 days with RPMI/B27-insulin supplemented with a small molecule 
Wnt inhibitor (IWP2 or IWP4). On day 5 medium was changed to RPMI/B27-insulin 
to be replaced by RPMI/B27 on day 7. This serum- and growth factor-free protocol 
consistently yielded more than 82% cardiomyocytes with three hES and three iPS 
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cell lines showing that manipulation of endogenous Wnt signalling is sufficient to 
drive undifferentiated stem cells towards a cardiac fate and while addition of 
exogenous activin A and BMP4 in that scenario is not necessary, inhibition of their 
endogenous counterparts at the same time drastically reduces cardiac differentiation 
efficiency.   
 
Taken together, hES and iPS cells differentiated in vitro not only represent a 
continuous supply of desired cell types such as cardiomyocytes but also provide a 
tool with which to study development. Investigations into Wnt signalling were driven 
by a desire to improve in vitro cardiac differentiation and not only provided the field 
with far more reliable, robust and efficient differentiation protocols with reduced 
inter-line variability, but also delivered new insight into the mechanisms involved in 
the control of mesoderm formation.  
 
 
1.3 Cardiomyocyte Biology 
 All of the information on cardiomyocyte physiology and function provided in this 




1.3.1 Physiology and structure 
The heart muscle, or myocardium, is located between layers of simple squamous 
epithelium called endocardium and epicardium, and is mostly made up of 
cardiomyocytes. There are a number of cardiomyocyte subtypes that differ in 
physiological aspects relating to their electrophysiological properties. Pacemaker 
cells, located in the sinoatrial node, spontaneously depolarise and initiate contraction, 
thereby controlling the heart-rate. Atrial cells are generally smaller then ventricular 
cells with fewer myofibrils, fewer transvers tubules (t-tubules) and a slightly 
different action potential pattern. Both contract in response to stimulation of 
pacemaker cells in a coordinated manner. Other subtypes include cells of the AV 
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node, conducting the pacemaker stimulation from atrium to ventricle, and cells of the 
Purkinje fibres conducting the stimulation signal throughout the ventricles. The 
following description will mainly be focusing on ventricular cardiomyocytes, the 
subtype causing fatal arrhythmias in patients with Brugada Syndrome.  
 
A typical cardiomyocyte, rod-shaped and branched, measures 100 µm in length and 
10 µm in width, contains one nucleus, mitochondria that take up 25-30% of the cell’s 
volume, several myofibrils, an extensive sarcoplasmic reticulum network and 
invaginations of the cell membrane called t-tubules (Figure 5). Cardiomyocytes are 
connected through intercalated discs allowing them to act as an electrical and 











Figure 5: Schematic of cardiac muscle cell 
 
 
1.3.1.1 Myofibrils and sarcomeres 
Myofibrils are bundles of fibres that run along the length of every cardiomyocyte and 
form their contractile apparatus. Thin filaments, mainly composed of actin 
molecules, and thick filaments, primarily composed of myosin molecules, are 
organised in sarcomeres, the repeating functional units of myofibrils. Each sarcomere 
is bordered by Z-lines and while thin filaments anchored at those Z-lines extent 
towards the middle (M-line), thick filaments are anchored at the M-line and extend 
towards the Z-lines (Figure 6). The binding of myosin to actin is what leads to 
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contraction and is described in more detail later on. The area surrounding the Z-line, 
where in a relaxed state thin filaments are not overlapping with thick filaments, are 
called I-bands. The area between two I-bands covering the entire length of a thick 
filament is labelled A-band, while the area surrounding the M-line where thick 
filaments are not overlapping with thin filaments is called H-band.  
 
Thin filaments are formed by monomeric (globular) actin molecules that polymerise 
into filamentous actin, a two-stranded helix, stretching along the cytoskeletal protein 
nebulin. Filamentous actin strands are anchored to Z-lines by α-actinin and capZ 
protein while tropomodulin, located at the other end of a thin filament, is thought to 
help regulate a filaments length. Actin filaments have myosin binding sites which in 
a relaxed muscle are covered by tropomyosin dimers. The binding of each 
tropomyosin dimer to the actin filament is facilitated by a troponin complex 
consisting of troponin C, troponin I and troponin T. 
 
Thick filaments are formed by polymerisation of myosin molecules. Each myosin 
molecule consists of one pair of heavy chains and two pairs of light chains. The 
C-terminus of each of the two heavy chains is called the tail region and together they 
form an α-helix. The N-terminus of each heavy chain, termed the head region, is 
associated with a pair of light chains and extents away from the thick and towards the 
thin filament. The head region is the part that during contraction interacts with the 
actin filament. It also has an ATPase activity essential during contraction which is 
modulated by one of the light chains. Thick filaments are connected to Z-lines 
through large elastic proteins called titin, which extend from Z-lines to M-lines. In 
the A-band, where thin and thick filaments overlap, each thin filament is surrounded 
by three thick filaments, while each thick filament is surrounded by 6 thin filaments. 
Along a thick filament myosin molecules are oriented in a helical array such that 




















Figure 6: Schematic of a single relaxed sarcomere 
 
 
1.3.1.2 Sarcoplasmic reticulum 
The sarcoplasmic reticulum (SR) is an extensive membrane network, equivalent to 
smooth endoplasmic reticulum in non-muscle cells, enveloping each myofibril in the 
area between two Z-lines. It functions as a calcium storage which releases calcium 
into the sarcoplasm during contraction and again removes it from the sarcoplasm for 
muscle relaxation. In cardiac muscle cells the terminal cisterna of an SR and a 
t-tubule in close proximity form a diad. This structure, located at the Z-lines of 
sarcomeres, plays an important role in excitation-contraction coupling, a process 
described in detail below.  
 
 
1.3.1.3 Intercalated discs 
Once a cardiomyocyte has been excited, the contraction spreads like a wave through 
the heart because neighbouring cardiomyocytes are connected through intercalated 
discs at their bipolar ends. Intercalated discs, always coinciding with Z-lines, are an 
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assembly of fascia adherens, desmosomes and gap junctions. Fascia adherens and 
desmosomes form a physical connection between two adjacent cardiomyocytes 
preventing damage during contractions. Fascia adherens establish intercellular 
contact through N-cadherin and anchor actin filaments of the nearest sarcomere 
through catenin and plakoglobin. At desmosomes, cadherins establish intercellular 
contact while desmoplakin, plakophilin, and plakoglobin anchor intermediate 
filaments171. Gap junctions form a direct electrical connection between the 
sarcoplasm of neighbouring cardiomyocytes. Hemichannels (connexons) shaped by 
six connexin molecules in each of the adjacent cell membranes connect to form a gap 
junction that is non-discriminately permeable to small ions. The connexin isoform 




Contraction of the heart is initiated by pacemaker cells in the sinoatrial node that 
spontaneously depolarise, generating an action potential. This initial action potential 
propagates through gap junctions from the sinoatrial node to atria, atrioventricular 
node and finally ventricles. In each cardiomyocyte action potentials trigger 
calcium-induced calcium release which results in contraction. This mechanism is 
called excitation-contraction coupling. 
  
 
1.3.2.1 Action potential 
Basis for any action potential is a concentration gradient of ions across the cell 
membrane. While extracellular concentration of sodium and calcium ions far 
supersedes their intracellular concentration, the opposite is true for potassium ions. 
Electrical and concentration gradients are defined by the electrochemical equilibrium 
for each ion. The normal membrane or resting potential of -90 mV is mostly 
determined by the equilibrium potential for potassium due to the relatively higher 
permeability of the membrane for potassium compared to other ions. Through the 
influx of ions from an excited neighbouring cardiomyocyte (through gap junctions) 
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the membrane potential becomes less negative. Should this increase pass the 
threshold of around -65 mV an action potential is initiated. An action potential 
travels as a wave of depolarisation along the length of a cell, the wave of 
depolarisation propagating in form of local circuit currents. Reaching the end of the 
cardiomyocyte the action potential propagates to the next cardiomyocyte through gap 
junctions.  
 
Action potentials in ventricular cardiomyocytes are characterised by 5 phases. In an 
action potential recording (Figure 7) the initial fast upstroke (depolarisation) is 












Figure 7: Schematic of a ventricular action potential 
ERP – effective refractory period, RRP – relative refractory period 
 
 
During the first phase, a sudden change in membrane potential causes voltage-gated 
sodium channels to increase their open probability for a very short time. The 
electrochemical gradient causes a drastic influx of sodium ions (INa) through the open 
channels resulting in fast depolarisation. Almost immediately after activation, a 
conformation change occurs in sodium channels shifting them into an inactive state. 
As long as they are in this inactive state (effective refractory period) they cannot be 
activated again. During the relative refractory period, channels gradually change 
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their conformation once more to the closed state, in which activation is again 
possible. This mechanism contributes to prevent sustained contraction and allows 
complete relaxation. The second phase begins with the opening of voltage-gated 
potassium channels triggered by the sudden decrease of membrane potential. The 
resulting transient outward current (Ito) starts to counteract sodium influx and the 
membrane potential begins to become more negative. The size of the notch in this 
early repolarisation phase is dependent on Ito density, which in the left ventricle is 
higher in epicardium and mid-myocardium compared to endocardium. In the third 
phase, the slight repolarisation caused by potassium efflux (Ito) opens voltage-gated 
L-type and T-type calcium channels as well as delayed rectifier potassium channels. 
The simultaneous continued efflux of potassium as Ito, IK and IK1 and influx of 
calcium balance each other out creating an action potential plateau. The fourth phase 
is marked by the closing of calcium channels while continued potassium efflux in 
form of Ito, IK, and IK1 drives final repolarisation. During the fifth and last phase, the 
resting state, electrochemical equilibria are restored to their pre-action potential state. 
The sodium-potassium-ATPase is utilised to transport potassium in while 
simultaneously transporting sodium out of the cell; with the energy gained through 
hydrolysis of one ATP molecule, three sodium and two potassium ions are 
transported. Calcium in turn is transported out of the cell through a calcium-ATPase 
pump (PMCa1b) and through the sodium-calcium exchanger (NCX1), an antiporter 
that carries three sodium ions into the cell in exchange for transporting one calcium 
ion out of the cell.  
 
 
1.3.2.2 Calcium-induced calcium release 
Calcium influx through L-type calcium channels during the third phase of an action 
potential causes calcium-induced calcium release (CICR) and is crucial for 
contraction in cardiomyocytes. Terminal cisternae of the SR, located near t-tubules 
above Z-lines, are enriched in ryanodine receptors. Ryanodine receptors are 
homotetrameric calcium-gated calcium channels that open in response to calcium 
entering the cell. RyR2, the cardiac ryanodine receptor isoform, forms a complex 
with junctin, triadin, and calsequestrin. Junctin and triadin are located in the SR 
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membrane near RyR2 and bind to both RyR2 channels and calsequestrin. 
Calsequestrin, a protein with low affinity for calcium, is located in the lumen of the 
SR particularly at the terminal cisternae. Its low-affinity binding of calcium not only 
helps establish the high concentration gradient of calcium across the SR membrane 
but also a quick release into the cytoplasm upon opening of RyR2. Another protein 
with a low affinity for calcium, histidine-rich calcium-binding protein (HRC), is also 
present in the lumen of the SR albeit at a lower concentration. Opening of RyR2 
leads to a massive calcium release from the SR causing a dramatic increase in 
intracellular calcium concentration. Calcium released into the cytoplasm this way 
binds to the troponin complexes exposing the myosin binding sides which results in 
contraction. The onset of contraction coincides with the peak of intracellular calcium 
concentration and maximum contraction corresponds approximately with calcium 
concentration half returned to baseline. 
 
In cardiomyocytes, even in the absence of extracellular calcium an action potential 
can be initiated. Without the influx of calcium however no calcium release from the 
SR is triggered and no contraction occurs.  
 
 
1.3.2.3 Contraction and relaxation 
During contraction, myosin molecules of thick filaments bind to actin molecules of 
thin filaments resulting in a sliding of the two filaments along each other. In the 
relaxed state, however, the myosin binding sites on the actin filaments are blocked by 
tropomyosin. Each tropomyosin dimer lies in the cleft of the actin double helix 
spanning 7 globular actin monomers and adjacent tropomyosin molecules are 
arranged head-to-tail. Inhibition of myosin binding through tropomyosin is facilitated 
by a complex of three troponins. Tropomyosin overlaps with the N-terminus of 
troponin T while the C-terminus of troponin T binds to troponin C and troponin I, 
which in turn interacts with actin. Troponin C has 4 calcium binding sites, two with 
high and two with low affinity for calcium. The two high-affinity sites bind calcium 
even in the relaxed state and appear to regulate interaction of troponin I and 
troponin T. Low-affinity sites in contrast only bind calcium after CICR when 
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intracellular calcium concentration crosses a threshold. Binding of calcium causes a 
conformational change that increases binding of troponin C and troponin I, which 
causes the latter to be released from the actin filament. This conformational shift 
increases tropomyosin movement exposing myosin binding sites. Because 
contraction is controlled by inhibition and exposure of myosin binding sites on actin 
filaments, it is said to be thin filament dependent.   
 
The binding and release of myosin is collectively termed the cross-bridge cycle, 
during which chemical energy stored as ATP is transformed into mechanical energy 
of contraction. In its relaxed state, myosin has partially hydrolysed ATP bound. Upon 
exposure of myosin binding sites due to increase in intracellular calcium 
concentration, a myosin head binds to an actin molecule creating a cross-bridge. 
Complete hydrolysis, resulting in the release of ADP and inorganic phosphate (Pi), 
causes a conformational change of the myosin head, pulling the actin filament 
towards the centre of the sarcomere. This change in conformation, also called ratchet 
action, is what causes the sliding of filaments. Binding of a new ATP molecule 
causes myosin to be released from actin and partial hydrolysis causes the myosin 
head to change its conformation back to the original state. As long as myosin binding 
sites on actin filaments are exposed, this cross-bridge cycle continues, progressively 
shortening the sarcomere until calcium is sequestered back into the SR. The 
shortening of a sarcomere during contraction is a consequence of the bipolar 
orientation of myosin molecules at the M-line. While at the M-line myosin molecules 
are arranged tail-to-tail, thick filaments polymerise away from the midline in a 
head-to-tail association resulting in Z-lines being drawn together towards the centre 
of the sarcomere during contraction. 
 
Relaxation after contraction occurs when intracellular calcium is extruded from the 
cytoplasm. Approximately 30% of intracellular calcium present during contraction 
will have entered the cell through voltage-gated calcium channels to trigger release 
of the remaining 70% from the SR. Were all intracellular calcium to be taken up by 
the SR at the end of contraction, the amount of calcium stored in the SR would 
continuously increase and result in calcium overload. Restoring cytosolic calcium 
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concentration to base-level therefore requires mechanisms by which calcium can be 
extruded from the cell as well as re-sequestered into the SR. As described above the 
sodium-calcium exchanger in the cell membrane transports one calcium ion out by 
using the electro-chemically favourable transport of three sodium ions into the cell. 
Up-take by the SR takes place through a calcium pump called sarcoplasmic 
endoplasmic reticulum calcium ATPase (SERCA) found in the SR membrane. For 
each ATP molecule SERCA hydrolyses it transports two calcium ions into the SR 
lumen. Although SERCA is less abundant than the sodium-calcium exchanger is has 
a greater affinity for calcium and therefore accounts for a greater percentage of 
calcium extrusion. With the removal of intracellular calcium the 
troponin-tropomyosin complex returns to its previous position at myosin binding 







I) Brugada Syndrome can be modelled in vitro using cardiomyocytes derived 
from induced pluripotent stem cells. 
 
II) Human stem cell-derived cardiomyocytes are structurally and functionally 






















I) To establish comprehensive tests to assess pluripotency and differentiation 
potential of pluripotent stem cells and to systematically compare and optimise 
cardiac differentiation protocols to establish a reliable, efficient and robust 
protocol. (Chapter3) 
 
II) To assess the maturity and functionality of pluripotent stem cell-derived 
cardiomyocytes by comparing them to isolated primary human adult and foetal 
cardiomyocytes. (Chapter 4) 
 
III) To generate iPS cells from a Brugada Syndrome patient and controls, to assess 
their pluripotency and differentiation potential, and to characterise 




















2.1 Solutions and media 
2.1.1 Solutions and reagents 
  
Reagent Supplier Catalogue number 
Boric acid Sigma-Aldrich 6768 




Phosphate buffered saline 
(PBS) 
LifeTechnologies 003002 
Paraformaldehyde (PFA) Sigma-Aldrich 158127 
Sodium phosphate  
dibasic anhydrous 
Sigma-Aldrich RES20908-A7 
Sodium phosphate  
monobasic dihydrate 
Sigma-Aldrich 71505 
Trizma base Sigma-Aldrich T1503 
Tween 20  Sigma-Aldrich P2287 
Matrigel BDBiosciences 354230 












A 200 U/mL collagenase IV solution was prepared in KO-DMEM, filter sterilised, 
aliquoted and stored at -20°. 
 
M buffer  




4% (w/v) PFA powder was added to PBS, heated to 60°C, and cleared by the addition 
of 1 M NaOH. Paraformaldehyde is an insoluble polymer. NaOH catalyses the 
hydrolysis to methylene hydrate, while addition of heat accelerates the reaction. 
 
PBS 1 PBS tablet dissolved in 500 mL MilliQ water 
 
PBST      PBS supplemented with 0.1% (v/v) Tween 20 
 
0.2 M Phosphate buffer (PO buffer) 
20.44 g Sodium phosphate dibasic anhydrous 
7.79 g Sodium phosphate monobasic dihydrate 
MilliQ water ad 1 L, pH 7.2 
 
10x TBE Electrophoresis Buffer  
108 g of Trizma base 
55 g of Boric acid 
7.5 g of EDTA 







2.1.2 Media and supplements 
 
Medium component Abbreviation Supplier 
Catalogue 
number 
B-27 supplement - LifeTechnologies 17504-044 
Bovine Serum Albumin BSA Sigma-Aldrich A7906 
Creatine - Sigma-Aldrich C0780 
Dimethyl sulfoxide DMSO Sigma-Aldrich D2650 
Dulbecco's Modified  
Eagle Medium 
DMEM LifeTechnologies 11995065 
Dulbecco's Modified  





Foetal calf serum FCS LifeTechnologies 10082-139 
Gentamicin, 
AmphotericinB 
- LifeTechnologies R01510 
Human basic fibroblast 
growth factor 
bFGF Peprotech 100-18B 




Knock-Out DMEM KO-DMEM LifeTechnologies 10829018 
Knock-Out Serum 
Replacement 
KOSR LifeTechnologies 10828028 
L-carnitine - Sigma-Aldrich C0283 
L-Glutamine L-Glut LifeTechnologies 25030024 
Medium 199 - LifeTechnologies 11150-059 
MEM Non-Essential 
Amino Acids 
NEAA LifeTechnologies 11140-035 
Penicillin, Streptomycin PenStrep LifeTechnologies 15070063 
RPMI - LifeTechnologies 11875-093 





β-Mercaptoethanol β-Merc LifeTechnologies 31350010 
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Table 3: Composition of growth and differentiation media 
 
Unless otherwise stated: PenStrep – 50 U/mL Penicillin, 50 µg/mL Streptomycin; L-Glut – 2 mM; β-Merc – 0.1 mM; NEAA – 1x 
Medium Base medium Serum (v/v) PenStrep NEAA L-Glut β-Merc Additives 
20% HyClone KO-DMEM 20% HyClone + + + + - 
basic serum-free 
medium (bSF) 
DMEM - - + + + - 




DMEM - + + + + - 





10% HyClone + - - - 
50 µg⁄mL Gentamicin, 
1.25 µg⁄mL Amphotericin B 
iPS medium KO-DMEM 20% KOSR + + + + 10 ng/mL bFGF 
M199 medium Medium 199 2% FCS + - - - 
20 mM taurine, 2 mM 
L-carnitine, 5 mM creatine, 
2 mg/mL BSA 
MEF medium/  
10% FCS 
DMEM 10% FCS + - + - - 





1% (v/v) DMSO 
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2.2 Cell lines 
Table 4: List of commercially obtained and in-house derived cell lines 
 Cell line Sex 
Age of 
donor 





hES cells WA09 (H9) Female N/A Inner cell mass N/A University of Wisconsin 
Human iPS cells  
33-D9 Male 56 
Fibroblast 
(CRL-2465) 
Retroviruses Dr Gareth J. Sullivan172 
34-D6 Female 40 
Fibroblast 
(CRL-2524) 
Retroviruses Dr Gareth J. Sullivan172 
BP-C5 Male 69 Fibroblast Episomal vectors Franziska Sendfeld 
BP-C6 Male 69 Fibroblast Episomal vectors Franziska Sendfeld 
BP-C11 Male 69 Fibroblast Episomal vectors Franziska Sendfeld 
BP-C15 Male 69 Fibroblast Episomal vectors Franziska Sendfeld 
BP-C26 Male 69 Fibroblast Episomal vectors Franziska Sendfeld 
HV3-C11 Male 65 Fibroblast Episomal vectors Franziska Sendfeld 
HV3-C19 Male 65 Fibroblast Episomal vectors Franziska Sendfeld 
HV3-C23 Male 65 Fibroblast Episomal vectors Franziska Sendfeld 
HV3-C24 Male 65 Fibroblast Episomal vectors Franziska Sendfeld 
HV3-C28 Male 65 Fibroblast Episomal vectors Franziska Sendfeld 
Fibroblasts 
CRL-2097 Male Neonatal Skin biopsy N/A Dr Gareth J. Sullivan 
BP Male 69 Skin biopsy N/A Franziska Sendfeld 
HV3 Male 65 Skin biopsy N/A Franziska Sendfeld 
BP – Brugada Syndrome patient, SCN5A (c.1100G>A - pARG367HIS); HV3 – Healthy volunteer 3 
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2.3 Isolation of human primary cardiomyocytes 
2.3.1 Isolation of foetal cardiomyocytes 




Buffer 1 Buffer 2 Buffer 3 Buffer 4 
HEPES Sigma-Aldrich H3375 10 mM 10 mM 10 mM 10 mM 
NaCl Sigma-Aldrich S5886 129 mM 129 mM 129 mM 129 mM 
KCl Sigma-Aldrich P5405 4.7 mM 4.7 mM 4.7 mM 4.7 mM 
KH2PO4 Sigma-Aldrich P0662 1.2 mM 1.2 mM 1.2 mM 1.2 mM 
MgSO4 Sigma-Aldrich M2643 1.2 mM 1.2 mM 1.2 mM 1.2 mM 
NaHCO3 Sigma-Aldrich S5761 5 mM 5 mM 5 mM 5 mM 
BSA Sigma-Aldrich A7906 2 mg/mL 2 mg/mL 2 mg/mL 2 mg/mL 
Taurine Sigma-Aldrich T8691 20 mM 20 mM 20 mM 20 mM 
L-carnitine Sigma-Aldrich C0283 2 mM 2 mM 2 mM 2 mM 
Creatine Sigma-Aldrich C0780 5 mM 5 mM 5 mM 5 mM 
BDM Sigma-Aldrich B0753 30 mM 30 mM 30 mM 30 mM 
Protease XXIV Sigma-Aldrich P8038 - 4 U/mL - - 
Collagenase A Roche 10103578001 - - 1 mg/mL 1 mg/mL 
Hyaluronidase Sigma-Aldrich H3506 - - 0.5 mg/mL - 
pH (NaOH)  
 
7.4 7.4 7.4 7.4 
Glucose Sigma-Aldrich G0350500 5.5 mM 5.5 mM 5.5 mM 5.5 mM 
Based on the method published by Mummery et al.173. 
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This study was approved by the South East Scotland Research Ethics Committee 
(REC reference 08/S1101/1) and written informed consent was obtained from all 
subjects. Buffers were prepared as detailed in Table 5, filter-sterilised and stored at 
-20°C in 5 and 10 mL aliquots. Glucose was added to each aliquot after thawing. 
Human foetal cardiac tissue from 11-16 week-old foetuses was obtained from 
patients undergoing elective termination of pregnancy. Cardiac samples were stored 
in PBS on ice immediately after dissection and processed within 30 min. Tissue was 
transferred to Buffer 1 and connective and adipose tissue was removed using 
scalpels, keeping shear stress to a minimum. After carefully mincing the tissue into 
~1 mm3 big pieces, they were washed with Buffer 1 for 3 x 3 min at room 
temperature. A 15 min incubation in Buffer 2 at room temperature was followed by 
3 x 20 min incubations in Buffer 3 and 1 x 20 min incubation in Buffer 4 in a shaking 
water bath at 37°C. Following each incubation in Buffer 3 or 4, supernatants were 
collected, centrifuged at 600 rpm for 4 min at room temperature and pellets 
resuspended in 1 mL of Buffer 1. All resuspended pellets were pooled and Ca2+ 
reintroduced by adding 1 M CaCl2 at 4 min intervals up to a final concentration of 
1.79 mM. Finally the cell suspension was centrifuged at 600 rpm for 4 min at room 
temperature and the pellet resuspended in 10% FCS and plated onto 1% gelatine. 
Alternatively cells were resuspended and plated in M199 medium. 
 
 
2.3.2 Isolation of adult cardiomyocytes 
Based on the method published by Smits at al.174 adult human cardiac ventricular and 
atrial tissue received from the Scottish National Blood Transfusion Service (SNBTS) 
was stored in PBS on ice and processed immediately upon arrival in the laboratory. 
Right atrial appendages from routine cardiac surgery were collected according to 
procedures approved by the South East Scotland SAHSC BioResource committee 
under existing ethical approvals. Written informed consent was obtained from all 
subjects. Cardiac tissue was collected and stored in 10% FCS and processed within 
30 min. Residual blood was washed off of cardiac samples with ice-cold M-buffer, 
adipose and scar tissue was removed with sterile scissors and the remaining tissue 
dissected into ~1 mm3 pieces using sterile scalpels. Minced tissue was transferred to 
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a conical tube, allowed to settle in M-buffer and washed twice with cold PBS, 
removing all serum before the enzymatic digestion. After estimating the volume of 
the tissue, a 1 mg/mL Collagenase A solution was added at a ratio of 1:2.5 and the 
mix was incubated in a 37°C shaking water bath. After 30 min the digested tissue 
was dissociated by pipetting and passed through a 40 μm cell strainer. Cells were 
collected on ice, the cell strainer washed 5 times with cold M-buffer and the 
flow-through collected and pooled on ice. The cell suspension was pelleted at 300 g 
for 5 min at room temperature, washed in cold M-buffer, pelleted again, resuspended 
in 10% FCS or M199 medium and plated onto 1% gelatine coated plastic-ware.  
 
 
2.4 Derivation and maintenance of iPS cells 
2.4.1 Skin biopsy and isolation of fibroblasts 
This study was approved by the South East Scotland Research Ethics Committee 
(REC reference 11-SS-0095) and written informed consent was obtained from all 
subjects. Dermal biopsies were collected in 10% FCS on ice and processed within an 
hour of collection. Tissue was transferred into minimal volume of fibroblast growth 
medium before dissecting off the epidermis and fat with sterile scalpels. The 
remaining tissue was dissected into 1 mm3 pieces. Four tissue pieces were transferred 
to each well of a tissue culture treated 6 well plate, covered by a sterile coverslip, 
leaving room for cell expansion, and slowly submerged in fibroblast growth medium. 
The tissue pieces were cultured at 37°C with 5% CO2 with the first medium change 
carried out after 7 days and subsequently every 4-5 days. Once fibroblasts had grown 
out from the tissue and expanded they were harvested and subsequently passaged 
using enzymatic treatment as follows. After medium had been removed with PBS, 
cells were incubated with 0.25% Trypsin/EDTA for 5 min at 37°C. Trypsin was 
deactivated through addition of medium containing serum. Cells were then harvested 
with minimal agitation to prevent cell damage, pelleted at 1000 rpm for 5 min, 
resuspended in medium and cultured in tissue culture treated flasks with media 




2.4.2 Reprogramming of fibroblasts to induced pluripotent stem cells 
using episomal vectors 
The following Addgene Y4 combination episomal vectors were used:   
pCXLE-hOCT3/4-shp53-F (Addgene 27077; Oct4 & shp53), pCXLE-hSK (Addgene 
27078; Sox2 & Klf), pCXLE-hUL (Addgene 27080; LMyc & Lin28) 
 
Fibroblasts were expanded, harvested as described above and counted using a 
haemocytometer. 0.5 x 106 cells per electroporation were resuspended in 100 L 
Amaxa NHDF buffer (Amaxa NHDF Nucleofector Kit, Lonza, VPD 1001) and 5g 
DNA (1.7 g hOct3/4-shp53, 1.6 g hSK and 1.7 g hUL vectors). The mixture was 
transferred into an Amaxa Nucleofector 2b (Lonza, AAB 1001) cuvette and cells 
were electroporated using program U023. During transfer, care was taken that no 
bubbles were introduced, as these would interfere with transfer of electricity 
resulting in an electric arc. Electroporated cells were resuspended in pre-warmed 
antibiotic-free fibroblast growth medium with an Amaxa pipette and plated in one 
well of a 6 well plate. After 24 hours and then again 4 days post-electroporation 
medium was replaced with 10% FCS. Seven days after electroporation cells were 
lifted with Trypsin/EDTA as described above and re-plated into a 0.1% gelatine 
coated tissue culture treated 10 cm culture dish in 10% FCS. After 24 hours, medium 
was aspirated and replaced with hES cell selection medium TeSR-E8. Media changes 
were subsequently carried out every two days and cell morphology was assessed 
using a Nikon Eclipse TE300 light microscope. Genuine induced pluripotent stem 
cell colonies appeared between 20-25 days after electroporation and were manually 
picked into separate wells of Matrigel coated 4 well plates in TeSR-E8. Colonies 
were treated as individual clones and expanded to give rise to independent cell lines. 
Since episomal vectors do not integrate into the host genome and are not 
co-replicated during cell proliferation, they are lost over time and therefore, clones 
that failed to express pluripotency genes endogenously would not give rise to stable 
pluripotent stem cell lines. 
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2.4.3 Maintenance of pluripotent stem cell lines 
2.4.3.1 Preparation of mouse embryonic fibroblasts (MEFs) as feeder 
cells and production of MEF conditioned medium (MEF CM) 
P0 MEFs were expanded in MEF medium on tissue culture treated flasks at 37°C and 
5% CO2. After reaching confluency, MEFs were harvested, using 
0.25% Trypsin-EDTA as described for fibroblasts, resuspended in MEF medium and 
irradiated at 40 Gy. The right amount of radiation causes DNA damage leading to 
senescence-like growth arrest. Afterwards MEFs were counted, using a 
haemocytometer, pelleted at 1000 rpm for 5 min, resuspended in FCS containing 
10% (v/v) DMSO (Sigma-Aldrich, D2650) and stored in aliquots at -80°C for a week 
before being transferred to liquid nitrogen (LN2). To limit cell death and improve 
recovery after thawing, MEFs were kept on ice whenever possible and were 
transferred to -80°C immediately after resuspension in a minimal volume of freezing 
mix. Alternatively MEFs were bought in from VHBio (07GSC6001G) in aliquots of 
4-5 x 106 cells. 
 
For MEF CM 12.5 x 106 irradiated MEFs were seeded per T225 tissue culture treated 
flask in MEF medium. The medium was replaced with 100 mL iPS medium 
supplemented with 4 ng/mL bFGF the next day and subsequently collected and 
replaced with new media every 24 hours for 7 days. All collected MEF conditioned 
media was pooled, filter sterilised and stored in aliquots at -20°C or -80°C for short 
or long-term storage. 
 
 
2.4.3.2 Feeder-layer system 
Pluripotent stem cells were maintained in iPS medium on Matrigel coated plates 
containing irradiated MEFs (106 cells per 6 well plate) and were cultured at 37°C and 
5% CO2. Media changes were carried out daily and cells were passaged 
enzymatically and mechanically using Collagenase IV and cell scrapers upon 




2.4.3.3 Feeder-free system 
Pluripotent stem cells were maintained on Matrigel coated plates in MEF conditioned 
medium or TeSR-E8 at 37°C and 5% CO2. Media changes were carried out daily and 
cells were passaged chemically and mechanically using sterile cell scrapers and 
0.5 mM EDTA (LifeTechnologies, AM9260G) for 4 min at room temperature.  
 
 
2.5 Differentiation of pluripotent stem cells to 
cardiomyocytes 
2.5.1 Three germ layer differentiation 
Embryoid bodies (EBs) were formed from confluent undifferentiated pluripotent 
stem cell colonies. After a 30 s incubation with Collagenase IV at 37°C, colonies 
were washed with PBS and mechanically disrupted with a sterile pipette to yield 
evenly sized clumps. These clumps were harvested, transferred onto non-treated 
tissue culture dishes and cultured in suspension in EB medium at 37°C and 5% CO2.  
Medium was changed every other day by letting EBs settle in a conical tube, 
carefully aspirating supernatant and resuspending in new medium. On day 7 EBs 
were plated onto 0.1% gelatine coated tissue culture treated plates and cultured for a 
further 10 days, continuing media changes every other day. EBs were fixed and 




2.5.2 Directed hepatic differentiation 
Protocol based on Sullivan et al.172 Undifferentiated pluripotent stem cells were 
cultured feeder-free before direct hepatic differentiation. Upon reaching 40-50% 
confluency the medium was changed to RMPI supplemented with B-27 supplement, 
PenStrep and Wnt3a (50 ng/mL) for 3 days, and with activin A (100 ng/mL) for 
2 days. Media changes were carried out daily for 3 days before changing medium to 
SR-DMSO continuing media changes every other day for 5 days. Hepatocyte 
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morphology was confirmed with a light microscope before fixation and staining for 
hepatic markers (2.6.3.2). 
 
 
2.5.3 END-2 co-culture 
2.5.3.1 Maintenance of END-2 cells 
END-2 (mouse visceral endoderm-like cell line) cells were grown on tissue culture 
treated flasks in END-2 medium at 37°C with 5% CO2. Cells were passaged 




2.5.3.2 Growth arrest of END-2 cells 
For growth arrest through radiation treatment END-2 cells were harvested, counted 
and irradiated as described for MEFs. Gamma radiation doses of 30, 35, 37 and 
40 Gy were tested in order to ensure cells survival and growth arrest.  
 
Alternatively, 100% confluent END-2 cells in a T175 flask were growth arrested 
with mitomycin C (Sigma-Aldrich, M4287). Mitomycin C was added to media at a 
final concentration of 10 µg/mL and incubated with the cells for 2 hours and 45 min. 
It was subsequently washed off with medium once and PBS twice. 
 
 
2.5.3.3 Production of END-2 conditioned medium 
To each T175 flask, 100% confluent with growth arrested END-2 cells, 55 mL of 
END-2 differentiation medium was added immediately after mitomycin C treatment. 
END-2 differentiation medium was conditioned at 37°C and 5% CO2 for 4 days 





2.5.4 Cardiac Differentiation 
Cardiac differentiation protocols previously published by Mummery146, Xu141, 150 and 
Graichen et al.149 were used as the basis for a systematic comparison and 
optimisation to find the most reliable, efficient and robust protocol for the cell lines 
studied in this project. EBs were formed as described above, cultured in suspension 
for up to 20 days without plating or for 4 days before being plated onto 0.1% gelatine 
coated tissue culture treated 6 well plates. Different media for EB formation as well 
as differentiation media with and without 5 μM SB203580 (Tocris, 1202) and 
2 μM PGI2 (Sigma-Aldrich, 18220-1) were tested. Three protocols were then tested 
on three cell lines (33-D9, 34-D6, H9) in biological as well as technical triplicate. 
The comparison is illustrated and discussed in further detail in Chapter 3. Efficiency 
was analysed with regard to the number of beating bodies derived from each well of 




Each of the three protocols was performed for each cell line in technical triplicate as 
well as biological triplicate. Technical triplicates for each experiment were averaged 
and used to calculate the mean and standard error of the mean for biological 
triplicates. Results were expressed as the number of beating bodies as well as the 
percentage of EBs that formed beating bodies per well of undifferentiated stem cells. 
Using GraphPad Prism 5.00 graphs were plotted and statistical analysis was carried 
out. After confirming normal distribution with the D'Agostino and Pearson omnibus 
K2 normality test data was analysed with regard to differences between protocols 
within the same cell line, differences between cell lines using the same protocol and 
differences between days 14 and 17 after EB formation. Differences between cell 
lines using the same protocol were analysed using a one-way analysis of variance 
(ANOVA) with a Tukey post-test. Differences between protocols within the same cell 
line and differences between days 14 and 17 after EB formation were analysed using 
a two-way ANOVA with a Bonferroni post-test. Both post-tests involved correction 
for multiple comparisons giving multiplicity adjusted p values. 
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2.5.5 Disaggregation of beating bodies 




Buffer 1 Buffer 2 Buffer 3 
NaCl Sigma-Aldrich S5886 120 mM 120 mM - 
KCl Sigma-Aldrich P5405 5.4 mM 5.4 mM 85 mM 
MgSO4 Sigma-Aldrich M2643 5 mM 5 mM 5 mM 
Na pyruvate Sigma-Aldrich P5280 5 mM 5 mM 5 mM 
Taurine Sigma-Aldrich T8691 20 mM 20 mM 20 mM 
HEPES Sigma-Aldrich H3784 10 mM 10 mM - 
EGTA Sigma-Aldrich E0396 - - 1 mM 
Creatine Sigma-Aldrich 27890 - - 5 mM 
CaCl2 Sigma-Aldrich C5080 - 30μM - 
K2HPO4 Sigma-Aldrich P3786 - - 30 mM 
Na2ATP Sigma-Aldrich A6419 - - 2 mM 
Collagenase B Roche 1088807 - 1 mg/mL - 
pH (NaOH) 
 
- 6.9 6.9 7.2 
 
Glucose Sigma-Aldrich G8270 20 mM 20 mM 20 mM 
Based on the methods published by Maltsev et al.175 and Mummery et al.176.  
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Buffers were prepared as listed in Table 6, filter-sterilised and stored at -20°C in 
1 mL aliquots. Glucose was added to each aliquot after thawing. Beating areas were 
dissected, transferred into Buffer 1 and incubated at room temperature for 30 min. 
Bodies were then incubated in Buffer 2 at 37°C for 25-45 min, depending on their 
size, before being transferred to Buffer 3 and incubated at 37°C for 1 hour. Finally, 
beating bodies were transferred to 10% FCS, carefully broken up by pipetting 8-12 
times using a P1000 pipette and plated onto 1% gelatine.  Plating disaggregated 
bodies in a minimal amount of medium in droplets enhanced attachment and 
recovery. After 24 hours the medium was topped up and cardiomyocytes started to 
spontaneously contract 24-48 hours post disaggregation. 
 
 
2.6 Characterisation of iPS cells and cardiomyocytes 
2.6.1 Single Nucleotide Polymorphism (SNP) analysis 
2.6.1.1 Sample preparation 
Confluent wells of undifferentiated pluripotent stem cells were harvested with EDTA 
and pelleted at 200 g for 5 min. Cells were washed with PBS, centrifuged again and 
dry pellets were stored at -20°C. Genomic DNA was isolated from cell pellets using 
the MasterPure™ Complete DNA & RNA Purification Kit (Cambio, MC85200) 
according to manufacturer’s specifications.  Purified genomic DNA (500 ng) was 
sent to AROS Applied Biotechnology A/S (Aarhus, Denmark) for single nucleotide 
polymorphism (SNP) analysis. The employed SNP array, Illumina CytoSNP-12, 




The SNP array data was visualised and analysed using the Illumina Genome Viewer 
1.9.0 of the Illumina GenomeStudio V2011.1 software. The Log R ratio and β-Allele 
Frequency (BAF) as indicators for genomic content were plotted and analysed for 
presence of microduplications and deletions. The Log R ratio was calculated as the 
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log2(sample/reference). The BAF was calculated as (B/(A + B)) with A and B 
representing the signals for each SNP. Figure 8 shows each SNP plotted according to 
its genotype with most SNPs clustering in the middle indicating heterozygosity. A 
duplication results in a sample value higher than the reference value and a shift of the 
Log R ratio away from zero towards more positive values. In the BAF plot 
duplications appear as a double band, representing genotypes of AAB or ABB. Loss 
of heterozygosity (LOH) as well as depletions lead to a loss of the heterozygous 
clusters in BAF. Deletions, but not LOH, result in a Log R ratio shift towards more 
negative values. Log R ratio and BAF were analysed for each chromosome for each 














Figure 8: Schematic of SNP array analysis 
The Log R ratio is calculated as the log2(sample/reference). The BAF is calculated as (B/(A + B)) with 
A and B representing the signals for each SNP. Analysed together BAF and Log R ratio can reveal the 
presence of deletions, duplications or loss of heterozygosity.  






The patient chosen for this study had previously undergone genetic testing which 
identified the SCN5A_c.1100G>A variation as the likely cause for his condition. To 
confirm the presence of this variation in the iPS cell lines derived from the Brugada 
Syndrome patient and its absence from the iPS cell lines derived from the healthy 
volunteer, SCN5A was amplified (Verities PCR, Applied Biosystems, Austin, TX, 
USA), the PCR products were purified (ExoSAP-IT, Affymetrix, Inc. USB® 
Products, Cleveland, OH, USA) and they were directly sequenced in both directions 
(Big Dye Terminator v3.1 cycle sequencing kit and 3130XL Genetic Analyzer, both 
from Applied Biosystems). DNA sequences obtained were compared with SCN5A 
reference sequence NM_198056.2 using SeqScape v2.6 (Applied Biosystems). DNA 




2.6.3.1 Cell fixation 
Cultured cells were PBS washed and subsequently fixed in 4% PFA for 10 min on ice 
or in 100% ice-cold methanol for 10 min at room temperature. The fixative was 
removed and cells were PBS washed and stored in PBS at 4°C until staining. PFA 
fixes cells by cross-linking proteins whereas methanol denatures them. Denaturation 
of proteins can cause epitopes to be either exposed or hidden; optimal fixation 





Cells fixed in 4% PFA were permeabilised with Triton X-100 (Sigma-Aldrich, 
T9284) in PBS for 10 min at room temperature. Unspecific antibody binding was 
limited by blocking with serum for 30-45 min and preparing primary antibody 
solutions in PBS supplemented with serum.  Dilutions and staining conditions were 
optimised for each primary antibody and are summarised in Table 7 and Table 8. 
 
Table 7: Antibodies used for immunostaining 
Antibody Specificity Cat # Source Isotype Dilution 
Nanog a AF1997 Goat  IgG 1/100 
Tra-1-60 b sc-21705 Mouse  IgM 1/200 
Oct-4 b sc-101534 Mouse IgG1 1/400 
α-fetoprotein c A8452 Mouse IgG2a 1/500 
β-tubulin III c T8660 Mouse IgG2b 1/1000 
Muscle actin d M0635 Mouse IgG1 1/50 
Cardiac troponin T e ab8295 Mouse IgG1 1/100 
Cardiac troponin I e ab47003 Rabbit IgG 1/100 
Alpha actinin e ab50599 Rat IgG2a 1/300 
Alpha actinin c A5044 Mouse IgM 1/500 
aR&D Systems, bSantaCruz Biotechnology, cSigma-Aldrich, dDako, eAbcam 
71 
 
Table 8: Detailed staining protocols for immunocytochemistry 
Cells were washed with PBS twice in between steps. After the last wash, cells were counterstained and mounted with ProLong Gold 
Antifade Reagent with DAPI (LifeTechnologies, P36935). DAPI (4',6-diamidino-2-phenylindole) is a fluorescent dye that visualises nuclei 
by binding strongly to A-T rich regions of the DNA. Cells grown on plastic were subsequently covered with coverslips. If cells had been 
grown on coverslips, these were transferred onto glass slides, cells facing down. 
 Fixation Permeabilisation and block Primary antibody Secondary antibody 
Nanog 4% PFA 
0.1% Triton X-100 in PBS, 10 min 
3% horse serum in PBS, 30 min 
in 3% horse  
serum in PBS, 1 hour 
Rabbit anti goat Alexa Fluor 568 
1/400 in PBS, 1 hour 
Tra-1-60 4% PFA 
0.1% Triton X-100 in PBS, 10 min 
3% goat serum in PBS, 30 min 
in 3% goat serum in 
PBS, 1 hour 
Goat anti mouse Alexa Fluor 488 
1/400 in PBS, 1 hour 
Oct-4 4% PFA 
0.1% Triton X-100 in PBS, 10 min 
3% goat serum, 30 min 
in 3% goat serum in 
PBS, 1 hour 
Goat anti mouse Alexa Fluor 488 
1/400 in PBS, 1 hour 
α-fetoprotein 100% Methanol 10% goat serum in PBST, 45 min 
in 1% goat serum in 
PBST, 1 hour 
Goat anti mouse Alexa Fluor 488 
1/400 in PBS, 1 hour 
β-tubulin III 100% Methanol 10% goat serum in PBST, 45 min 
in 1% goat serum in 
PBST, 1 hour 
Goat anti mouse Alexa Fluor 488 
1/400 in PBS, 1 hour 
Muscle actin 100% Methanol 10% goat serum in PBST, 45 min 
in 1% goat serum in 
PBST, 1 hour 
Goat anti mouse Alexa Fluor 488 




0.5% Triton X-100 in PBS, 10 min 
3% goat serum, 30 min 
in 3% goat serum in 
PBS, 1 hour 
Goat anti mouse Alexa Fluor 488 




0.5% Triton X-100 in PBS, 10 min 
3% goat serum, 30 min 
in 3% goat serum in 
PBS, 1 hour 
Goat anti rabbit Alexa Fluor 568 




0.5% Triton X-100 in PBS, 10 min 
3% goat serum, 30 min 
in 3% goat serum in 
PBS, 1 hour 
Goat anti mouse Alexa Fluor 488 




0.5% Triton X-100 in PBS, 10 min 
3% goat serum, 30 min 
in 3% goat serum in 
PBS, 1 hour 
Chicken anti rat Alexa Fluor 488 
1/400 in PBS, 1 hour 
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2.6.3.3 Tissue sectioning 
Human cardiac tissue samples were processed within 30 min of arrival in the 
laboratory. Samples were washed with PBS and dissected into pieces <1 cm3. Tissue 
pieces were snap frozen for 10 s in an isopentane (Sigma-Aldrich, M32631) bath in 
LN2 before being stored in a small volume of isopentane at -80°C. Frozen tissue 
pieces were mounted onto a metal base with Tissue-Tek O.C.T. Compound (VWR 
International, 25608-930) and sectioned on a Vibratome UltraPro 5000 Cryostat. 
Each 6 µm thick section was transferred onto adhesion slides (VWR International, 
631-0446) and allowed to dry at room temperature overnight. 
 
 
2.6.3.4 Immunohistochemistry  
Tissue sections were fixed in 4% PFA as before or in ice-cold methanol for 2 min, 
followed by 7 min in ice-cold acetone. After permeabilisation with 1 or 2% 
Triton X-100, sections were washed with PBS for 3 x 5 min. Slides were incubated 
with primary antibodies (Table 7) diluted in PBS or PBST for 1 hour at room 
temperature in a moist chamber. After 3 x 5 min washes with PBS, sections were 
incubated with secondary antibodies as described above (Table 8) in a moist 
chamber. Surplus antibodies were removed with 3 x 5 min PBS washes before briefly 
submerging slides in MilliQ water followed by 100% ethanol. Finally, stained tissue 
sections were mounted with DAPI Fluoromount-G (SouthernBiotech, 0100-20) and 
sealed under a coverslip. Slides were left to dry at room temperature in the dark for 
24 hours before imaging. Fluorescent images were acquired at room temperature on a 
Zeiss Axio Observer Z1 motorised microscope using the AxioVision Software or 
Leica TCS SP8 using the Leica Application Suite Advanced Fluorescence Software 







2.6.3.5 Flow cytometry 
For each cell line three independent wells were analysed for expression of 
pluripotency markers SSEA-3 and SSEA-4. Pluripotent stem cells at ~80% 
confluency were incubated with TrypLE Select (LifeTechnologies, 12563-011) at 
37°C, harvested in TeSR-E8 medium, counted and resuspended at 106 cells/mL. Two 
FACS tubes with cell strainer caps were set up with 105 cells each, one for staining, 
and the other one to be used as an unstained control. Cells were double stained 
according to specification given in Table 9 and both stained and unstained cells were 
incubated for 30 min at room temperature in the dark. Cells were then washed with 
PBS and pelleted at 900 rpm (Sigma-Aldrich, 4-16K) for 5 min at room temperature. 
The supernatant was decanted and cells were resuspended in 300 µL of 10% 
BD FACS Lysing solution (BD Biosciences, 349202) and stored at 4°C for up to 
7 days before flow cytometry analysis.  
 






Conjugate Dilution Isotype 
SSEA-3 BioLegend 330306 Alexa Fluor 488 1/50 Rat IgM, κ 
SSEA-4 BD Biosciences 560128 Phycoerythrin (PE) 1/50 Mouse IgG3 
 
Samples were run on a FACS Fortessa Flow Cytometry System acquiring a 
minimum of 10,000 events. Flow cytometry data was analysed using FlowJo 
(Treestar, Inc., San Carlos, CA). A general gating strategy applied to all samples is 
depicted below. In the unstained controls the cell population of interest was selected 
based on cell-size and granularity (Figure 9 A), excluding dead cells and debris, 
before selecting single cells based on their height (SSC-H) to area (SSC-A) ratio 
(Figure 9 B). Afterwards, a gate was drawn for each conjugate around the negative 
population to exclude false positives before applying these gates to the stained 
samples (Figure 9 C and D). The percentage of false positive cells was subtracted 
from the percentage of positive cells in the stained sample. Colour compensation was 
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applied to compensate for overlapping emission spectra of PE and Alexa Fluor 488. 
Results from three independent replicates for each cell line were pooled, expressed as 

















Figure 9: Representative gating strategy for flow cytometry analysis 
A – cell population, B – single cells, C – Alexa Fluor 488 (SSEA-3) positive cells in unstained 
control, D – PE (SSEA-4) positive cells in unstained control 
 
 
2.6.4 Reverse transcriptase polymerase chain reaction (RT-PCR) 
2.6.4.1 RNA extraction and purification 
RNA was extracted from cells in culture using the single-step method of RNA 
isolation by acid guanidinium thiocyanate-phenol-chloroform extraction developed 
by Chomczynski and Sacchi177. Cells were lysed with TRIzol reagent 
(LifeTechnologies, 15596-026) containing phenol and guanidine isothiocyanate. 
TRIzol preserves RNA integrity while disrupting cells and denaturing proteins 
including RNases. Samples were either processed immediately or stored at 
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-20°C/-80°C. To extract RNA, samples were thawed on ice before adding 200 µL of 
chloroform per 1 mL TRIzol. Organic and aqueous phase were mixed by shaking 
vigorously and separated by centrifuging at 12000 rpm at 4°C for 15 min. In acidic 
conditions RNA partitions into the aqueous phase (top) while hydrophobic denatured 
proteins will partition into the organic phenol-chloroform phase (bottom). RNA was 
precipitated from the aqueous phase by transferring it to a new tube and adding an 
equal volume of isopropanol. After a 30 min incubation on ice RNA was pelleted by 
centrifuging at 12000 rpm for 15 min at 4°C, washed with 70% ethanol and pelleted 
again for 5 min at 4°C and 7500 rpm. After removing the supernatant the RNA pellet 
was air-dried without letting it dry out and resuspended in 20 µL of nuclease-free 
water. Dissolved RNA was stored at -20°C. Extracted RNA was purified with 
RQ1 RNase-Free DNase (Promega, M6101) according to the manufacturer’s 
specifications. In summary, 1 µg of RNA was treated with 1 unit of DNase for 
30-60 min at 37°C. The reaction was then stopped with Stop Solution and DNase 
was deactivated at 65°C for 10 min. Purified RNA was stored at -20°C. 
 
 
2.6.4.2 Complementary DNA synthesis 
Complementary DNA (cDNA) was synthesised by reverse transcribing 0.5-2 µg 
purified RNA using the High Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems, 4368814) according to manufacturer’s specifications in a final volume 
of 20 µL. The synthesis was performed in a Thermo Hybaid MBS 0.5G Satellite 
Thermal Cycler with the following programme: 25°C for 10 min, 37°C for 2 hours 
(reverse transcription) and 85°C for 5 min (reverse transcriptase deactivation). 
Synthesised cDNA was stored at -20°C or used immediately for PCR. For each 
cDNA synthesis a –RT control sample was prepared containing all RT-PCR reagents 
except the reverse transcriptase (RT). PCR amplicons of any –RT samples would 





2.6.4.3 Polymerase chain reaction (PCR) 
Synthesized cDNA was amplified using the AmpliTaq Gold PCR Master Mix 
(Applied Biosystems, 4318739) according to the manufacturer’s specifications with 
12.5 ng cDNA per reaction and primers at 500 nM final concentration. Samples were 
run on a Thermo Hybaid MBS 0.5G Satellite Thermal Cycler with the program 
detailed below.  Steps 2-4 were repeated several times while steps 1, 5 and 6 only ran 
once.  
 
Step 1 (activation of Taq polymerase) :  95°C  – 5 min 
Step 2 (denaturation)    :  95°C  – 15 s  
Step 3 (annealing)    :  TA  – 15 s 
Step 4 (elongation)    :  72°C  – 1.05 min 
Step 5 (final prolongation)   :  72°C  – 7 min 
Step 6      :  4°C  – hold  
 
For analysis 20 µL of PCR product were mixed with 6x loading dye (Promega, 
G1881) and loaded onto a 1.5% (w/v) agarose (Sigma-Aldrich, A9539) gel prepared 
with 1x TBE and 1/25000 GelRed Nucleic Acid Gel Stain (Cambridge Bioscience, 
BT41002). The loading dye contained 0.4% orange G, 0.03% bromophenol blue, 
0.03% xylene cyanol FF to track progress of migration and 15% Ficoll 400, a sucrose 
polymer, to increase the density of the sample to concentrate it at the bottom of the 
well. GelRed, intercalated in double stranded DNA, was visualised with a Gel Doc 
imaging system. A 1kb DNA ladder was run in order to estimate the size of the PCR 
products. The optimal annealing temperature (TA) and number of cycle repeats of 
steps 2-4 were systematically optimised for each primer on one representative cell 
line (34-D6). Reactions with each primer pair were run with 30 cycles at different TA 
employing a temperature gradient covering 54°C, 56°C, 58°C and 60°C (Figure 
10 A). The temperature resulting in the strongest band was chosen for each primer 
pair and used in reactions changing the number of cycles to either 32 or 35 (Figure 
10 B). Each reaction was run with cDNA as well as –RT controls and the conditions 
resulting in the strongest bands for cDNA reactions while showing no genomic DNA 













Figure 10: PCR optimisation of primers for pluripotency markers 
Annealing temperature (TA) and number of amplification cycles were systematically optimised for 
each primer pair on one representative cell line (34-D6). PCR products were run out on a 1.5% 
agarose gel. A – Reactions with primers for Oct-4, Sox2, Klf4, c-Myc, Nanog and β-tubulin were run 
with 30 amplification cycles and a TA gradient (54°C, 56°C, 58°C and 60°C). B – PCR reactions for 
the same primer pairs were repeated with TA=56°C and 32 or 35 amplification cycles. Each reaction 
was run with cDNA as well as –RT controls and the conditions resulting in the strongest bands for 
cDNA reactions while showing no genomic DNA contamination in the –RT controls were chosen for 
each primer pair.  
 
Table 10: Primers used for RT-PCR with optimised conditions 
Gene 
Sequence forward primer (5’->3’) 
























160bp 30 56°C 
TA – annealing temperature 
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2.6.4.4 Real-time quantitative reverse transcription PCR (qPCR) 
qPCR reactions were set up using the GoTaq qPCR Master Mix (Promega, A6001) 
kit with the following protocol. Steps 2-4 were repeated 40 times. 
 
Master Mix  :       10 µL 
Primer mix  :         3 µL 
CXR reference dye :      0.2 µL 
cDNA   :         3 µL 
H2O   :  ad 20 µL 
 
Step 1 (activation of Taq polymerase) :  95°C  – 10 min 
Step 2 (denaturation)     :  95°C  – 10 s  
Step 3 (annealing)     :  56°C  – 15 s 
Step 4 (elongation)     :  72°C  – 20 s 
  
The GoTaq qPCR Master Mix contains the BRYT Green dye, which fluoresces upon 
binding double stranded DNA. As more double stranded DNA is synthesised over the 
course of the PCR reaction the fluorescence signal increases. Fluorescence intensity 
was traced over time using a Rotor-Gene 6000 (Corbett Life Science). In addition to 
BRYT Green, the orange CXR signal was measured in each tube. CXR is a reference 
dye to which the BRYT Green signal was normalised, reducing the error between 
technical replicas. Finally, the melting temperature of each PCR product was 
investigated between 72°C-95°C, increasing temperature by 1°C per step, each step 
being 5 s long. Primer and cDNA concentrations were optimised before generating a 
standard curve for every primer pair. To that end samples were run using 1, 10, 25 
and 50 ng of cDNA per reaction with a final primer concentration of 1500 nM 
(Figure 11 A). Next, final primer concentrations of 50, 100, 250, 500, 1000 and 
1500 nM were compared using 10 ng of cDNA as template. The optimal conditions 
resulting in good amplification as well as no primer dimer formation were identified 
for each primer pair. Primer dimers were identified as secondary peaks in the melt 
curve analysis (Figure 11 B). Using the optimised conditions a standard curve using 
1, 10, 25 and 50 ng of cDNA was generated for each primer pair to confirm R2>0.99 











Figure 11: Optimisation of qPCR conditions 
A – Primers at 1500 nM final concentration were tested with 1, 10, 25 and 
50 ng of H9 cDNA to determine the detection limit of each primer pair.            
B – Primers at final concentrations of 50, 100, 250, 500, 1000 and 1500 nM 
were compared using 10 ng of cDNA as template to identify primer 
concentrations resulting in good amplification as well as no primer dimer 
formation. Primer dimers were identified as secondary peaks in the melt curve 
analysis. C – Using optimised primer concentrations a standard curve with 1, 




In order to investigate the relative expression of pluripotency markers in each 
pluripotent stem cell line, each sample was run in biological triplicate using the 
established optimised qPCR conditions summarised in Table 11. 











Employing the Rotor-Gene 6000 series software 1.7 (Corbett Life Science), all 
BRYT Green signals were normalised to CXR signals before further analysis. Using 
the analysis tool a threshold was set and cycle threshold (Ct) values for each sample 
were exported into Microsoft Excel. Relative expression of each gene of interest 
(GOI) for each sample was calculated by averaging technical triplicates, relating 
expression of the GOI in each sample to the expression of the house-keeping gene in 
the same sample (ΔCt), before normalising expression to the positive control (ΔΔCt) 
and converting it to relative expression (2(-ΔΔCt)). β-actin was used as the 
house-keeping gene while H9 served as positive control. 
 
ΔCt = Ct (GOI) - Ct (House-keeping gene) 
ΔΔCt = ΔCt(sample) – ΔCt(positive control) 
Relative expression = 2(-ΔΔCt) 
 
Biological triplicates were averaged, standard errors of the mean were calculated and 
graphs were plotted using GraphPad Prism 5.00. The relative expression of the gene 
of interest in different cell lines was compared using a one-way ANOVA with either 
the Dunnett’s or Tukey post-test. 
Gene 
Sequence forward primer (5’->3’) 

























2.6.5 Transmission electron microscopy (TEM) 
2.6.5.1 Sample preparation 
Overnight resin:   1:1 (w/w) Araldite CY212 and Dodecenyl Succinic 
Anhydride (DDSA) 
 
Final embedding resin: 11.5 g Araldite CY212, 11 g DDSA, 0.55 mLs Benzyl
    Dimethylamine (BDMA), 0.5 mLs Dibutylphthalate 
 
Araldite CY212 (Agar Scientific, AGR1040) - Epoxy resins 
DDSA (Agar Scientific, AGR1051)   - Hardener for epoxy resins 
BDMA (Agar Scientific, AGR1062)   - Accelerator for epoxy resins 
Dibutylphthalate (Agar Scientific, R1071)  - Plasticisers 
 
In preparation for TEM, samples underwent protein fixation, lipid fixation, 
dehydration and finally embedding in resin. Primary human cardiac tissue from 
foetal hearts, right atrial appendages and donor hearts was processed to yield pieces 
with a maximum diameter of 1 mm. Foetal hearts and right atrial appendages were 
processed within 30 min of obtaining the sample. The width of the sample was 
restricted by the limited penetration abilities of the fixative Glutaraldehyde 
(maximum penetration 0.5 mm). Proteins were fixed with 2.5% Glutaraldehyde 
(Sigma-Aldrich, G5882) in 4% PFA either for 1 hour at room temperature or 
overnight at 4°C. Samples were then either processed or stored up to 7 days at 4°C in 
1% Glutaraldehyde in 0.1 M Phosphate buffer. The fixative was removed with 
3 x 15 min washes in 0.1 M Phosphate buffer. Next, lipids were fixed with 1% OsO4 
in 0.1M Phosphate buffer for 1 hour at room temperature. During fixation osmium 
dioxide is deposited in the polar head regions of lipids resulting in staining of the 
plasma membrane in contrast to cytoplasm178.  
 
Lipid fixation was again followed by 3 x 15 min washes in 0.1 M Phosphate buffer 
and osmium tetroxide waste was deactivated with corn oil. Next, the tissue was 
dehydrated through a series of washes with increasing concentrations of ethanol at 
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50%, 70% and 90% for 3 x 5 min each. Dehydration was finalised with 2 x 10 min 
washes in 100% ethanol and 1 x 10 min wash in propylene oxide (Sigma-Aldrich, 
82320). The tissue was transitioned to embedding resin in a 1:1 (v/v) mixture of 
propylene oxide and overnight resin for 1 hour at room temperature on a carousel. 
After propylene oxide had evaporated the tissue was transferred to overnight resin 
and left overnight on a carousel. The next day, the overnight resin was changed every 
1.5 hours for 3.5 hours after which it was replaced with final embedding resin. Final 
embedding resin was changed every hour for 3 hours to ensure complete replacement 
of the previous resin mixture which would not harden during the final step. For the 
final embedding step tissues were transferred to fresh final embedding resin and left 
in a 60°C oven for 48 hours in order for the resin to fully harden for sectioning.  
 
 
2.6.5.2 Sectioning and analysis 
The final sample preparation including sectioning and staining was done by Stephen 
Mitchell (Manager of TEM facility) as follows. Sections (1 μm thick) were cut on a 
Reichert OMU4 ultramicrotome, stained with Toluidine Blue, and viewed in a light 
microscope to select suitable areas for investigation.  Ultrathin sections (60 nm thick) 
were cut from selected areas, stained in Uranyl Acetate and Lead Citrate then viewed 
in a Philips CM120 Transmission electron microscope.  Images were taken on a 
Gatan Orius CCD camera. 
 
 
2.6.6 Intracellular Ca2+ handling 
2.6.6.1 Sample preparation 
In preparation for intracellular calcium imaging, primary tissue or beating bodies 
were disaggregated as described above (2.5.5 Disaggregation of beating bodies) and 
cells plated onto 1% gelatine coated 22 mm glass coverslips. Cells were washed 
3 times with CM isolation buffer 1 with a final concentration of CaCl2 of 1.78 mM. 
Intracellular Ca2+ was visualised using Fluo-4 (LifeTechnologies, F-14217), a dye 
that fluoresces when it comes in contact with Ca2+. Fluo-4 AM, the 
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non-fluorescent acetoxymethyl ester, was added to CM isolation buffer 1 (CaCl2 
1.78 mM) at a final concentration of 5 µM and cells were incubated for 30 min at 
room temperature in the dark during which the ester diffused into the cells and was 
cleaved into its active fluorescent form. The cells were washed 3 times with CM 
isolation buffer 1 before transferring the coverslip to a coverslip chamber and 
replacing the medium. Cells were incubated for a further 30 min at 37°C and 
5% CO2 before imaging. For investigation of excitation-contraction coupling a 
beating body was incubated for 5 min with 10 µM of the sodium channel blocker 
Tetrodotoxin before imaging.  
 
 
2.6.6.2 Image acquisition and analysis 
Spontaneously contracting cardiomyocytes were imaged at room temperature on an 
Olympus 1X50 microscope through a FITC filter with an optical camera (QImaging 
Retiga-2000R, Fast 1394) linked to the Velocity software (Version 4.2.0.). Videos 
were recorded in black and white at 20x or 40x magnification at a constant 
frame-rate of 17.8 frames per second for 20 s. Videos were analysed using the 
Velocity software version 6. Regions of interest (ROIs) were marked in the centre of 
each recorded cell and fluorescence intensity was traced over time. Data sets were 
exported into Microsoft Excel and fluorescence intensity plotted against time. For 
each cell the data set corresponding to one calcium-flash over a period of 2 s was 
taken, the background fluorescence subtracted, and each data point normalised to the 
peak value. For each cell line 14-35 cells were analysed and data for all analysed 
cells was pooled and each time point plotted as a mean with SEM.  
 
 
2.6.7 Membrane visualisation 
2.6.7.1 Sample preparation 
In preparation for membrane visualisation, primary tissue or beating bodies were 
disaggregated as described above and cells plated onto 1% gelatine coated 22 mm 
glass coverslip. The outer cell membrane of single cardiomyocytes was visualised 
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with the membrane dye Di-8-ANEPPS (Pyridinium, 4-[2-[6-(dioctylamino)-2-
naphthalenyl]ethenyl]-1-(3-sulfopropyl)-, inner salt/ 157134-53-7, LifeTechnologies, 
D-3167). The staining was done up to 72 hours after disaggregation of beating bodies 
and within 48 hours of isolation from primary tissue. This dye is less susceptible to 
internalisation and hence suitable to visualise outer membrane structures such as 
transverse tubules. Di-8-ANEPPS was added to cells in culture medium at a final 
concentration of 5 µM and incubated for 10 min at 37°C. Surplus Di-8-ANEPPS was 
removed with 3 washes of PBS before coverslips were transferred to a coverslip 
chamber and medium was replaced. Cells were incubated for 30 min at 37°C before 
imaging to allow recovery of spontaneous contraction.   
 
 
2.6.7.2 Image acquisition and analysis 
Cardiomyocytes were identified through spontaneous contraction and imaged at 
37°C and 5% CO2 using the Leica TCS SP8 STED. Di-8-ANEPPS was excited at 
400-500nm with the 488 nm line of the argon-ion laser, emission was measured at 
550-700nm. Z-stacks were recorded using the Leica Application Suite Advanced 




Beating bodies were disaggregated and plated onto gelatine-coated glass coverslips 
as described previously for immunocytochemistry. In collaboration with Prof Ramon 
Brugada’s research group at the Universitat de Girona, in particular with Dr Fabiana 
Scornik and Dr Guillermo Pérez, settings for sodium current recordings in single 
stem cell-derived cardiomyocytes were optimised. Electrophysiological recordings 
were performed on singles cells, identified as cardiomyocytes by their morphology 
and/or spontaneous contraction, usually 1-2 days after disaggregation. Short recovery 
time ensured limited attachment to culture plastic. While attachment of cells itself is 
crucial, limited contact area between the cell and the culture surface largely 
contributes to good voltage control. Buffers were prepared as listed in  
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, filter sterilised and stored at -20°C. Pipettes were pulled from glass capillaries 
(BF150-117-10, Sutter Instruments Co) with a PC-10 vertical Puller (Narishige). 
Pipette resistances ranged from 2.8 to 3.5 MΩ when filled with pipette solution. 
Whole cell sodium currents were measured at room temperature using the perforated 
patch-clamp technique in voltage clamp mode. In this set-up, one electrode is placed 
in the bath solution and is connected to ground, while a second electrode, inside a 
glass pipette filled with the mentioned solution, is electrically connected to the 
cytoplasm of a cell of interest. 
 
Table 12: Buffers for electrophysiology 











































A9187 - - 2 mM 




G0350500 ~323 mOsm ~323 mOsm ~305 mOsm 
 







In this perforated patch-clamp setting the pipette solutions ionic composition 
matches that of cytoplasm and contained 240 µg/mL Amphotericin B 
(Sigma-Aldrich, A9528). Over time (~15-30 min) Amphotericin B permeabilises the 
cell membrane, thereby creating an electrical connection between the electrode in the 
pipette and the inside of the target cell. In voltage-clamp experiments the voltage is 
kept constant while changes in current are recorded. Voltage clamp experiments were 
controlled and analysed with an Axopatch 200B amplifier and pClamp 10.2 / 
Digidata 1440A acquisition system (Molecular Devices) and OriginPro 8 software 
(OriginLab Corporation). Data were typically filtered at 5 kHz and sampled at 
20 kHz. To study the relationship of current-density to the voltage applied (I-V), 
currents were elicited by 50 ms depolarising steps (from -80 to +80 mV in 5 mV 
increments) from a holding potential of -120 mV. Current density was calculated by 
normalising the peak current for each applied potential to the cell’s capacitance. A 
cell’s capacitance (Cm) depends on its size and normalisation of recorded currents to 
Cm, termed current density, allowed comparison between different sized cells. The 
current density for each applied potential was plotted as the mean ± SEM using 
GraphPad Prism 5.00.  
 
Initial recordings of H9-derived cardiomyocytes in a bath solution containing 
140 mM sodium showed sodium currents too large to accurately represent 
voltage-dependent sodium channel activation (Figure 12). As mentioned in the 
introduction, in normal sodium conditions, a small change in membrane potential 
leads to a drastic influx of sodium ions, producing large inward currents which make 
it difficult to accurately control the voltage in an experimental setting. In order to get 
a more accurate representation of voltage-dependent sodium channel activation, a 
low sodium bath solution was used. Sodium currents in 34-D6 and BP-derived 

















Figure 12: Sodium current recordings in High Na+ and Low Na+ bath solution 
Sodium currents in a single pluripotent stem cell-derived cardiomyocyte were elicited by increasing 
potentials and recorded in bath solutions containing high (140 mM) or low (40 mM) concentrations of 
sodium. When using High Na+ bath solution, a sudden increase in sodium current was recorded, while 




2.7 Statistical Analysis 
Data was plotted as mean ± SEM and statistically analysed in GraphPad Prism 5.00. 
Normal distribution was confirmed with the D'Agostino and Pearson omnibus K2 
normality test. Differences between independent groups, each consisting of three or 
more samples, were investigated using a one-way ANOVA. To correct for multiple 
comparisons the Tukey post-test was employed in cases where all groups were 
compared to each other and the Dunnett’s post-test in cases where all groups were 
compared to a control group. Where two independent variables were analysed a 


















CHAPTER 3  
 
CHARACTERISATION OF PLURIPOTENT STEM CELLS 





Human embryonic and induced pluripotent stem cells can be differentiated towards 
any lineage, providing a source for otherwise difficult to obtain cell types, including 
cardiomyocytes. Using a set of comprehensive tests, three pluripotent stem cell lines 
(H9, 33-D9, 34-D6) were assessed. Under a light microscope cells showed stem cell 
morphology while quantitative reverse transcription PCR demonstrated expression of 
pluripotency markers Oct-4, Sox2, Nanog and c-Myc. Flow cytometry and 
immunocytochemistry additionally demonstrated presence of pluripotency cell 
surface markers SSEA-3, SSEA-4 and Tra-1-60. All tested pluripotent stem cell lines 
were able to form the three germ layers. SNP analysis identified microduplications in 
H9 in chromosome 7 and 14, both regions are not associated with genes, and one 
common microduplication in 33-D9 and 34-D6 that has been associated with long 
term cell culture. Subsequent differentiation towards cardiomyocytes employed a 
systematic comparison of a variety of protocols investigating efficiency with total 
numbers as well as percentages of beating bodies as the end-point. Results revealed 
significant inter-line variability and found that guided differentiation protocols could 
be used to reliably and efficiently generate beating bodies. Protocols optimised in 
this chapter can be used at subsequent stages to characterise newly generated 
patient-derived iPS cell lines and to efficiently generate beating bodies from them in 





Human embryonic stem (hES) cells can be differentiated into any cell type, 
theoretically offering an unlimited supply of cells of interest that might otherwise be 
difficult to obtain from primary sources. However, in addition to their controversial 
nature, hES cells are less than ideal as a disease model system for numerous reasons. 
Access to hES cells harbouring the disease of interest is very limited and genetically 
manipulating hES cells has its own challenges179. Furthermore, it would require 
knowledge of the genetic background that causes the disease, and therefore limits 
this approach to monogenic diseases. Yamanaka and colleagues105 demonstrated that 
somatic cells can be reprogrammed to a pluripotent state by the introduction of a 
number of transcription factors involved in pluripotency and proliferation180, 181, 
thereby providing an alternative for hES cells. The initial experiments were 
conducted using the transcription factors for octamer-binding transcription factor 4 
(Oct-4), sex determining region Y-box 2 (Sox2), Krüppel-like factor 4 (Klf4) and 
c-Myc, introducing them to the host cell through retroviruses105. The resulting 
reprogrammed cells (induced pluripotent stem (iPS) cells) were almost 
indistinguishable from embryonic stem cells in morphology, cell surface markers, 
gene expression and their ability to differentiate into cells from all three germ layers. 
The major advantage of this technique is that skin cells carrying a desired genetic 
profile can be obtained directly from the patient, reprogrammed and differentiated to 
cells from the specific tissue affected by the disease. Additionally, this technique 
allows the study of mutant proteins in their native environment, including all 
modifier proteins, independent of whether the genetic alteration is known or not.  
 
A variety of differentiation protocols for deriving cardiomyocytes from pluripotent 
stem cells have been published (Figure 13), all of which belong to one of three 
categories. Protocols are based on unguided differentiation, guided differentiation or 
co-culture, with efficiency being the lowest for unguided and highest for guided 
differentiation141, 146, 150. However, comparison of the different protocols is 
complicated by the fact that efficiency might be expressed as either total number or 
percentage of beating bodies. A common problem with most methods remains the 
inter-line variability of cardiac differentiation potential which has been attributed to 
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genetic as well as epigenetic differences between cell lines182, 183. Furthermore, 
considerable heterogeneity of cardiac and non-cardiac cells exists within beating 
bodies. Interestingly, depending on which differentiation protocol is applied the ratio 
of the specific cardiac cell types within the contractile tissue changes184.  
 
Model systems utilising iPS cell technology rely on the fact that the cell lines derived 
are pluripotent and genetically unaltered after reprogramming. Comprehensive tests 
to assess pluripotency and differentiation potential of derived cell lines are therefore 
crucial. Because of the differences in assessment of efficiency and inter-line 
variability, a systematic comparison of cardiac differentiation protocols investigating 
numbers as well as percentages of beating bodies derived from three pluripotent stem 

























Figure 13: Overview of protocols employed to generate cardiomyocytes from iPS and hES cells  
I - Unguided differentiation, EBs are formed from undifferentiated hES and iPS cells and cultured in 
suspension in low-attachment plates for 7 days before being plated onto coated plates185.  Unguided 
differentiation is the least efficient way to generate cardiomyocytes and shows vast inter-line 
variability; II – Guided differentiation, undifferentiated hES and iPS cells are cultured either as a 
feeder-free monolayer or as EBs in suspension in low-attachment plates. Alternatively, for a more 
standardised protocol, 3D structures are formed using the hanging drop or forced aggregate method. 
Monolayer and aggregates are then treated with various factors such as BMP4 and activin-A for 
several days134, 157. EBs are plated onto coated plates after 6 days in suspension. Protocols based on 
guided differentiation show the highest efficiency for generating cardiomyocytes but the same 
inter-line variability as unguided differentiation; III – END-2 co-culture, undifferentiated hES or iPS 
cells are either co-cultured feeder-free with growth arrested END-2 cells or as EBs in END-2 
conditioned medium (END-2 CM). Removal of serum and insulin, as well as supplementation with 






To establish comprehensive tests to assess pluripotency and differentiation potential 
of pluripotent stem cells and to systematically compare and optimise cardiac 
differentiation protocols to establish a reliable, efficient and robust protocol. 
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3.4 Results  
One hES (H9) and two previously generated human iPS cell lines (33-D9 and 34-D6) 
were fully characterised investigating their morphology, genomic integrity, 
expression of pluripotency markers and ability to differentiate into all three germ 
layers. These cell lines were subsequently used to compare efficiency and 
reproducibility of published guided and unguided cardiac differentiation protocols. 
Protocols optimised in this chapter were later used to characterise newly generated 
healthy volunteer and patient-derived iPS cell lines and to efficiently differentiate 




Pluripotent stem cells were cultured either on a mouse embryonic fibroblast (MEF) 
feeder layer or feeder-free in TeSR-E8 medium (Figure 14). The morphology of 
pluripotent stem cells in culture was assessed daily with a light microscope and used 
as an indicator of pluripotency. H9, 33-D9 and 34-D6 grew in flat densely packed 
colonies, cells exhibiting the high nucleus to cytoplasm ratio typical for hES and 
iPS cells. Spontaneously differentiated cells were observed occasionally in the 
feeder-free culture system using TeSR-E8 medium and regularly when cultured on a 
MEF feeder-layer. In addition, colonies grown feeder-free appeared more densely 
packed and survived lower seeding densities after passaging. No obvious differences 






















Figure 14: Morphology of hES and iPS cells in culture 
Representative light microscopy images of human pluripotent stem cell lines H9, 33-D9 and 34-D6 in 
culture on MEFs and feeder-free. Scale bars represent 1000 µm. 
 
 
3.4.2 Chromosomal integrity 
Genomic DNA was extracted from each of the three pluripotent stem cell lines and 
analysed for genomic integrity with a single nucleotide polymorphism (SNP) array. 
Analysis of the LogR ratio in combination with the β-Allele frequency revealed two 
microduplications in H9 and one microduplication each in 33-D9 and 34-D6   
(Figure 15). No microdeletions were detected. A complete list of all chromosomes is 
supplied in the Appendix 1. 
 
Microduplications in H9 were found in chromosome 7 (q11.21, 62.139.338 - 
62.834.662) and chromosome 14 (q23.2, 63.569.297 - 63.668.333) in regions that are 
not associated with known genes. Both 33-D9 and 34-D6 showed microduplications 
in q11.21 in chromosome 20, including ID1, BCL2L1 and HM13, genes expressed in 
hES cells. This particular microduplication has previously been described in cultured 
hES and iPS cells and was expected not to interfere with pluripotency or 
























Figure 15: Microduplications identified through SNP analysis 
Analysis of the β-Allele Frequency of a SNP array revealed microduplications in H9 in 
chromosomes 7 (q11.21, 62.139.338 - 62.834.662) and 14 (q23.2, 63.569.297 - 63.668.333), both in 
non-coding regions. Microduplications in chromosome 20 (q11.21) in 33-D9 and 34-D6 affected 
several genes, including ID1, BCL2L1 and HM13, genes expressed in hES cells. Red box indicates 
position of microduplication. BAF – β-Allele Frequency. 
 
 
3.4.3 Expression of pluripotency markers – Reverse transcription 
polymerase chain reaction  
Expression of pluripotency markers in undifferentiated cultures was investigated 
using reverse transcription followed by polymerase chain reaction (RT-PCR). RNA 
from fibroblasts and undifferentiated cell lines H9, 33-D9 and 34-D6 was extracted, 
purified and reverse transcribed to complementary DNA (cDNA). Reverse 
transcription of messenger RNA (mRNA) to cDNA allows investigation into whether 
a gene of interest is being expressed. To that end, cDNA was PCR amplified using 
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exon spanning primers designed to prevent amplification of genomic DNA. PCR 
conditions for primers for pluripotency markers Oct-4, Sox2, Nanog and c-Myc, and 
the house-keeping gene β-tubulin were optimised with regard to annealing 
temperature and number of amplification cycles as described in Materials and 
Methods (2.6.4.3 Polymerase chain reaction). H9, 33-D9 and 34-D6 showed 
expression of Oct-4, Sox2, Nanog, c-Myc and β-tubulin, while fibroblasts exhibited 
expression of c-Myc and β-tubulin but not Oct-4, Sox2 or Nanog (Figure 16). 
Although the intensity of a band can be indicative of relative expression of the gene 
of interest in different cell lines RT-PCRs are not quantitative. A –RT control sample 
contains all RT-PCR reagents except the reverse transcriptase and therefore PCR 











Figure 16: RT-PCR analysis of pluripotency markers 
RNA from fibroblasts and undifferentiated H9, 33-D9 and 34-D6 was extracted, purified and reverse 
transcribed to cDNA. cDNA was PCR amplified using exon spanning primers for pluripotency 
markers Oct-4, Sox2, Nanog and c-Myc, and the house-keeping gene β-tubulin. PCR products were 
run out on a 1.5% agarose gel and visualised with GelRed Nucleic Acid Gel Stain. H9, 33-D9 and 
34-D6 show expression of β-tubulin, Oct-4, Sox2, Nanog and c-Myc while fibroblasts exhibit 
expression of β-tubulin and c-Myc but not Oct-4, Sox2 or Nanog. Fib – fibroblasts; –RT control – test 








3.4.4 Expression of pluripotency markers – Quantitative RT-PCR 
In order to compare relative expression of pluripotency markers, quantitative 
RT-PCR (qPCR) was employed. RNA from undifferentiated cultures was extracted, 
purified and reverse transcribed as before for each sample in biological triplicate. 
Primer and cDNA concentrations were optimised for each primer-set as detailed in 
Materials and Methods (2.6.4.4 Real-time quantitative reverse transcription PCR) 
and samples were run in technical triplicate. H9, 33-D9, 34-D6 and fibroblasts were 
tested for expression of Oct-4, Sox2, c-Myc and Nanog.  
 
For each sample the expression of the gene of interest was related to expression of 
the house-keeping gene β-actin in the same sample, before normalising expression to 
the positive control H9. Relative expression of all genes of interest, given as the 
mean of biological triplicates with the standard error of the mean (SEM), is shown in 
Figure 17. The relative expression of the gene of interest in different cell lines was 
compared using a one-way analysis of variance (ANOVA) with a Tukey post-test. 
Undifferentiated H9, 33-D9 and 34-D6 express all pluripotency transcription factors 
at similar levels with no significant differences. Fibroblasts, as previously observed 
with RT-PCR, expressed no Oct-4, Sox2 or Nanog but c-Myc at levels not 




















































Figure 17: Pluripotency transcription factor expression 
Relative expression of pluripotency transcription factors Oct-4, Sox2, c-Myc and Nanog was 
investigated in fibroblasts and undifferentiated H9, 33-D9 and 34-D6. Fibroblasts express no Oct-4, 
Sox2 or Nanog but c-Myc. H9, 33-D9 and 34-D6 express pluripotency transcription factors at similar 
levels with no significant differences (one-way ANOVA). Bars represent mean values of biological 
triplicates with error bars representing SEM.  
 
 
3.4.5 Expression of pluripotency markers – Immunocytochemistry 
Undifferentiated pluripotent stem cells were fixed 2 days after passaging and stained 
for pluripotency markers Nanog, Oct-4 and Tra-1-60. Nuclei were counterstained 
with DAPI. As Nanog and Oct-4 are transcription factors, the staining co-localises 
with the DAPI counterstain. Tra-1-60, a keratan sulfate proteoglycan, on the other 
hand is a cell surface antigen. All three cell lines showed Nanog and Oct-4 staining 
co-localising with DAPI and cell surface staining with Tra-1-60 (Figure 18). 
Differentiated cells surrounding the colonies did not stain for pluripotency markers 






















Figure 18: Immunocytochemistry for pluripotency markers Nanog, Oct-4 and Tra-1-60 
H9, 33-D9 and 34-D6 stain positive for pluripotency markers Nanog, Oct-4 and Tra-1-60. Nuclei were 
counterstained with DAPI (blue). Scale bars represent 100 µm. 
 
 
3.4.6 Expression of pluripotency markers – Flow cytometry 
The percentages of stage-specific embryonic antigen 3 (SSEA-3) and SSEA-4 
positive cells in the undifferentiated population of H9, 33-D9 and 34-D6 were 
investigated using flow cytometry. SSEA-3 and SSEA-4 are cell surface markers 
associated with stem cells. Each cell line was harvested, stained and analysed in 
biological triplicate. For each sample an unstained control was used to eliminate false 
positive cells. Cells were gated as described in detail in the Materials and Methods 
(2.6.3.5 Flow cytometry) to include single cells of the cell population of interest and 
exclude debris and cell aggregates. Figure 19 shows representative histograms of 

















Figure 19: Flow cytometry analysis of pluripotency markers SSEA-3 and SSEA-4 
Representative histograms of undifferentiated H9, 33-D9 and 34-D6 stained for cell surface markers 




Results of biological triplicates were pooled and expressed as a mean value with the 
SEM. Undifferentiated cultures of all three cell lines contained a high percentage of 
SSEA-3 (H9 80.1±5.7%, 33-D9 74.7±7%, 34-D6 81.1±2.9%) and SSEA-4 (H9 
88.3±2.2%, 33-D9 85.1±2.4%, 34-D6 92±2.7%) positive cells (Table 13).  
 
Table 13: Percentage of cells expressing SSEA-3 and SSEA-4 
 H9 33-D9 34-D6 
SSEA-3 80.1 ± 5.7 74.7 ± 7.0 81.1 ± 2.9 






3.4.7 Three germ layer formation 
Embryoid bodies (EBs) formed from undifferentiated H9, 33-D9 and 34-D6 grown 
on a feeder layer were cultured in EB medium in suspension for 7 days before being 
cultured for 10 additional days on gelatine coated dishes. EBs were then fixed and 
stained for markers of the three germ layers endoderm (Alpha-fetoprotein, AFP), 
ectoderm (β-tubulin III) and mesoderm (muscle actin). All three pluripotent stem cell 


















Figure 20: Immunocytochemistry for the three germ layers 
EBs were formed from undifferentiated H9, 33-D9 and 34-D6 and differentiated in suspension for 
7 days and for an additional 10 days adherent to plates. Fixed EBs stained positive for markers of all 
three germ layers endoderm (AFP), ectoderm (β-tubulin III) and mesoderm (muscle actin). Nuclei 






3.4.8 Comparison of cardiac differentiation protocols 
At the start of this project, several cardiac differentiation protocols had been 
published, all of which belonged to one of three categories: guided differentiation, 
unguided differentiation or co-culture with END-2 cells. To make results comparable 
and efficiency quickly assessable only protocols involving EB formation were 
selected. All differentiation protocols involved EB formation for 24 hours and 
subsequent culture in suspension with media changes every 3 days for 15-25 days. 
EBs were formed from undifferentiated cultures with and without incubation with 
collagenase and in different media with the aim to form EBs of equal size. Size, 
morphology and survival of EBs were assessed for 7 days after EB formation and the 
most efficient protocol (30 s collagenase treatment, media supplemented with serum) 
was used for the following experiments. In order to identify a protocol that would 
efficiently, robustly and reliably generate cardiac tissue from a number of pluripotent 
stem cell lines, one protocol from each category was chosen. For unguided 
differentiation, EBs were cultured in medium supplemented with 20% HyClone FCS. 
The medium for guided differentiation consisted of a serum-free base medium (bSF) 
supplemented with SB203580, an inhibitor of the p38-MAPK pathway, and 
Prostaglandin I2 (PGI2). Instead of direct co-culture, EBs were cultured in END-2 
cell conditioned medium (END-2 CM). The initial screen, a summary of which is 
provided in Figure 21, solely considered if a protocol generated beating bodies. 
Results showed that at least one protocol from each of the three categories generated 
beating bodies.  
 
Unguided differentiation: Culturing EBs in medium supplemented with 
20% HyClone serum for the entire duration of differentiation was successful in 
generating beating bodies. 
 
Guided differentiation: Differentiation in bSF supplemented with SB203580 and 
PGI2 generated contracting cardiac tissue when EBs were formed in medium 



















Figure 21: Initial comparison of different EB formation media and cardiac differentiation media 
All differentiation protocols tested were based on EB formation for 24 hours and subsequent culture in 
suspension with media changes every 3 days for 15-25 days. Different combinations of EB formation 
media and differentiation media were assessed for beating body formation in an initial screen using 
one iPS cell line. Media were chosen based on previously published work on cardiac differentiation 
using unguided, guided and co-culture protocols. Compositions of media are listed in section 
2.1.2 Media. bSF – basic serum-free medium; CM – conditioned medium; PGI2 – Prostaglandin I2; 
SB – p38 MAPK inhibitor SB203580 
 
 
Co-culture: END-2 CM by itself failed to produce beating bodies but succeeded in 
combination with the small molecule SB203580 when EBs were formed in bSF or 
SB203580 supplemented END-2 CM. 
 
Based on data from the initial screen 3 protocols were chosen for in-depth 
comparison of efficiency. The first protocol, unguided differentiation, was chosen 
because of its simplicity. The second protocol selected was the guided differentiation 
protocol using bSF supplemented with SB203580 and PGI2. Although the initial 
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screen showed cardiac differentiation for both guided differentiation and END-2 
co-culture, the former had been developed as a chemically defined medium 
mimicking the cardiogenic effects of END-2 CM and was therefore considered 
preferable because of its xeno-free composition. Lastly, a third protocol was created 
by combining the first two, differentiating EBs in medium supplemented with 
20% HyClone serum, SB203580 and PGI2. Two previously published studies had 
reported an inhibitory effect of serum on cardiac differentiation efficiency150,148. 
However, one study counted the total number of beating bodies, whereas the other 
assessed the percentage of beating bodies of all EBs. In both studies beating areas 
were scored on day 12 of the differentiation.  
 
We hypothesised that the presence of serum might not inhibit cardiac formation but 
rather delay it and therefore counted beating bodies on days 14 and 17 after EB 
formation. In order to make counting beating bodies faster, the above listed 
differentiation protocols used for the efficiency comparison were altered to allow for 
attachment of EBs. To that end, EBs were maintained in suspension for the first 
4 days and were subsequently plated onto tissue-culture treated plates. In addition to 
simplifying the assessment, attachment on day 4 after EB formation had previously 
been shown to enhance cardiomyocyte development139.  Each of the 3 protocols was 
performed for each cell line (H9, 33-D9 and 34-D6) in technical triplicate as well as 
biological triplicate. Technical triplicates for each experiment were averaged and 
results were expressed as the total number of beating bodies formed per well of a 6 
well plate of undifferentiated cells as well as the percentage of EBs that formed 
beating bodies. The D'Agostino and Pearson omnibus K2 normality test showed 
normal distribution of the data. In accordance with that, means and SEM of 
biological triplicates, displayed in Figure 22, were analysed with tests appropriate for 
normally distributed data. Using GraphPad Prism, data was analysed with regard to 
differences between cell lines using the same protocol, differences between protocols 
within the same cell line and differences between days 14 and 17 after EB formation. 
Differences between cell lines using the same protocol were analysed using a 
one-way ANOVA with a Tukey post-test. Differences between protocols within the 
same cell line and differences between days 14 and 17 after EB formation were 
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analysed using a two-way ANOVA with a Bonferroni post-test. Both post-tests 
involved correction for multiple comparisons resulting in multiplicity adjusted 
p-values.  
 
Results from the statistical analysis of total numbers of beating bodies are 
summarised in Table 14. The serum-free guided protocol (bSF+SB+PGI2) generated 
significantly more beating bodies for 34-D6 than 33-D9 on day 14 (p<0.05).  The 
unguided protocol produced significantly more beating bodies on day 17 for H9 than 
33-D9 (p<0.05). There were no significant increases from day 14 to day 17 for any 
protocol using any cell line. 34-D6 showed significant differences between protocols 
(p<0.05). The Bonferroni post-test showed that for 34-D6, significantly more beating 
bodies were generated with the serum-free guided protocol (bSF+SB+PGI2) on 
day 17 compared to using the unguided protocol (p<0.05). Similarly, for 33-D9 the 
guided protocol containing serum resulted in significantly more beating bodies on 
day 17 than the unguided protocol (p<0.05).  
 
Results from the statistical analysis of percentages of beating bodies are summarised 
in Table 15. Comparing percentages of beating bodies, the unguided protocol 
produced significantly more beating bodies on day 17 for H9 compared to 33-D9 
(p<0.05) and 34-D6 (p<0.05). Again, there were no significant increases from day 14 
to day 17 for any protocol using any cell line. 34-D6 showed significant differences 
between protocols (p<0.01). The Bonferroni post-test showed that significantly more 
beating bodies had been generated after 17 days with guided protocols compared to 































Figure 22: Comparison of unguided and guided cardiac differentiation protocols in three 
pluripotent stem cell lines 
EBs were formed from undifferentiated 33-D9, 34-D6 and H9 and cultured in suspension in 
20% HyClone (unguided), 20% HyClone supplemented with SB203580 and PGI2 (guided) or bSF 
supplemented with SB203580 and PGI2 (guided). After 4 days, EBs were plated onto 0.1% gelatine, 
cultured for a further 13 days and beating bodies were counted on day 14 and day 17 after EB 
formation. Each of the 3 protocols was performed for each cell line in technical triplicate as well as 
biological triplicate. Technical triplicates for each experiment were averaged and results were 
expressed as the total number of beating bodies formed per well of a 6 well plate of undifferentiated 
cells as well as the percentage of EBs that formed beating bodies. Bars represent means of biological 
triplicates with error bars representing SEM. Means and SEM are shown for total numbers and 
percentages on day 14 and day 17. 
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Table 14: Statistical comparison of total numbers of beating bodies generated during cardiac differentiation 
 
 
†   p<0.05 Tukey's Multiple Comparison post-test comparing cell line 33-D9 and 34-D6 for the guided protocol (bSF+SB+PGI2) 
#   p<0.05 Tukey's Multiple Comparison post-test comparing cell line 33-D9 and H9 for the unguided protocol 
‡   p<0.05 Bonferroni Multiple Comparison post-test comparing unguided and guided protocol (20% HyClone+SB+PGI2) for cell line 33-D9 




 Day 14 Day 17 Two-way ANOVA 













33-D9 0.33 ± 0.001 3.11 ± 1.25 
1.33 ± 0.51 
† 
0.33 ± 0.001 
# 
6.78 ± 2.06 
‡ 
3.67 ± 2.27 0.051 0.160 
34-D6 1.33 ± 0.001 2.33 ± 0.77 6.56 ± 1.44 
2 ± 0.67 
* 
7.67 ± 3.53 9.22 ± 1.22 0.011 0.058 
H9 2 ± 0.69 4.22 ± 2.54 2.22 ± 0.97 3.5 ± 0.17 6.67 ± 3 3.33 ± 1.33 0.273 0.277 
One-way 
ANOVA 
0.145 0.743 0.026 0.045 0.966 0.112   
109 
 
Table 15: Statistical comparison of percentage of beating bodies generated during cardiac differentiation 
 
**   p<0.01 Bonferroni post-test comparing unguided and guided protocol (bSF+SB+PGI2) for cell line 34-D6 
$     p<0.05 Bonferroni post-test comparing guided protocols (20% HyClone +SB+PGI2 and bSF+SB+PGI2) for cell line 34-D6 
#     p<0.05 Tukey's Multiple Comparison post-test comparing cell line H9 and 33-D9 for the unguided protocol 
§     p<0.05 Tukey's Multiple Comparison post-test comparing cell line H9 and 34-D6 for the unguided protocol 
 Day 14 Day 17 Two-way ANOVA 










Protocols Day of count 
33-D9 0.22 ± 0.01 2.6 ± 1.25 2.36 ± 0.46 0.21 ± 0.001 5.59 ± 2.24 5.96 ± 3.55 0.156 0.235 
34-D6 0.98 ± 0.05 1.73 ± 0.42 21.91 ± 9.27 
1.44 ± 0.41 
§ 
5.71 ± 2.25 
$ 
30.95 ± 10.57 
** 
0.002 0.363 
H9 3.28 ± 1.4 6.56 ± 4.7 5.16 ± 2.23 
5.6 ± 1.65 
# 
10.46 ± 6.59 7.45 ± 3.66 0.564 0.370 
One-way 
ANOVA 
0.149 0.478 0.09 0.027 0.590 0.107   
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3.5 Discussion and Conclusion 
The aims of this chapter were to establish comprehensive tests to assess pluripotency 
and differentiation potential of pluripotent stem cells and to establish a reliable, 
efficient and robust cardiac differentiation protocol, both to be used at a later stage 
on patient-derived iPS cell lines. Analysis of one hES cell line and two iPS cell lines 
showed comparable morphology and expression of pluripotency markers on mRNA 
and protein level. All analysed pluripotent stem cell lines formed all three germ 
layers and successfully underwent cardiac differentiation. Comparison of three 
cardiac differentiation protocols for these three stem cell lines showed significant 
inter-line variability with regard to efficiency of cardiac formation.  
 
Evaluating the morphology of pluripotent stem cells in culture is the easiest and 
quickest way to evaluate the state of the cells in question on a daily basis. Changes in 
morphology can be indicative of karyotypic abnormalities or cells leaving their 
undifferentiated state. However, morphology of stem cells can differ between cell 
lines as well as between culture systems making it more difficult to notice and 
interpret changes in morphology. For an accurate characterisation of stem cells, a 
more in depth analysis is required to determine karyotypic integrity, pluripotency and 
differentiation potential. Genomic integrity was examined with a SNP array instead 
of the traditional karyotyping; because of their higher resolution, SNP arrays are 
more accurate than regular karyotyping, detecting microdeletions and 
microduplications that would otherwise be missed. However, SNP arrays are unable 
to detect translocations and inversions because all individually detected SNPs are 
subsequently sorted by a computer program to generate a digital karyogram. 
Genomic integrity is known to decrease over time in long-term cultures186 and should 
therefore be investigated regularly. Indeed, both iPS cell lines 33-D9 and 34-D6 
carried a microduplication in chromosome 20q11.21, which has been shown to occur 
in >20% of stem cell lines in culture. The region includes three genes, ID1, BCL2L1 
and HM13, which are expressed in human pluripotent stem cells. With its 
anti-apoptotic role, BCL2L1 is likely the reason for positive selection of this 
microduplication in culture186. Based on this assessment, the 20q11.21 
microduplication was not expected to adversely interfere with pluripotency or 
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differentiation in the affected cell lines. Microduplications found on chromosomes 7 
and 14 in the hES cell line H9 were not associated with known genes and were 
therefore not expected to have an effect on pluripotency or differentiation potential.  
Pluripotency was assessed and confirmed for all three stem cell lines on an mRNA as 
well as protein level. RT-PCR offers a fast if not quantitative screening method for 
expression of genes of interest. Beside the difference in band intensity, all pluripotent 
stem cell lines showed a profile distinctly different from fibroblasts. Although often 
associated with pluripotency or cancer cells, c-Myc plays an integral role in 
proliferating cells187, expression in fibroblasts was therefore expected. The difference 
in band intensity of the house-keeping gene β-tubulin between different samples 
suggests that an unequal amount of cDNA was used as template for PCR 
amplification. The β-tubulin band was the weakest for 33-D9 suggesting the least 
amount of cDNA was used. Less cDNA as a template for the PCR reaction in 33-D9 
compared to the other samples could explain the weaker bands observed for Nanog 
and Sox2. Quantitative RT-PCR confirmed that in spite of different band intensities 
in the RT-PCR there are in fact no significant differences in expression levels of the 
pluripotency markers in 33-D9 compared to H9. Since the data is presented as the 
mean of three biological replicas with varying passage numbers, the relatively large 
error bars could be indicative of changes in pluripotency marker expression over 
time. The error could also result from a varying number of differentiated cells in the 
culture.  
 
On a protein level, flow cytometry analysis showed that pluripotency markers were 
expressed on a high percentage of pluripotent stem cells. The small number of cells 
negative for SSEA3 and SSEA4 might be explained by the gating strategy based on 
forward and side scatter not entirely excluding differentiated or differentiating cells. 
Prior to these experiments, both antibodies had been titrated to find the optimal 
working concentration; insufficient amounts of antibody could therefore be excluded 
as an issue. Expression of pluripotency markers was also confirmed visually with 
immunocytochemistry. Colonies showed nuclear staining for transcription factors 




Besides differentiating to all three germ layers, all tested stem cell lines formed 
spontaneously beating cardiac tissue using a variety of protocols. Guided protocols 
generated significantly more beating bodies than the unguided protocol for both iPS 
cell lines but not the hES cell line. Due to the small sample size there is no reason to 
assume that this is due to inherent differences between iPS and hES cell lines rather 
than inter-line variability. Variability of cardiac differentiation potential can be 
attributed to genetic as well as epigenetic differences between cell lines182, 183. 
Overall, the comparison showed that different protocols work significantly better 
than others across the different cell lines. Inter-line variability for the same protocol 
as well as differences between protocols investigating the same cell line had been 
expected based on previous publications188, 189. Contrary to expectations, serum did 
not have an inhibitory effect on the total number or percentage of beating bodies for 
two of the three pluripotent stem cell lines (H9 and 33-D9). The third cell line 
(34-D6) showed little difference in terms of total numbers but a significantly higher 
percentage of beating bodies under serum-free conditions. These results emphasised 
the importance of keeping the assessment of efficiency consistent in order to make 
direct comparisons between published protocols possible.  
 
Employing three pluripotent stem cell lines, a set of comprehensive tests to assess 
pluripotency and differentiation potential was established. Comparison of cardiac 
differentiation protocols using the same stem cell lines found that guided 
differentiation protocols could be used to reliably and efficiently generate beating 
bodies. Protocols optimised in this chapter can be used at subsequent stages to 
characterise newly generated patient-derived iPS cell lines and to efficiently generate 






















CHARACTERISATION OF HUMAN CARDIAC TISSUE 






During development of the heart, cardiomyocytes undergo changes in physiology 
and electrophysiological properties and detailed characterisation of adult and foetal 
cardiomyocytes will enable assessment of the maturity and function of stem 
cell-derived cardiomyocytes. Cardiomyocytes were successfully isolated from foetal 
and adult cardiac tissue. Morphological and structural comparison using light 
microscopy, immunocytochemistry, immunohistochemistry, and transmission 
electron microscopy demonstrated the expected classical adult and foetal phenotypes 
with great differences in morphology and organisation and ultrastructure of their 
contractile apparatus. Adult cardiomyocytes displayed rod-shaped morphology and 
parallel aligned myofibrils with fully formed sarcomeres. In contrast, foetal cardiac 
cells were not rod-shaped, had fewer myofibrils that lacked parallel alignment and 
showed immature sarcomeres lacking I-bands, A-bands, H-zones and M-lines. 
Cardiomyocytes derived from hES cells (H9) and healthy control iPS cells (34-D6) 
using guided differentiation more closely resembled foetal than adult cardiomyocytes 
but altogether showed an intermediary phenotype. While most cells had immature 
contractile apparatus comparable with foetal cardiomyocytes, a few cells showed 
greater numbers of myofibrils with increased alignment and sarcomeres with I-bands 
and A-bands in addition to Z-lines. Membrane staining revealed that like foetal 
cardiomyocytes they exhibited no t-tubules, however, compared to foetal controls, 
stem cell-derived cardiomyocytes displayed faster calcium removal from sarcoplasm. 
Finally, sodium currents were recorded from individual pluripotent stem cell-derived 
cardiomyocytes. Protocols optimised in this chapter will subsequently be used to 





The heart is the first functional organ to be formed in the human embryo and starts to 
spontaneously contract at the beginning of the fourth week190. During cardiac 
morphogenesis, cell clusters containing cardiac progenitor cells form a tube that later 
loops and divides into the four chambers of the adult heart.  
 
During gastrulation cells migrate through the primitive streak to form the three germ 
layers ectoderm, endoderm, and mesoderm191. The mesoderm, the layer between 
ectoderm and endoderm, spreads laterally and cranially within the embryonic disc 
and ultimately gives rise to the lateral plate mesoderm. Approximately, on day 18 
blood islands are formed from these lateral plate mesoderm cells which migrate and 
form a crescent shape at the cranial border, the prospective head of the embryo192. 
Blood islands contain haemangioblasts and cardiac progenitors. While endothelial 
cells differentiated from haemangioblasts form an endocardial tube on either side of 
the midline, cardiac progenitor cells differentiate to myoblasts and then 
cardiomyocytes that will form the myocardium surrounding the endocardial tubes. At 
the beginning of the fourth week the two endocardial tubes migrate towards the 
midline where they fuse into the primitive heart tube and start to spontaneously 
contract. Cells of the endocardial tubes will line the inside of the heart chambers and 
valves, while the surrounding myocardium forms the cardiac muscle of the ventricles 
and the atria. As the brain develops during the fourth week, the primitive heart tube is 
moved in a ventral direction, away from the head, forcing it to fold in on itself, 
resulting in the formation of the first primitive atrium and ventricle.   
 
Cardiac morphogenesis is driven by spatially and temporally regulated inhibition and 
activation of signalling proteins and transcription factors. Proteins secreted by the 
anterior endoderm induce cardiac specification of the lateral mesoderm. While neural 
differentiation of these cells is prevented through Wnt inhibitors, Bone 
morphogenetic protein 2 (BMP-2) and Fibroblast growth factor 8 (FGF-8) activate 
expression of Nkx2.5 leading to the formation of cardiac myoblasts193. Nkx2.5 is a 
cardiac specific transcription factor that induces expression of the transcription 
factors Myocyte-specific enhancer factor 2C (MEF-2c) and GATA-4 that in turn 
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activate the expression of cardiac muscle specific proteins194. This activation causes 
the differentiation from cardiac myoblasts to cardiomyocytes. Laterality of each cell, 
meaning whether they will contribute to the left or right side of the heart, is mainly 
determined by transcription factors Heart- and neural crest derivatives-expressed 
protein 1 (HAND1) and HAND2. This decision is made even before fusion of the 
endocardial tubes.  
 
While little is known about the mechanisms that subsequently drive maturation of 
foetal to adult cardiomyocytes, the changes in gene expression, morphology and 
functionality that accompany this transition have been well documented. Prior to 
tube formation smooth muscle actin is the only isoform present before up-regulation 
of cardiac sarcomeric actin marks the onset of spontaneous contraction195, 196. For a 
short period of time contractions are isotropic, uniform in all directions, before they 
become directionally dependent, i.e. anisotropic.  
 
Regulation of myfibrilogenesis is not well understood but different steps involved 
have been described197. Initially, myofibrils are disorganised but become aligned in 
response to mechanical load throughout development. The number of myofibrils 
increases at the same rate as the number of mitochondria supplying ATP essential for 
contractions. As the cardiomyocytes become more mature, mitochondria increase in 
size and gain cristae, folds of a mitochondrion’s inner membrane198, 199. Formation of 
the sarcoplasmic reticulum (SR) coincides with the development of transverse 
tubules (t-tubules), invaginations in the cell membrane closely associated with the 
SR network and crucial for excitation-contraction coupling, at a relatively late stage 
of structural morphogenesis of the heart200, 201.  
 
Maturation also sees changes in electrophysiological properties largely due to 
increased expression of ion channels. The resting potential increases, i.e. becomes 
more negative200, the peak calcium current and density increase202 and while in foetal 
cells calcium release from SR is triggered by Na+-Ca2+ exchange, in adult 




Being able to evaluate the level of maturity of iPS cell-derived cardiomyocytes will 
be helpful in interpreting the results from patient-specific cardiomyocytes and to 
determine their use and limitations for modelling disease. However, while it might be 
essential to have cardiomyocytes with an adult phenotype in case of modelling 
cardiac diseases that are acquired or affect channels that are expressed only at a 
relatively late stage of myogenesis (e.g. Phospholamban) that does not apply to 
modelling cases of Brugada Syndrome caused by a mutation in SCN5A. The gene 
encoding for the alpha subunit of cardiac sodium channel Nav1.5 is expressed at high 
levels in immature cardiomyocytes and Brugada Syndrome affects children as well 





To assess the maturity and functionality of pluripotent stem cell-derived 





4.4 Results  
Considering the extent of cardiomyocyte characterisation and the fact that no 
differences between 34-D6 and 33-D9 had been observed in Chapter 3, analysis of 
stem cell-derived cardiomyocytes was limited to one hES and one iPS cell line. 
 
Beating bodies were generated from human ES (H9) and iPS (34-D6) cell lines 
characterised in Chapter 3 using guided cardiac differentiation established to be the 
most efficient protocol for these lines in the same chapter. Protocols to assess 
cardiomyocytes for cardiac markers, ultrastructure and functionality were first tested 
and optimised on primary human tissue. These validated protocols were subsequently 
used to characterise the cardiomyocytes derived from H9 and 34-D6. Finally, the 
results obtained were compared to primary human cardiomyocytes isolated from 




4.4.1.1 Primary cardiac tissue 
Previously published protocols for the isolation of viable human cardiomyocytes173, 
174 were tested and modified as required for adult and foetal cardiac tissue.  
 
Adult cardiac tissue was obtained with consent from two sources, atrial and 
ventricular donor tissue from the Scottish National Blood Transfusion Service 
(SNBTS) and right atrial appendages (RAA) from patients undergoing cardiac 
surgery. All samples were processed within 30 min of collection. 
 
At 24-48 hours post isolation, adult cardiomyocytes had typical rod-shaped 
morphology with visible striations (Figure 23 A, B) but showed very limited 
attachment and survival in both 10% DMEM and M199 medium. SNBTS, 
particularly ventricular, tissue yielded considerably more cells than RAA due to vast 
differences in available tissue size. Foetal cardiomyocytes, more spindle than 
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rod-shaped without visible striations, attached quickly and spontaneously contracted 
after 24 hours (Figure 23 C, D) with no apparent differences between culture in 
10% DMEM and M199 medium. A video of spontaneously contracting foetal 



















Figure 23: Morphology of adult and foetal cardiomyocytes 
Cardiomyocytes were isolated from primary human adult and foetal tissues through enzymatic 
digestion. Morphology was assessed 24-48 hours after isolation. A and B – Adult cardiomyocytes, 
isolated from atrial and ventricular donor tissue and right atrial appendages, had typical rod-shaped 
morphology with visible striations but showed very limited attachment and survival. C and D – Foetal 
cardiomyocytes, isolated from 11-16 week old foetuses, were more spindle shaped, showed no visible 
striations, attached quickly and contracted spontaneously. Representative images of 3 biological 
replicates for each sample are shown. B and D are magnified areas in A and C respectively. Scale bars 






4.4.1.2 Pluripotent stem cell-derived beating bodies and 
cardiomyocytes 
Beating bodies were generated from human ES (H9) and iPS (34-D6) cell lines using 
the guided cardiac differentiation protocols established in Chapter 3 (Figure 24 A 
and C). Beating bodies varied in size and rate at which they contracted even when 
derived from the same stem cell line using the same differentiation protocol. The 
percentage of cardiomyocytes within a beating body, estimated by the size of the 
contracting area, also differed. With regular dissections to remove surrounding 
















Figure 24: hES and iPS cell-derived beating bodies and single cardiomyocytes 
A and C (10x magnification) – H9 (hES) and 34-D6 (iPS) were differentiated using guided cardiac 
differentiation protocols. Size, contraction rate and percentage of contractile tissue within a beating 
body differed between beating bodies. Beating bodies were cultured for 3-4 weeks before enzymatic 
and mechanical disaggregation. B and D (40x magnification) – Disaggregation resulted in single as 
well as clusters of beating cardiomyocytes, with groups of connected cardiomyocytes exhibiting 
synchronised contraction. Spontaneously contracting stem cell-derived cardiomyocytes showed 
morphologies similar to foetal cardiomyocytes. Representative images of 5 biological replicates for 
each sample are shown. 
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Cardiomyocytes characterised in this chapter were isolated from beating bodies 
cultured for 3-4 weeks. To investigate the morphological and functional properties of 
pluripotent stem cell-derived cardiomyocytes on a single cell level, beating bodies 
were enzymatically and mechanically disaggregated and plated onto 1% gelatine. 
Disaggregation resulted in single as well as clusters of beating cardiomyocytes, with 
groups of connected cardiomyocytes exhibiting synchronised contraction. Stem 
cell-derived cardiomyocytes started contracting as early as 24 hours post 
disaggregation and showed morphologies similar to foetal cardiomyocytes (Figure 24 
B and D). Videos of spontaneously contracting stem cell-derived beating bodies and 
cardiomyocytes in culture are supplied in Appendix 2. Beating bodies do not contain 
a pure population of cardiomyocytes but rather a mixture of cell types. Therefore, to 
allow for attachment but prevent overgrowth by proliferating non-cardiac cells, 
cardiomyocytes were analysed 3-4 days after disaggregation.  
 
 
4.4.2 Expression of cardiac markers 
4.4.2.1 Primary human cardiac tissue 
Staining protocols for cardiac markers were optimised on primary human cardiac 
tissue varying conditions for permeabilisation, blocking of unspecific antibody 
binding and antibody concentrations. Adult cardiac tissue from SNBTS donors and 
RAA were dissociated and plated onto 1% gelatine or laminin. Cells were fixed 24 or 
72 hours post isolation and stained for alpha actinin, a protein of the cardiac 
contractile apparatus that is localised at the Z-lines. Staining of cells fixed 24 hours 
after isolation for alpha actinin resulted in the characteristic striation pattern of intact 
and parallel aligned myofibrils (Figure 25 A, B). Cardiomyocytes isolated from both 
tissues showed limited attachment and survival. Cells fixed 72 hours post isolation 
exhibited a loss of rod-shaped morphology, loss of parallel alignment of myofibrils 
as well as a lack of myofibril organisation with some striation patterns remaining 



















Figure 25: Immunocytochemistry for cardiac marker alpha actinin in adult cardiomyocytes in 
culture 
A and B – Adult cardiomyocytes plated onto 1% gelatine, fixed after 24 hours and stained for alpha 
actinin showed rod-shaped morphology with striated parallel myofibrils. C and D – Adult 
cardiomyocytes plated onto 1% gelatine, fixed after 72 hours and stained for alpha actinin showed loss 
of rod-shaped morphology and myofibril organisation. Nuclei were counterstained with DAPI (blue). 
Figure shows merged images. Representative images of 2 biological replicates are shown. B and D are 
magnified areas in A and C respectively. Scale bars represent 50 µm. 
 
 
Hearts from 14-15 week old foetuses were dissociated and plated onto 1% gelatine 
coated glass coverslips. Well attached and spontaneously contracting cells were fixed 
48-72 hours after dissociation and stained for alpha actinin, cardiac troponin I (cTnI) 
and cardiac troponin T (cTnT). Single cTnT staining exhibited the striated pattern of 
thin filaments while double stainings for cTnI and alpha actinin resulted in 
alternating striations, staining thin filaments and Z-lines respectively (Figure 26). 
Both cTnI and cTnT are proteins of the contractile apparatus and are localised at the 
thin filaments. As observed with light microscopy, foetal cardiomyocytes had no 
distinct rod-shaped morphology. Stainings showed myofibrils throughout the cells 



















Figure 26: Immunocytochemistry for cardiac markers in foetal cardiomyocytes in culture 
Cardiomyocytes isolated from 14-15 week old foetal hearts were plated onto 1% gelatine coated glass 
coverslips and fixed after 48-72 hours once cells had attached and resumed to spontaneously contract. 
A and C – Cells stained positive for alpha actinin (green), cTnI (red) and cTnT (green) and showed no 
rod-shaped morphology. B and D – Striated myofibrils were not aligned in parallel. Nuclei were 
counterstained with DAPI (blue). Figure shows merged images. Representative images of 3 biological 




To investigate the effects of dissociation and culture on the morphology and 
structural organisation of myofibrils, part of the intact cardiac tissue obtained was 
immediately cryopreserved for sectioning and staining. Samples were dissected into 
pieces <1 cm3 before cryopreservation in an isopentane bath in liquid nitrogen. 
Frozen tissue pieces were sectioned on a Vibratome Cryostat into 6 µm thick sections 
and stained for cardiac markers alpha actinin, cTnI and cTnT.  
 
Adult cardiac tissue sections stained positive for all three markers showing the 
characteristic striation pattern (Figure 27 A, C). Single cTnT staining exhibited the 
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striated pattern of thin filaments while double stainings for cTnI and alpha actinin 
resulted in alternating striations, staining thin filaments and Z-lines respectively. 
Myofibrils were aligned in parallel, with Z-lines lined-up across the width of cells 
















Figure 27: Immunohistochemistry for cardiac markers in sections of adult cardiac tissue 
Adult cardiac tissue pieces of <1 cm3 were cryopreserved in liquid nitrogen cooled isopentane and 
sectioned. 6 µm thick sections were stained for alpha actinin, cTnI and cTnT. A and B – Sections 
double stained with alpha actinin (green) and cTnI (red) showed highlighted Z-lines and thin filaments 
in an alternating striation pattern. C and D – Sections stained with cTnT (green) showed striation 
patterns consistent with stained thin filaments. Myofibrils running along the length of a cell were 
aligned parallel with Z-lines of neighbouring myofibrils. Nuclei were counterstained with DAPI 
(blue). Figure shows merged images. Representative images of 2 biological replicates are shown. B 
and D are magnified areas in A and C respectively. Scale bars represent 50 µm. 
 
 
In 14-15 week old foetal hearts double staining for alpha actinin and cTnI showed 
the characteristic striations of myofibrils (Figure 28). Myofibrils in foetal sections 
were observed throughout the cells but showed no alignment of Z-lines across the 











Figure 28: Immunohistochemistry for cardiac markers in sections of foetal cardiac tissue 
Pieces of 14-15 week old foetal hearts with <1 cm3 were cryopreserved in liquid nitrogen cooled 
isopentane and sectioned. 6 µm thick sections were stained for alpha actinin and cTnI. A – Sections 
double stained with alpha actinin (green) and cTnI (red) showed highlighted Z-lines and thin filaments 
in an alternating striation pattern. B – Myofibrils running along the length of cells displayed no 
parallel alignment of Z-lines across the width of cells. Nuclei were counterstained with DAPI (blue). 
Figure shows merged images. Representative images of 2 biological replicates are shown. B shows a 
magnified area in A. Scale bar represents 50 µm. 
 
 
4.4.2.2 Pluripotent stem cell-derived cardiomyocytes 
Staining protocols optimised on primary human cardiac tissue were used to stain 
pluripotent stem cell-derived cardiomyocytes. H9 and 34-D6 beating bodies were 
enzymatically and mechanically disaggregated and plated onto 1% gelatine coated 
glass coverslips. After 3-5 days of recovery, cells were fixed and stained for markers 
of the cardiac contractile apparatus. Cells isolated from beating bodies stained 
positive for alpha actinin (green), cTnI (red) and cTnT (green) showing intact 
myofibrils (Figure 29). Single cTnT staining exhibited the striated pattern of thin 
filaments while double stainings for cTnI and alpha actinin resulted in alternating 
striations, staining thin filaments and Z-lines respectively. Stainings showed 
myofibrils throughout the cells that lacked the parallel alignment of Z-lines detected 
in mature cardiomyocytes (Figure 29 B, E). As observed with light microscopy, 


















Figure 29: Immunocytochemistry for cardiac markers in pluripotent stem cell-derived cardiomyocytes 
3-4 week old beating bodies were disaggregated, plated onto 1% gelatine coated glass coverslips, fixed after 3-5 days and stained for proteins of the cardiac contractile 
apparatus. Cells stained positive for alpha actinin (green), cTnI (red) and cTnT (green) showing intact myofibrils but displayed no rod-shaped morphology. Nuclei were 
counterstained with DAPI (blue). Figure shows merged images. Representative images of 20-30 cells from 5 beating bodies are shown for each sample. B and E are 




4.4.3.1 Primary tissue 
The ultrastructure of primary cardiomyocytes was investigated using transmission 
electron microscopy (TEM). Primary human cardiac tissue from foetal hearts, adult 
RAA and SNBTS donor ventricles was processed within 30 min of obtaining the 
sample. In preparation for TEM, samples underwent protein fixation, lipid fixation 
and serial dehydration. Samples embedded in resin were stained and ultrathin 
sections were imaged. Figure 30 shows representative images of 3 biological 














Figure 30: TEM images of primary human cardiomyocytes 
Primary human adult and foetal cardiac tissue was prepared for TEM through protein fixation, lipid 
fixation and dehydration. Samples embedded in resin were stained and ultrathin sections were imaged. 
A – Adult ventricular cardiomyocytes isolated from SNBTS donor tissue showed parallel aligned 
myofibrils (MF) with Z-lines (Z) of neighbouring myofibrils aligned across the width of a cell.           
B – Higher magnification of sarcomeres showed I-bands (I), A-bands (A), H-zones (H), M-lines (M) 
and Z-lines. C – Cardiomyocytes of 14.5-16.5 week old foetal hearts had fewer and shorter 
myofibrils. Z-lines of neighbouring myofibrils were not aligned. D – At higher magnification foetal 
sarcomeres showed Z-lines. Representative images of 2 and 4 biological replicates for adult (one 




Adult cardiomyocytes exhibited characteristic striation patterns of intact and parallel 
aligned myofibrils with Z-lines of neighbouring myofibrils aligned across the width 
of a cell. All cardiomyocytes of 14.5-16.5 week old foetal hearts had fewer and 
shorter myofibrils, some only a few sarcomeres long, that lacked the alignment 
observed in adult cardiomyocytes. At high magnification, sarcomeres in adult 
cardiomyocytes showed I-bands, A-bands, H-zones, M-lines and Z-lines. In foetal 
cardiomyocytes, only Z-lines were observed. Adult cardiomyocytes contained a large 
number of mitochondria and lipid deposits (Figure 31 A, C). Although present in 
SNBTS tissue as well as RAA, cardiomyocytes of the latter contained more glycogen 
granules in between myofibril filaments (Figure 31 B, D). Foetal cardiomyocytes 
also contained mitochondria and lipid deposits, albeit less than the adult cells, as well 









































Figure 31: TEM images of primary human cardiomyocytes 
A and C – Adult cardiomyocytes contained a large number of mitochondria and lipid deposits. 
B and D – Cardiomyocytes in RAA contained more glycogen granules in between myofibril filaments 
compared to cardiomyocytes in atrial SNBTS donor tissue. E – Cardiomyocytes from 14.5-16.5 week 
old foetuses contained fewer mitochondria and lipid deposits than those in adult tissue. F – Glycogen 
granules were found in between myofibril filaments of foetal cardiomyocytes. B, D and F are 
magnified areas in A, C and E respectively. Mito – mitochondrion. 
 
 
4.4.3.2 Pluripotent stem cell-derived cardiomyocytes 
Beating bodies derived from a hES (H9) and an iPS (34-D6) cell line were cultured 
for 3-4 weeks before being processed for TEM as described above for primary 
cardiac tissue. TEM images from different layers of beating bodies confirmed the 
presence of cardiac and non-cardiac cells. Images of cardiomyocytes found in hES 
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and iPS cell-derived beating bodies shown in Figure 32 are representative of 























Figure 32: TEM images of pluripotent stem cell-derived cardiomyocytes 
A – Most stem cell-derived cardiomyocytes of 3-4 week old beating bodies showed myofibrils (MF) 
comparable to foetal cells in number, size and sarcomere structure. B – Some cells contained a greater 
number of myofibrils with increased organisation and alignment of Z-lines (Z). C and E – A few cells 
contained sarcomeres with I-bands (I) and A-bands (A) in addition to Z-lines. D and F – Stem 
cell-derived cardiomyocytes contained mitochondria and lipid deposits as well as glycogen granules in 
between myofibril filaments. Representative images of 3 biological replicates for each sample are 




Most stem cell-derived cardiomyocytes showed great resemblance with 
14.5-16.5 week old foetal cardiomyocytes. Myofibrils varied in size with some 
consisting of a single sarcomere. Myofibrils were generally sparser than in adult 
cardiomyocyte and lacked the alignment of Z-lines (Figure 32 A). However, some 
cells contained a greater number of myofibrils with increased organisation, 
exhibiting some alignment of Z-lines between neighbouring myofibrils            
(Figure 32 B). Stem cell-derived cardiomyocytes contained mitochondria and lipid 
deposits (Figure 32 D) as well as glycogen granules in between myofibril filaments 
(Figure 32 F) as seen in both adult and foetal samples. At high magnification, all 
sarcomeres showed Z-lines but a small number of cells contained sarcomeres with 
I-bands and A-bands in addition to Z-lines (Figure 32 E). Overall there were no 




4.4.4 Membrane visualisation 
The cell membrane of foetal and stem cell-derived cardiomyocytes was visualised 
using a membrane dye in order to determine if t-tubules were present.  
 
Beating bodies cultured for 3-4 weeks post differentiation and 14.5-16.5 week old 
foetal hearts were disaggregated and plated onto glass coverslips as detailed above 
for immunocytochemistry. After disaggregated cells resumed to spontaneously 
contract (48-72 hours), cell membranes of disaggregated single cells were stained 
with the membrane dye Di-8-ANEPPS. This dye is not susceptible to internalisation 
and hence suitable to visualise outer membrane structures such as t-tubules.  
 
Spontaneously contracting cells, regarded to be cardiomyocytes, were imaged in 
Z-stacks on a confocal microscope at 37°C. No t-tubule structures were visible in 
stained cell membranes of foetal or stem cell-derived cardiomyocytes; representative 
images are shown in Figure 33. Staining membranes of adult cardiomyocytes was 












Figure 33: Visualisation of cell membrane 
Single cells from disaggregated 14.5-16.5 week old foetal hearts and 3-4 week old beating bodies 
were stained with the membrane dye Di-8-ANEPPS. Z-stacks of spontaneously contracting cells were 
recorded on a confocal microscope. Visualised cell membranes of foetal and stem cell-derived 
cardiomyocytes showed no t-tubules. Representative images of 10 cells from 2 biological replicates 
for each sample are shown.   
 
 
4.4.5 Intracellular calcium imaging 
An essential characteristic of functional cardiomyocytes is excitation-contraction 
coupling in which an action potential triggers calcium-induced calcium release 
(CICR) leading to muscle contraction. Calcium-induced calcium release refers to a 
mechanism by which extracellular calcium entering a cell induces the release of 
calcium from intracellular calcium storages like the sarcoplasmic reticulum. This 
vast increase in cytosolic calcium concentration results in cardiac muscle contraction 
that ends when calcium is pumped back into the sarcoplasmic reticulum. This release 
of calcium into the cytosol can be detected as spatiotemporally restricted calcium 
transients in cells loaded with Fluo-4, a dye that fluoresces upon binding calcium. 
To investigate if spontaneous contraction of stem cell-derived cardiomyocytes was 
due to excitation-contraction coupling, one stem cell-derived beating body was 
treated with Tetrodotoxin (TTX). TTX selectively inhibits voltage gated sodium 
channels preventing action potentials. In cells with functional excitation-contraction 
coupling, the absence of action potentials will hinder the activation of voltage-gated 
calcium channels, thus impeding CICR.  
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Cytoplasmic calcium in a beating body derived from H9 was visualised with 5 µM 
Fluo-4 and continuously imaged at room temperature. A video of the Fluo-4 loaded 
beating body is supplied in Appendix 2.  Intensity of fluorescence was displayed 
through an intensity map (Figure 34 A). Peaks in fluorescence coincided with 
contractions, and fluorescence peaks in different regions of interest throughout the 
beating body were in-sync. For investigation of excitation-contraction coupling, the 
same beating body was incubated with 10 µM Tetrodotoxin. Fluorescence intensity 
in a region of interest traced over time before and after TTX treatment is shown in 










Figure 34: Effect of Tetrodotoxin on calcium-induced calcium release in a beating body  
Cytoplasmic calcium in a beating body derived from H9 was visualised with Fluo-4, a 
green-fluorescent calcium indicator. Peaks in fluorescence, i.e. calcium transients, coincided with 
contractions. A – Fluorescence intensities were displayed through an intensity map, green indicating 
low and red indicating high intensity. B – Fluorescence intensity in a region of interest (indicated by 
white line in A was recorded over time. Incubation with the competitive sodium channel inhibitor 
TTX supressed calcium transients, suggesting functional excitation-contraction coupling. 










Prior to TTX treatment, the beating body showed regular calcium transients. After 
adding sodium channel inhibitor TTX, the number of calcium transients, which were 
still coinciding with contractions, decreased and time intervals between flashes 
became irregular and increased over time.  
 
For visualisation of calcium transients in single cells, a 16 week old foetal heart and 
beating bodies derived from pluripotent stem cell lines H9 and 34-D6 were 
disaggregated and plated onto glass coverslips as described for 
immunocytochemistry. Beating bodies from both cell lines had been cultured for 
5 weeks after differentiation before disaggregation. After disaggregated cells 
resumed to spontaneously contract, cytoplasmic calcium was visualised as above 
with Fluo-4. Spontaneously contracting cells, regarded to be cardiomyocytes, were 
imaged for 20 s at room temperature using an optical camera connected to a 
fluorescence microscope. Representative videos are supplied in Appendix 2. 
Fluorescence intensities were traced over time and representative traces of calcium 
transients in single foetal, hES and iPS cell-derived cardiomyocytes are shown in 
Figure 35. The width and height of fluorescence peaks differed between foetal and 

















Figure 35: Calcium transients in foetal and stem cell-derived cardiomyocytes 
A heart from a 16 week old foetus and beating bodies generated from H9 and 34-D6 were disaggregated and plated as single cells. Beating bodies had been cultured for 
5 weeks prior to disaggregation. After spontaneous contractions resumed, intracellular calcium was visualised with Fluo-4 and fluorescence intensities were recorded. 
Images show representative traces of fluorescence intensity in one cell over 20 s. The width and height of fluorescence peaks differed in foetal and stem cell-derived 
cardiomyocytes and peak heights decreased in both over time. Fluorescence intensity is shown in arbitrary units (a.u.). Representative traces of 14-16 cells from one 








































In order to compare the kinetics of calcium transients in foetal and pluripotent stem 
cell-derived cardiomyocytes, data from a representative calcium transient from each 
of 14-16 cells was analysed and pooled for each cell line. For each calcium transient, 
the background fluorescence was subtracted, and each data point normalised to the 
peak value. Pooled data for each time point was plotted as a mean ± SEM and is 
















Figure 36: Single calcium transient in spontaneously contracting cardiomyocytes 
Calcium transients in foetal and pluripotent stem cell-derived cardiomyocytes were analysed in 
14-16 cells for each group. One representative calcium transient from each cell was analysed and data 
from all cells from each cell line were pooled. For each calcium transient the background fluorescence 
was subtracted and each data point normalised to the peak value. Fluorescence intensity is shown in 
arbitrary units (a.u.) as the mean value of 14-16 data points with error bars representing SEM. 
 
 
Cardiomyocytes derived from 34-D6 generally showed less variability, i.e. smaller 
SEM, between cells compared to H9 and were hence chosen for comparison with 
foetal cells. Because data had been normalised, amplitude (F/F0) was the same for all 
cells and could not be compared between foetal and stem cell-derived 
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cardiomyocytes. However, differences were detected between their decay kinetics 
(t50, t75, t90) shown in Figure 37. The decay kinetics are related to the speed at which 
calcium is pumped back into the sarcoplasmic reticulum and t50, t75 and t90 refer to 
the times correlating to 50%, 75% and 90% decay of calcium transients. Decay of 
calcium transients was considerably slower in foetal cardiomyocytes compared to 
stem cell-derived cardiomyocytes (t50=0.96 s vs 0.81 s, Δt50=0.15 s). The difference 

















Figure 37: Decay kinetics of calcium transients in foetal and stem cell-derived cardiomyocytes 
Decay kinetics differed considerably between foetal and stem cell-derived cardiomyocytes at times 
correlating to 50%, 75% and 90% decay of calcium transients (t50, t75 and t90 respectively). Decay of 
calcium transients was markedly slower in foetal compared to stem cell-derived cardiomyocytes 
(t50=0.96 s vs 0.81 s, t75= 1.28 s vs 0.96 s and t90=1.53 s vs 1.13 s). The difference between foetal and 
stem cell-derived cells increased over time (Δt50=0.15 s, Δt75=0.32 s, Δt90=0.4 s). Fluorescence 
intensity is shown in arbitrary units (a.u.) as the mean value of 14-15 data points with error bars 





Sodium currents were recorded in cardiomyocytes derived from human ES cells (H9) 
to identify appropriate buffer compositions, equipment settings, and patch-clamp 
technique. Perforated patch-clamping using Amphotericin B and a low sodium bath 
solution was identified as the suitable technique. In preparation for sodium current 
recordings beating bodies were generated from undifferentiated H9, disaggregated 
and plated onto gelatine-coated glass coverslips as described previously for 
immunocytochemistry. Electrophysiological recordings were performed on single 
cells, identified as cardiomyocytes by their morphology and/or spontaneous 
contraction, 2-3 days after disaggregation.  
 
Sodium currents were elicited by applying gradually increasing potentials and 
current-potential relationships were plotted as an I-V curve. The I-V curve shown in 
Figure 38 was plotted from recordings of one H9-derived cardiomyocyte. It displays 
a gradual increase in measured current corresponding to a gradual increase in applied 
































Figure 38: I-V curve of H9-derived cardiomyocytes 
Using perforated patch clamping sodium currents were elicited from single H9-derived 
cardiomyocytes by applying gradually increasing potentials. The representative current-potential 




4.5 Discussion and Conclusion 
The aims of this chapter were to I) isolate and characterise viable and functional 
cardiomyocytes from human foetal and adult primary tissue, II) isolate and 
characterise pluripotent stem cell-derived cardiomyocytes from beating bodies and 
III) compare them to human adult and foetal cardiomyocytes to evaluate their 
maturity. Adult and foetal cardiomyocytes showed great differences with regard to 
morphology, survival in culture, and organisation and ultrastructure of their 
contractile apparatus. Analysis of one hES cell line (H9) and one previously derived 
healthy control iPS cell line (34-D6) showed stem cell-derived cardiomyocytes more 
closely resembled foetal than adult cardiomyocytes but overall showed an 
intermediary phenotype. 
 
Successful isolation of viable cardiomyocytes from adult and foetal cardiac tissue 
was crucial for optimisation of protocols for structural and functional 
characterisation and as a control to compare stem cell-derived cardiomyocytes 
against. Dissociation of right atrial appendages (RAA) yielded far fewer cells than 
that of SNBTS donor tissue due to the vast difference in tissue size and even though 
donor tissue would have had the advantage of allowing access to atrial as well as 
ventricular cells, these cells showed drastically reduced survival in culture. This was 
most likely due to the fact that up to 24 hours could pass post-mortem before samples 
were available for collection and despite storage on ice during that period. 
Dissociation of foetal hearts, available within 30 min post-mortem, produced much 
greater numbers of viable cells that quickly attached and spontaneously contracted. 
Spontaneous contraction was also observed in cardiomyocytes isolated from beating 
bodies, but not adult cardiomyocytes, indicating stem cell-derived cardiomyocytes 
have a more foetal than adult phenotype. The different rates at which beating bodies 
contracted could be caused by the presence of different cells with varying inherent 
rhythmicity. All cardiomyocytes have an inherent rhythmicity but the rate at which 
they spontaneously depolarise and contract differs depending on the cell type. The 
cells with the fastest depolarisation dictate the contraction rate of the heart, therefore 
different contraction rates observed in beating bodies possibly mirror different 
populations of cardiomyocyte subtypes present. External factors like stress, 
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restriction of movement due to surrounding tissue and matrix could also play a role 
and influence contraction rate.  
 
Investigation of structural and functional characteristics of stem cell-derived 
cardiomyocytes required single cells rather than beating clusters. Disaggregation of 
beating clusters was carried out with the fragile nature of cardiomyocytes in mind, 
prioritising survival of the cells over complete disaggregation. This resulted in a 
mixed population of single cells and groups of cells with varying sizes. In clusters of 
connected cells, contractions appeared to be initiated at one end and spread to the 
other, showing functional electrophysiological coupling of neighbouring 
cardiomyocytes.  
 
All adult cardiomyocytes that survived isolation showed rapid de-differentiation, 
observed as de-organisation of myofibrils compared to freshly isolated cells. 
Myofibrils were visualised by immunocytochemistry using antibodies against alpha 
actinin, cardiac troponin I (cTnI) and cardiac troponin T (cTnT), three proteins of the 
contractile apparatus, and while alpha actinin is localised to Z-lines, both cTnI and 
cTnT are localised at the thin filaments. Stainings of tissue sections instead of 
cultured cells circumvented the issue of culture-induced dedifferentiation and 
accurately represented the characteristic adult phenotype with striated myofibrils 
aligned in parallel across the entire width of a rod-shaped cell173, 204. Foetal 
cardiomyocytes on the other hand showed no differences in myofibril organisation 
between cultured cells and tissue sections. Both contained myofibrils that stained for 
alpha actinin, cTnI and cTnT but lacked alignment and the organisation seen in adult 
cardiomyocytes, confirming that unaligned myofibrils are a feature of immaturity 
rather than culture-induced dedifferentiation in foetal cardiomyocytes205. Pluripotent 
stem cell (H9 and 34-D6) derived cardiomyocytes showed myofibril organisation 
and alignment similar to foetal cardiomyocytes. Some however had a greater number 
of myofibrils with increased alignment possibly suggesting that some hES and iPS 
cell-derived cardiomyocytes possessed a more mature phenotype than 




All fluorescent images were acquired using standard fluorescent rather than confocal 
microscopy. The resulting lower quality of pictures limited the possibilities of more 
detailed analysis such as the length of sarcomeres in individual cells. This parameter 
can be used as an indicator for an adult vs foetal or healthy vs diseased phenotype 
and could have been used as another characteristic for comparison of stem 
cell-derived with primary cardiomyocytes. Adult sarcomeres measure approximately 
2 µm in their resting state, while foetal sarcomeres measure approximately 
1.5-1.6 µm206. 
 
Investigation of the ultrastructure of myofibrils in hES and iPS cell-derived 
cardiomyocytes with transmission electron microscopy (TEM) confirmed their 
predominantly immature phenotype and similarity to 16 week old foetal 
cardiomyocytes. However, as observed with immunocytochemistry, a few stem 
cell-derived cardiomyocytes exhibited a more organised alignment of myofibrils, as 
well as more complex sarcomeres, indicative of a mixture of maturities with more 
and less mature cardiomyocytes in the same beating body. Although slightly more 
developed than foetal cells, stem cell-derived cardiomyocytes were considerably 
different from adult cells with regard to myofibril organisation, ultrastructure of 
sarcomeres and number of mitochondria. Myofibrils of varying lengths observed in 
foetal samples as well as beating bodies were not an artefact of fixation or sample 
preparation but have indeed previously been shown to represent myofibril formation 
throughout different stages197. 
 
Another feature shared by foetal and stem cell-derived cardiomyocytes was the 
anticipated absence of transverse tubules (t-tubules) in their cell membrane. Absence 
of t-tubules in stem cell-derived cardiomyocytes, expected and in accordance with 
observations made in mouse and human embryonic stem cell-derived 
cardiomyocytes207, further underlined their immature phenotype. Cell membrane 
visualisation of rat cardiomyocytes throughout development showed that t-tubules 
only started being formed postnatally208. Staining membranes of adult 
cardiomyocytes was unsuccessful since only a small number of cells survived 
isolation and those that were viable, had de-differentiated by the time they 
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successfully attached. Attachment however was crucial, since imaging of t-tubules 
required Z-stack imaging using a confocal microscope. 
 
Investigation of calcium transients proved similarly difficult in adult cardiomyocytes 
not only because of issues with viability but also because they require electrical 
stimulation to trigger calcium-induced calcium release (CICR) and the necessary 
equipment was not available. Foetal and stem cell-derived cardiomyocytes, 
spontaneously contracting and thus not requiring electrical stimulation, showed 
calcium transients that were almost indistinguishable from each other in their 
upstroke but differed noticeably with regard to decay kinetics. The shape of calcium 
transients measured in foetal cells paralleled previously published observations and 
was distinctly different from transients seen in adult cells in the same study208. 
Compared to foetal cardiomyocytes, adult calcium transients are marked by a faster 
upstroke (calcium release into the sarcoplasm) and faster decay (calcium removal 
from sarcoplasm). Faster calcium decay measured in stem cell-derived compared to 
foetal cardiomyocytes could be interpreted as another indication that they have a 
slightly more mature phenotype. Results from a recent publication indicating 
that calcium handling properties of cardiomyocytes derived from iPS cells are 
relatively immature compared to those derived from hES cells could not be 
confirmed209.  
 
Calcium transient signals were recorded using time-lapse recordings because a 
continuous recording was not possible with the equipment available. Data 
reconstruction from signals sampled over time can lead to distortion of the original 
continuous signal referred to as temporal aliasing. In addition, the frame rate at 
which the calcium signals were recorded was limited by the equipment and at 17 fps 
relatively low. Faster acquisition would of course allow for a more detailed and 
accurate representation of calcium transients but considering how well the recorded 
results of foetal cardiomyocytes compared to previously published data the loss of 
information caused by the experimental set-up was of minor concern.  
 
Due to variability in fluorescence intensity, partly due to photobleaching, the 
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fluorescence for each of the calcium transients was normalised to their respective 
amplitude (F/F0). Therefore, F/F0 is the same for all cells and could not be used to 
estimate and compare intracellular calcium concentrations.  
 
Calcium imaging on a beating body treated with the sodium channel inhibitor 
Tetrodotoxin (TTX) proved functional excitation-contraction coupling in stem 
cell-derived cardiomyocytes. Tetrodotoxin competes with sodium ions, binds to the 
pore region and blocks the sodium channel until it slowly diffuses off. By blocking 
flow of sodium ions through the channel, it prevents the development of action 
potentials and thereby CICR. The cardiac sodium channel Nav1.5 is classed as TTX 
resistant in contrast to TTX sensitive sodium channels. The TTX concentration 
chosen would have blocked all sensitive channels but recordings showed some peaks 
indicating the presence of resistant channels, therefore indicating the presence of 
resistant cardiac sodium channels. Contractions and calcium transients slowed over 
time as TTX diffused throughout the buffer. As the recording was made at room 
temperature it would have been difficult to prove that an eventual complete halt of 
calcium transients would have been caused by TTX rather than by low temperature.  
 
 
Finally, the most important functional test of Brugada Syndrome patient-derived 
cardiomyocytes will be the recording of sodium currents as it will reveal if they 
accurately recapitulate the expected disease phenotype and are therefore a suitable 
model system. In a proof of principle experiment, sodium currents were recorded 
from H9-derived cardiomyocytes. Despite their relative immaturity, pluripotent stem 
cell-derived cardiomyocytes expressed functional voltage-dependent cardiac sodium 
channels at levels high enough that the resulting sodium current necessitated a switch 
to Low Na+ bath solution. The absence of potassium in the bath solution ensured, that 
only sodium currents were recorded. In the heart most of the sodium current is 
conducted by Nav1.5, the channel implicated in the majority of Brugada Syndrome 
cases with identified genetic alterations. Recording sodium currents in single cells 
will be the crucial functional assessment of Brugada Syndrome patient-derived 
cardiomyocytes in the subsequent chapter. It is expected that although structurally 
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indistinguishable from healthy controls, patient-specific cardiomyocytes will show 
reduced maximum sodium current density. 
 
In conclusion, cardiomyocytes were successfully isolated from foetal cardiac tissue 
while isolation of viable cells from adult tissue proved challenging. Morphological 
and structural comparisons demonstrated the expected classical foetal and adult 
phenotypes. Structural and functional characterisation of cardiomyocytes derived 
from healthy hES and iPS cell lines showed varying degrees of maturity but overall a 
more foetal-like phenotype. Protocols optimised in this chapter can subsequently be 
used to characterise newly derived patient-specific cardiomyocytes while the data 
gathered will provide a platform for comparison against healthy control pluripotent 
















GENERATION AND CHARACTERISATION OF BRUGADA 





Brugada Syndrome is an autosomal dominant congenital cardiac disorder that is 
responsible for 20% of sudden deaths of patients with structurally normal hearts. The 
majority of mutations are found in SCN5A, the gene encoding for the alpha subunit 
of cardiac sodium channel Nav1.5. Fibroblasts from a patient with Brugada 
Syndrome (male, 69) and classical ST segment elevation in his ECG due to a 
mutation (c.1100G>A) in SCN5A and a healthy age- and sex-matched volunteer were 
reprogrammed using episomal vectors carrying Oct-4, shp53, Sox2, Klf4, L-Myc and 
Lin28. Newly derived patient (BP) and control iPS cell lines (HV3) did not differ 
significantly from hES cells (H9) in terms of morphology and expression of 
pluripotency markers as detected by immunocytochemistry and quantitative RT-PCR, 
however flow cytometry revealed three clones (BP-C5, BP-C6, HV3-C28) had a 
significantly lower percentage of SSEA3 positive cells. Patient-specific 
cardiomyocytes, derived from 2 patient iPS cell lines, were similar to foetal 
cardiomyocytes and indistinguishable from cardiomyocytes derived from hES (H9) 
and other iPS cell lines (34-D6) in terms of morphology, myofibril organisation, 
sarcomere structure, t-tubule structures and kinetics of intracellular calcium 
transients. However, electrophysiological analysis showed a 48.4% reduction of 
sodium current in patient-derived compared to healthy control-derived 
cardiomyocytes. This finding is consistent with previous observations in HEK293 
cells and Xenopus oocytes, but for the first time demonstrates that classical Brugada 






Brugada Syndrome is an autosomal dominant congenital disease that is responsible 
for 20% of sudden cardiac deaths of patients with structurally normal hearts1. First 
described by the Brugada brothers in 19922, it is characterised by an abnormal 
electrocardiogram (ECG) with ST segment elevation in the right precordial leads V1 
to V3 and right bundle-branch block frequently leading to ventricular fibrillation 
(VF). Patients often present with symptoms of ventricular tachycardia (VT), 
bradycardia, and atrial ventricular (AV) node conduction disorder, and more males 
than females are diagnosed with Brugada Syndrome. To date, the implantation of a 
cardioverter defibrillator is the only proven effective treatment of the disease4, 5.  
 
Even though Brugada Syndrome has been associated with mutations in 17 genes15, 
its main identified genetic cause is a mutation in SCN5A16. This gene encodes for the 
alpha-subunit of the cardiac sodium channel Nav1.5, the channel responsible for 
sodium inward current (INa). In order to understand the underlying mechanisms of the 
Brugada phenotype, a variety of model systems have been utilised. These models 
include transgenic mice17, canine heart preparations18 and expression of mutant 
SCN5A in different cellular expression systems16.  These three model systems have 
provided some insight into the molecular basis of Brugada Syndrome. The main 
limitation for all model systems thus far remains that they are only able to model 
cases in which the underlying genetic alteration has been identified. However, a 
potentially pathogenic mutation is identified in only one third of Brugada Syndrome 
patients102.  
 
A new model system, based on the generation of iPS cells, could for the first time 
allow us to study the molecular basis of this disorder in patients without an identified 
mutation. Reprogramming fibroblasts from patients with Brugada Syndrome to 
generate iPS cells could generate new insight into the effects of mutations in their 
natural genetic environment. Not only will patient-specific iPS cells allow for the 
generation of the cell type directly affected by the disease, they also carry the 
patient’s exact genetic background. To date, several other cardiac disorders including 
LQT1126, LQT2127 and Timothy syndrome128 have been modelled using the iPS cell 
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approach. Although there are no studies looking at pure Brugada phenotypes, Davis 
et al. recently derived cardiomyocytes from patients carrying the SCN5A-1795insD 
mutation129. SCN5A-1795insD causes Brugada Syndrome/LQT3 overlap symptoms 
and has previously been studied in both mouse model and expression systems. The 
patient-specific iPS cell-derived cardiomyocytes recapitulated the decreased INa peak 
and persistent INa associated with Brugada Syndrome and LQT3 respectively. To 
validate this system’s viability as a model system for classical Brugada Syndrome, a 
patient with classical Brugada Syndrome ECG and an identified mutation in SCN5A 
was chosen. The missense mutation that this patient carried (c.1100G>A, leading to 
p.R367H) had previously been studied in cellular expression systems, allowing direct 
comparison of electrophysiological findings across model systems.  
 
Expression of the sodium channel carrying the missense mutation c.1100G>A in 
SCN5A in HEK293 cells and Xenopus oocytes showed no sodium current, while 
normal currents were recorded from cells expressing wild type channels74, 210. Should 
iPS cell-derived cardiomyocytes prove to be a feasible model system for Brugada 
Syndrome, they would offer the possibility to investigate Brugada Syndrome patients 
without known genetic cause and mutation carriers that show no symptoms. This is 
an advantage that none of the other model systems possess. It would also deliver the 
most accurate and relevant setting for drug toxicity screenings of all the model 
systems which could help exclude possible drugs, based on their toxic effects on 







To generate iPS cells lines from a Brugada Syndrome patient and a matched healthy 
control, to assess their pluripotency and differentiation potential and finally to derive, 




5.4 Results  
A male Caucasian aged 69 with Brugada Syndrome, with a classical ST segment 
elevation in the ECG and a missense mutation in SCN5A (c.1100G>A – p.R367H), 
was identified through the Familial Arrhythmia Network for Scotland (FANS). Skin 
biopsies from this patient with Brugada Syndrome (BP) and one age- and 
sex-matched healthy volunteer (HV3) were obtained and processed within an hour of 
collection. The dermal tissue was dissected into 1 mm3 pieces and cultured under a 
sterile glass coverslip for 2 weeks in fibroblast growth medium before harvesting 
emerging fibroblasts. After further expansion, 0.5 x 106 fibroblasts were transfected 
with Addgene Y4 combination episomes and cultured in fibroblast growth medium 
for 7 days. After transferring transformed fibroblasts onto 0.1% gelatine, the medium 
was changed to hES cell selection medium TeSR-E8. Possible iPS cell colonies, 
assessed based on morphology, appeared between 20-25 days after electroporation 
and were manually picked into separate Matrigel coated wells. Colonies were treated 
as individual clones and expanded to give rise to independent cell lines. The name of 
each cell line was derived from the donor, BP or HV3, the abbreviation ‘C’ for clone 
and number of the clone at the time of picking. Since episomal vectors do not 
integrate into the host genome and are not co-replicated during cell proliferation, 
they are lost over time and therefore, clones that failed to express pluripotency genes 
endogenously would not give rise to stable pluripotent stem cell lines. Based on 
previous experience, cell lines exhibiting pluripotent stem cell morphology after 8 
passages were considered stable. Five patient (BP-C5, C6, C11, C15 and C26) and 
three healthy control (HV3-C23, C24 and C28) cell lines were fully characterised 
investigating morphology, chromosomal integrity, expression of pluripotency 
markers and the ability to differentiate into all three germ layers. Once fully 
validated, cardiomyocytes generated from BP iPS cell lines were investigated and 







5.4.1 Generation and characterisation of iPS cells  
The patient recruited for this study had been diagnosed 30 years ago based on the 
classical ST segment elevation in his ECG (Figure 39 A). Genetic screening 
identified a mutation in SCN5A as the likely cause of his disorder which has since 
been studied in cellular expression systems. He has experienced syncope but neither 
VT nor VF and does hence not carry a cardioverter defibrillator or receive ajmaline 
or flecainide treatment. After his diagnosis other family members were identified 
who carried the same mutation and were either symptomatic or asymptomatic 















Figure 39: Clinical and genetic characterization of the patient and his family.  
A – V1-V3 of a 12-lead ECG of the patient showing the ST segment elevation characteristic of 
Brugada Syndrome. B – Family pedigree of the patient with Brugada Syndrome. Squares indicate 
males, circles females, solid symbols individuals with Brugada Syndrome, and open symbols 
unaffected family members. Plus signs indicate the carriers of the mutation c.1100G>A in SCN5A and 
minus signs, non-carriers. Family members for whom genetic information was not available are 







All 5 Brugada Syndrome patient (BP) and three healthy control (HV3) derived iPS 
cell lines grew in flat densely packed colonies with cells exhibiting the high nucleus 
to cytoplasm ratio typical for hES cells (Figure 40). For routine culture, cells were 
maintained on matrigel in feeder-free conditions in TeSR-E8 medium with very few 
spontaneously differentiated cells surrounding colonies. There were no obvious 
morphological differences observed between BP and HV3 clones compared to 
control cell lines H9, 33-D9 and 34-D6. No obvious differences in morphology were 



















Figure 40: Morphology of BP and HV3 iPS cell lines in culture 
Representative light microscopy images of induced pluripotent stem cell lines derived from a patient 
with Brugada Syndrome (BP) and a healthy volunteer (HV3) in feeder-free culture. Scale bars 
represent 1000 µm, p indicates passage number. 
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5.4.1.2 Mutation in SCN5A 
Patient BP carries the missense mutation c.1100G>A in SCN5A resulting in an 
Arginine to Histidine substitution at position 367 (p.R367H) in the alpha subunit of 
cardiac sodium channel Nav1.5. To assess if this mutation was still present after 
reprogramming in patient and absent in healthy control iPS cells, genomic DNA was 
isolated from each iPS cell line. Sequencing of exon 9 of SCN5A in all genomic 
DNA samples confirmed the presence of c.1100G>A in BP-C5, C6, C11, C15 and 











Figure 41: Sequencing analysis of SCN5A in BP and HV3 cell lines 
The missense mutation c.1100G>A was identified in genomic DNA isolated from BP-C5, C6, C11, 
C15 and C26 but not in HV3-C23, C24 or C28. Sequencing was carried out by Dr Elisabet Selga. 
 
 
5.4.1.3 Expression of pluripotency markers – Quantitative RT-PCR 
RNA from undifferentiated cultures was extracted, purified and reverse transcribed 
as before for each sample in biological triplicate. BP clones, HV3 clones and H9 
were assessed for relative expression of Oct-4, Sox2, c-Myc and Nanog using 
previously optimised quantitative RT-PCR conditions. For each sample the 
expression of the gene of interest was related to expression of the house-keeping 
gene β-actin in the same sample, before normalising expression to the positive 
control H9. Relative expression of all genes of interest is shown in Figure 42. 
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One-way ANOVA with a Dunnett's post-test for multiple comparison showed no 
significant difference in expression of the tested pluripotency transcription factors 
between any of the newly derived iPS cell lines and H9 but significantly (p<0.05) 

















Figure 42: Pluripotency transcription factor expression 
Relative expression of pluripotency transcription factors Oct-4, Sox2, Nanog and c-Myc was 
investigated in undifferentiated H9, BP iPS cell clones and HV3 iPS cell clones. A one-way ANOVA 
with a Dunnett's post-test for multiple comparison showed no significant difference in pluripotency 
transcription factor expression in any of the newly derived iPS cell lines and H9 but significantly 
lower expression of Nanog in BP-C11, C15, C26 and HV3-C28 compared to 34-D6 (p<0.05). Bars 
represent mean values of biological triplicates with error bars representing SEM.  
 
 
5.4.1.4 Expression of pluripotency markers – Immunocytochemistry 
To assess pluripotency on a protein level, undifferentiated pluripotent stem cells were 
fixed 2 days after passaging or upon reaching 30% confluency and stained for 
pluripotency markers Nanog, Oct-4 and Tra-1-60. Nuclei were counterstained with 
DAPI. All cell lines showed nuclear Nanog and Oct-4 staining and cell surface 
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staining for Tra-1-60 (Figure 43 and Figure 44). Differentiated cells surrounding the 
colonies did not stain for pluripotency markers but are visible as DAPI stained 
nuclei. These stainings were indistinguishable from those of undifferentiated H9 and 
























Figure 43: Immunocytochemistry for pluripotency markers Nanog, Oct-4 and Tra-1-60 in BP 
iPS cell clones 
BP-C5, C6, C11, C15 and C26 stained positive for pluripotency markers Nanog, Oct-4 and Tra-1-60. 
Nuclei were counterstained with DAPI (blue). Representative merged images of 10 colonies per clone 


















Figure 44: Immunocytochemistry for pluripotency markers Nanog, Oct-4 and Tra-1-60 in HV3 
iPS cell clones 
HV3-C23, C24 and C28 stained positive for pluripotency markers Nanog, Oct-4 and Tra-1-60. Nuclei 
were counterstained with DAPI (blue). Representative merged images of 10 colonies per clone are 
shown. Scale bars represent 100 µm.  
 
 
5.4.1.5 Expression of pluripotency markers – Flow cytometry 
The percentage of cells expressing cell surface markers SSEA-3 and SSEA-4 in 
undifferentiated populations of BP and HV3 iPS cell clones was investigated using 
flow cytometry and compared to undifferentiated H9 and 34-D6.  Each cell line was 
harvested, stained and analysed in biological triplicate using the protocols optimised 
in Chapter 3. The percentages of SSEA-3 and SSEA-4 positive cells in each 
undifferentiated culture, expressed as the mean value of biological triplicates with the 






Table 16: Percentage of cells expressing SSEA-3 and SSEA-4 
 H9 34-D6 BP HV3 













































Undifferentiated cultures of all BP- and HV3-derived iPS cell lines contained a high 
percentage of SSEA-4 positive cells at levels similar to undifferentiated H9 and 
34-D6. One-way ANOVA with a Dunnett's post-test for multiple comparison showed 
percentages of SSEA-3 positive cells in those same cultures were significantly lower 
in BP-C6, BP-C15, BP-C26 and HV3-C28 (p<0.05) compared to H9 and 34-D6. 
 
 
5.4.1.6 Three germ layer formation 
Before embryoid body (EB) formation, all clones were transitioned from a 
feeder-free culture system onto a feeder layer and cultured for three passages. EBs 
were then formed from undifferentiated cultures of BP and HV3 iPS cell clones and 
cultured in EB media in suspension for 7 days. Subsequently, EBs were plated onto 
gelatine-coated dishes, cultured for 10 additional days and finally fixed and stained 
for markers of the three germ layers endoderm (Alpha-fetoprotein, AFP), ectoderm 
(β-tubulin III) and mesoderm (muscle actin). EBs from all BP and HV3 iPS cell 
clones showed positive staining for markers of all three germ layers (Figure 45 and 
Figure 46). Unlike H9 and 34-D6, EBs from newly derived BP and HV3 iPS cell 
lines did not spontaneously differentiate to cells that stain for AFP. Guided hepatic 
differentiation of these cell lines however gave rise to AFP positive cells of the 




























Figure 45: Immunocytochemistry for the three germ layers formed by BP iPS cell clones 
EBs were formed from undifferentiated BP iPS cell clones and differentiated in suspension for 7 days 
and for an additional 10 days adherent to plates. EBs from all clones showed formation of all three 
germ layers endoderm (AFP), ectoderm (β-tubulin III) and mesoderm (muscle actin). Nuclei were 





















Figure 46: Immunocytochemistry for the three germ layers formed by HV3 iPS cell clones 
EBs were formed from undifferentiated HV3 iPS cell clones and differentiated in suspension for 7 
days and for an additional 10 days adherent to plates. EBs from all clones showed formation of all 
three germ layers endoderm (AFP), ectoderm (β-tubulin III) and mesoderm (muscle actin). Nuclei 
were counterstained with DAPI (blue). Scale bars represent 100 µm. 
 
5.4.1.7 Chromosomal integrity 
Genomic DNA from each iPS cell line was analysed for chromosomal integrity as 
before with a single nucleotide polymorphism (SNP) array. Analysis of the LogR 
ratio in combination with the β-Allele Frequency revealed no microduplications in 
BP-C5, C15, C26 or any of the HV3 clones. A complete overview of all 
chromosomes is supplied in Appendix 1. Microduplications, shown in Figure 47, 
were detected in BP-C6 in chromosome 5 (q33.2, 155.453.475 - 155.967.030) and 
BP-C11 in chromosome 2 (q31.1, 171.032.090 - 171.435.002), chromosome 3 (p13, 
71.688.564 – 74.289.885), chromosome 4 (q32.1, 155.654.421 - 155.938.012), 
chromosome 12 (p13.1, 13.394.582 - 13.446.880) and chromosome 17 (q12, 
36.821.619 - 37.024.319). No microdeletions were detected in any of the samples. A 
list of the genes affected by microduplications in BP-C6 and C11 is provided in Table 





























Figure 47: Microduplications identified through SNP analysis 
Analysis of the β-Allele Frequency of a SNP array revealed microduplications in BP-C6 in 
chromosome 5 (q33.2, 155.453.475 - 155.967.030) and BP-C11 in chromosome 2 (q31.1, 171.032.090 
- 171.435.002), chromosome 3 (p13, 71.688.564 – 74.289.885), chromosome 4 (q32.1, 155.654.421 - 
155.938.012), chromosome 12 (p13.1, 13.394.582 - 13.446.880) and chromosome 17 (q12, 
36.821.619 - 37.024.319). No microdeletions were detected in any of the samples. Red box indicates 











Chromosome 5  




Chromosome 2  
(q31.1, 171.032.090 - 
171.435.002)  
MYO3B (myosin IIIB) 
Chromosome 3  
(p13, 71.688.564 - 
74.289.885) 
PROK2 (prokineticin 2 isoform a precursor) 
GPR27 (G protein-coupled receptor 27) 
EIF4E3 (eukaryotic translation initiation factor 4E) 
RYBP (RING1 and YY1 binding protein) 
SHQ1 (SHQ1 homolog) 
GLT8D4 (glycosyltransferase 8 domain containing 4) 
PPP4R2 (protein phosphatase 4, regulatory subunit 2) 
FLJ10213 (hypothetical protein LOC55096) 
PDZRN3 (PDZ domain containing ring finger 3) 
Chromosome 4  
(q32.1, 155.654.421 - 
155.938.012)  
LRAT (lecithin retinol acyltransferase),  
RBM46 (RNA binding motif protein 46) 
Putative uncharacterized protein MGC27016 
Chromosome 12  
(p13.1, 13.394.582 - 
13.446.880)  
no gene associated 
Chromosome 17  
(q12, 36.821.619 - 
37.024.319) 
C17orf96 (hypothetical protein LOC100170841)  
MLLT6 (myeloid/lymphoid or mixed-lineage 
leukemia) 
CISD3 (CDGSH iron sulfur domain 3 precursor) 
PCGF2 (ring finger protein 110) 
PSMB3 (proteasome beta 3 subunit) 
PIP4K2B (phosphatidylinositol-5-phosphate 4-kinase, 
type) 
CCDC49 (coiled-coil domain containing 49) 
C17orf96 (hypothetical protein LOC388381) 
RPL23 (ribosomal protein L23) 
SNORA21 (Homo sapiens small nucleolar RNA, 




5.4.2 Generation and characterisation of cardiomyocytes 
Previous experiments (3.2.8 Comparison of cardiac differentiation protocols) showed 
that, despite inter-line variability, guided differentiation protocols could be used to 
reliably and efficiently generate beating bodies. Due to technical difficulties 
discussed later on, no beating bodies were generated from HV3 iPS cell lines. No 
such issues were encountered with BP-derived iPS cell lines and beating bodies were 
generated from two patient-specific lines, BP-C5 and C26. 
 
 
5.4.2.1 BP-derived cardiomyocytes – Morphology  
Beating bodies generated from Brugada Syndrome patient iPS cell lines BP-C5 and 
BP-C26 (Figure 48 A, C) varied in size and rate at which they contracted even when 
derived from the same iPS cell line using the same differentiation protocol. The 
percentage of cardiomyocytes within a beating body, observed as the size of the 
contracting area, also differed. With regular dissections to remove surrounding 
proliferating non-cardiac tissue, beating bodies were maintained in culture for 3-4 
weeks before disaggregation and analysis of single cardiomyocytes.   
 
To investigate the properties of single BP iPS cell line derived cardiomyocytes, 
beating bodies were enzymatically and mechanically disaggregated and plated onto 
1% gelatine. Disaggregation resulted in single as well as clusters of beating 
cardiomyocytes, with groups of connected cardiomyocytes exhibiting synchronised 
contraction. Cardiomyocytes derived from BP iPS cell lines resumed to contract 
24-48 hours post disaggregation and showed morphologies similar to foetal 
cardiomyocytes (Figure 48 B, D). To allow for attachment but prevent overgrowth by 
proliferating non-cardiac cells, cardiomyocytes were analysed 3-4 days after 
disaggregation. Videos of spontaneously contracting beating bodies and single 






















Figure 48: Beating bodies and single cardiomyocytes derived from BP-C5 and BP-C26  
A and C (10x magnification) – BP-C5 and BP-C26 were differentiated using guided cardiac 
differentiation protocols. Size, contraction rate and percentage of contractile tissue differed between 
beating bodies. Beating bodies were cultured for 3-4 weeks before enzymatic and mechanical 
disaggregation. B and D (40x magnification) – Disaggregation resulted in single as well as clusters of 
beating cardiomyocytes, with groups of connected cardiomyocytes exhibiting synchronised 
contraction. Spontaneously contracting stem cell-derived cardiomyocytes showed morphologies 
similar to foetal cardiomyocytes. 
 
 
5.4.2.2 BP-derived cardiomyocytes – Cardiac markers 
Staining protocols optimised on primary human cardiac tissue were used to stain 
cardiomyocytes derived from BP-C5 and BP-C26. After 3-4 weeks of culture, 
beating bodies were enzymatically and mechanically disaggregated and plated onto 
1% gelatine-coated glass coverslips. After 3-5 days of recovery, cells were fixed and 
stained for markers of the cardiac contractile apparatus. Cells isolated from beating 
bodies stained positive for alpha actinin, cardiac troponin I (cTnI) and cardiac 
troponin T (cTnT) (Figure 49 and Figure 50). Single cTnT staining exhibited the 
166 
 
striated pattern of thin filaments while double stainings for cTnI and alpha actinin 
resulted in alternating striations, staining thin filaments and Z-lines respectively. In 
most BP iPS cell-derived cardiomyocytes stainings showed myofibrils throughout 
the cells that lacked the complete parallel alignment of Z-lines detected in mature 
cardiomyocytes (Figure 49 B and Figure 50 F). Some cells, however, showed a 
greater number of myofibrils that exhibited a higher level of organisation         
(Figure 49 D and Figure 50 B).  As observed with light microscopy, pluripotent stem 

















Figure 49: Immunocytochemistry for cardiac markers in cardiomyocytes derived from BP-C26 
3-4 week old beating bodies were disaggregated, plated onto 1% gelatine-coated glass coverslips, 
fixed after 3-5 days and stained for proteins of the cardiac contractile apparatus. Cells stained positive 
for (A and B) alpha actinin (green) and cTnI (red) and (C and D) cTnT, showing intact myofibrils but 
they displayed no rod shaped morphology. Nuclei were counterstained with DAPI (blue). Figure 
shows merged images. B and D are magnified areas in A and C respectively. Scale bars represent 


























Figure 50: Immunocytochemistry for cardiac markers in cardiomyocytes derived from BP-C5 
3-4 week old beating bodies were disaggregated, plated onto 1% gelatine-coated glass coverslips, 
fixed after 3-5 days and stained for proteins of the cardiac contractile apparatus. Cells stained positive 
for alpha actinin (A and D), cTnI (B and E) and cTnT (C and F) showing intact myofibrils but 
displayed no rod shaped morphology. Nuclei were counterstained with DAPI (blue). Figure shows 
merged images. D, E and F are magnified areas in A, B and C respectively. Scale bars represent 50 









5.4.2.3 BP-derived cardiomyocytes – Ultrastructure 
Beating bodies derived from BP-C5 and BP-C26 were cultured for 3-4 weeks before 
being processed for transmission electron microscopy (TEM). In preparation for 
TEM, samples underwent protein fixation, lipid fixation and serial dehydration. 
Samples embedded in resin were stained and ultrathin sections were imaged. TEM 
images from different layers of beating bodies showed the presence of cardiac and 
non-cardiac cells. Images of cardiomyocytes are shown in Figure 51 and are 
representative of cells found in beating bodies derived from BP-C5 and BP-C26.  
 
The ultrastructure of cardiomyocytes found in these beating bodies resembled that of 
those generated from healthy control hES and iPS cells (Chapter 4, page 120). 
Myofibrils varied in size with some consisting of a single sarcomere. Myofibrils 
were generally sparser than in adult cardiomyocytes and lacked the alignment of 
Z-lines (Figure 51 A). However, some cells contained a greater number of myofibrils 
with increased organisation, exhibiting some alignment of Z-lines between adjacent 
myofibrils (Figure 51 B). Patient-specific iPS cell-derived cardiomyocytes contained 
mitochondria and lipid deposits (Figure 51 C) as observed in adult and foetal 
cardiomyocytes. At high magnification, all sarcomeres showed Z-lines but a small 
number of cells contained sarcomeres with I-bands and A-bands in addition to 



























Figure 51: TEM of BP iPS cell-derived cardiomyocytes 
A – After 3-4 weeks in culture most BP iPS cell-derived cardiomyocytes showed myofibrils (MF) 
comparable to foetal cells in number, size and sarcomere structure. B – Some cells contained a greater 
number of myofibrils with increased organisation and alignment of Z-lines (Z) of adjacent myofibrils. 
C – Mitochondria and lipid deposits were present. D – A few cells contained sarcomeres with 
I-bands (I) and A-bands (A) in addition to Z-lines. Representative images of cardiomyocytes derived 
from BP-C5 and BP-C26 from 3 beating bodies each are shown. Mito – mitochondrion 
 
5.4.2.4 BP-derived cardiomyocytes – Membrane visualisation 
The cell membrane of cardiomyocytes derived from BP-C5 and BP-C26 was 
visualised using a membrane dye in order to determine if transverse tubules 
(t-tubules) were present.  Beating bodies that had been cultured for 3-4 weeks were 
disaggregated and seeded onto glass coverslips as described above for 
immunocytochemistry. After disaggregated cells resumed to spontaneously contract, 
their cell membrane was stained with the membrane dye Di-8-ANEPPS. 
Spontaneously contracting cells, regarded to be cardiomyocytes, were imaged in 
Z-stacks on a confocal microscope at 37°C. As observed in cardiomyocytes derived 
from H9 and 34-D6, no t-tubule structures were visible in stained cell membranes of 
cardiomyocytes derived from BP-C5 or BP-C26, representative images of which are 












Figure 52: Visualisation of cell membrane of BP iPS cell-derived cardiomyocytes 
Single cells from disaggregated 3-4 week old beating bodies were stained with the membrane dye 
Di-8-ANEPPS. Z-stacks of spontaneously contracting cells were imaged on a confocal microscope at 
37°C. Visualised cell membranes of cardiomyocytes derived from BP-C5 or BP-C26 showed no 
t-tubules.  Representative images of 5 cells for both BP-C5 and BP-C26 are shown.  
 
 
5.4.2.5 BP-derived cardiomyocytes – Intracellular calcium imaging 
For visualisation of calcium transients in patient-specific single cardiomyocytes, 
beating bodies derived from BP-C5 and BP-C26, which had been cultured for 
2-3 weeks, were disaggregated and seeded onto glass coverslips as described for 
immunocytochemistry. After disaggregated cells resumed to spontaneously contract, 
cytoplasmic calcium was visualised with Fluo-4 as described in Chapter 4 (4.3.5 
Intracellular calcium imaging). Spontaneously contracting cells were imaged for 20 s 
at room temperature using an optical camera connected to a fluorescence 
microscope. Representative videos of calcium transients are supplied in Appendix 2. 
Fluorescence intensities were traced over time and representative traces of calcium 
transients in BP-C5 and BP-C26 iPS cell-derived cardiomyocyte are shown in Figure 

















Figure 53: Calcium transients in BP iPS cell-derived cardiomyocytes 
Beating bodies generated from BP-C5 and BP-C26 that had been cultured for 2-3 weeks were 
disaggregated and plated as single cells. After spontaneous contractions resumed, intracellular calcium 
was visualised with Fluo-4 and fluorescence intensities were recorded. Images show traces of 
fluorescence intensity in one cell over 20 s for both cell lines. Images are representative of 32 cells 
and 20 cells derived from three BP-C5 and three BP-C26 beating bodies respectively. Peak heights 
decreased in both over time. Fluorescence intensity is shown in arbitrary units (a.u.). 
 
 
In order to compare the kinetics of calcium transients in patient-derived 
cardiomyocytes to previously analysed foetal and healthy control iPS cell-derived 
cardiomyocytes, data from one representative calcium transient from each of 52 cells 
(BP-C5 and C26 derived) was analysed and pooled. For each calcium transient, the 
background fluorescence was subtracted, and each data point normalised to the peak 



























































Figure 54: Single calcium transient in spontaneously contracting cardiomyocytes 
One representative calcium transient from each of 52 BP iPS cell-derived cardiomyocytes was 
analysed as previously described in Chapter 4. Calcium transients of patient-specific derived 
cardiomyocytes resemble healthy control iPS cell-derived cardiomyocytes with faster decay kinetics 
than foetal cardiomyocytes. Fluorescence intensity is shown in arbitrary units (a.u.) as mean values 
with error bars representing SEM. 
 
 
Because data had been normalised, amplitude (F/F0) was the same for all cells and 
could not be compared between different cell lines. However, considerable 
differences were detected between their decay kinetics (t50, t75, t90) (Figure 55). The 
decay kinetics are related to the speed at which calcium is pumped back into the 
sarcoplasmic reticulum and t50, t75 and t90 refer to the times correlating to 50%, 75% 
and 90% decay of calcium transients. Decay of calcium transients was considerably 
slower in foetal cardiomyocytes compared to BP iPS cell-derived cardiomyocytes 
(t50=0.96 s vs 0.86 s, Δt50=0.1 s). The difference further increased at t75 (1.28 s vs 
1.02 s, Δt75=0.26 s) and t90 (1.53 s vs 1.19 s, Δt90=0.34 s). Two-way ANOVA with a 
Bonferroni post-test showed no significant difference in calcium transients between 
















Figure 55: Decay kinetics of calcium transients in foetal and BP iPS cell-derived cardiomyocytes 
Decay kinetics differed between foetal and BP iPS cell-derived cardiomyocytes at times correlating to 
50%, 75% and 90% decay of calcium transients (t50, t75 and t90 respectively). Decay of calcium 
transients was markedly slower in foetal cells (t50=0.96 s vs 0.86 s, t75= 1.28 s vs 1.02 s and t90=1.53 s 
vs 1.19 s). The difference between foetal and BP iPS cell-derived cells increased over time 
(Δt50=0.1 s, Δt75=0.26 s, Δt90=0.34 s). Fluorescence intensity is shown in arbitrary units (a.u.) as the 




Sodium currents in patient (BP-C5, BP-C26) and healthy (34-D6) control-derived 
cardiomyocytes were studied using the perforated patch-clamp technique previously 
optimised on hES cell-derived cardiomyocytes. Beating bodies were derived from 
undifferentiated BP-C5, BP-C26 and 34-D6 at the same time and cultured for similar 
lengths of time before shipment to Spain. In preparation for sodium current 
recordings of single cells beating bodies were disaggregated and plated onto gelatine 
as described previously for immunocytochemistry. Electrophysiological recordings 
were performed on singles cells, identified as cardiomyocytes by their morphology 
and/or spontaneous contraction, 2-3 days after disaggregation. Sodium currents in 
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patient (n=10) and healthy control (n=4) iPS cell-derived cardiomyocytes at varying 
potentials were recorded and are shown in Figure 56 as mean ± SEM. Recordings 
from BP-C5 (n=7) and BP-C26 (n=3) derived cardiomyocytes were pooled. Average 
sodium current density, calculated as the measured current normalised to the cells 
capacitance, was significantly reduced in patient-derived compared to healthy 
control-derived cardiomyocytes (p=0.0027) when analysing peak current densities 
with an unpaired student t-test. Maximum sodium current density was reduced by 





















Figure 56: Sodium current densities of cardiomyocytes derived from Brugada Syndrome patient 
and healthy control iPS cells 
A – Representative sodium current traces recorded from cardiomyocytes derived from Brugada 
Syndrome patient BP (C5 and C26) and healthy control 34-D6 iPS cells using perforated patch 
clamping. B – Current-voltage relationships for patient (n=10) and control-derived (n=4) 
cardiomyocytes are shown as mean ± SEM. Maximum sodium current density of patient-derived cells 
was reduced to 51.62% of the healthy control-derived cardiomyocytes. Sodium currents were recorded 
by Dr Elisabet Selga. 
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5.5 Discussion and Conclusion 
The aims of this chapter were to I) generate and fully characterise iPS cells from one 
Brugada Syndrome patient and one age- and sex-matched healthy volunteer and 
II) characterise cardiomyocytes derived from these iPS cell lines. Using techniques 
optimised in Chapter 3, newly generated iPS cell lines showed morphology and 
pluripotency marker expression on mRNA and protein level comparable to control 
lines H9, 33-D9 and 34-D6 and formed all three germ layers upon differentiation. 
Investigation of structural and functional characteristics of Brugada Syndrome 
patient-specific cardiomyocytes, using protocols optimised in Chapter 4, showed 
they more closely resembled foetal rather than adult cardiomyocytes and were 
indistinguishable from healthy control iPS cell line (34-D6) derived cardiomyocytes. 
Electrophysiological analysis of sodium current density however revealed a 48.38% 
reduction in patient-derived compared to healthy control cardiomyocytes. 
 
Our patient with Brugada Syndrome was chosen for a number of reasons. Brugada 
Syndrome is a relatively rare disorder and only a handful of families in Scotland are 
known to be affected, not all of whom carry a known mutation. The recruited patient 
carried the missense mutation c.1100G>A in SCN5A resulting in a substitution of 
Arginine for Histidine at position 367 (p.R367H) in the alpha subunit of the cardiac 
sodium channel Nav1.5. His classical Brugada Syndrome ECG with ST segment 
elevation and a mutation in SCN5A, the main identified genetic cause in Brugada 
Syndrome patients, made him an ideal candidate for this study. In addition, this 
particular mutation, in the first P segment of a pore-lining region, had previously 
been studied in expression systems allowing a comparison of results across different 
model systems. Since this was the first time classical Brugada Syndrome was 
modelled using iPS cell-derived cardiomyocytes a direct comparison with an 
analogous conventional expression system looking at the same mutation was deemed 
beneficial as a control before investigating novel mutations. Furthermore, studying 
the same mutation in its natural environment could reveal other alterations in the 
properties of the Nav1.5 channel undetected by conventional expression systems. 
Genetic screening of the immediate family had identified siblings of the patient with 
and without the mutation with and without an abnormal ECG allowing for future 
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studies of symptomatic and asymptomatic patients that not only carry the same 
mutation but also have a very similar genetic background. 
 
Reprogrammed fibroblasts from patient BP and age- and sex-matched healthy 
volunteer HV3 gave rise to 5 and 3 stable iPS cell lines respectively. The newly 
derived iPS cell lines did not differ from the hES control line H9 characterised in 
Chapter 3 in terms of morphology or expression of pluripotency markers as detected 
by immunocytochemistry and quantitative RT-PCR. Despite a trend towards lower 
expression of pluripotency markers Nanog, Sox-2 and c-Myc in most newly derived 
lines, none of the differences to H9 were significant, likely due to the large 
variability between biological repeats of H9. It is possible H9 samples showed 
greater variability because samples had been collected over a longer period of time 
whereas samples from BP and HV3 iPS cell clones usually differed by 2-3 passages. 
Analysed by flow cytometry, undifferentiated cultures of BP-C5, BP-C26 and 
HV3-C28 had a significantly lower percentage of SSEA3 positive cells. The 
differences observed might be attributed to genetic abnormalities or natural 
variability between pluripotent stem cell lines. To exclude genomic instability, all 
newly derived iPS cell lines were analysed with a SNP array. Microduplications 
found in BP-C6 and C11 were specific to those cell lines and were therefore acquired 
during reprogramming or subsequent culture. The multitude of microduplications 
found in BP-C11 made it difficult to predict the specific effects they would have on 
cardiac differentiation or on cardiomyocytes function. Based on the SNP analysis BP 
clones 6 and 11 were deemed unsuitable for disease modelling and excluded from 
further experiments. Detection of these microduplications again underlined the 
importance of SNP analysis instead of or at least in addition to regular karyotyping. 
Since lower expression levels of pluripotency markers did not appear to correlate 
with genomic instability, with the exception of BP-C6, it seems likely that different 
expression levels represented normal variability. None of these slight variations 
appeared to have an effect on the cell line’s potential to differentiate into cells from 
all three germ layers and were therefore no reason for exclusion from further 
experiments. For subsequent experiments BP-C5 and BP-C26 were chosen, two cell 




Due to reoccurring issues with mycoplasma exclusively in healthy volunteer 
HV3-derived iPS cell cultures, no characterisation of cardiomyocytes derived from 
these cell lines was possible. Mycoplasma contamination is one of the main problems 
associated with cell culture211 effecting cell morphology as well as metabolism212. 
Contaminated HV3 iPS cells were treated repeatedly for reoccurring mycoplasma 
contamination that likely affected their cardiac differentiation potential negatively. 
Mycoplasma treatment has been shown to significantly reduce cardiac differentiation 
in hES cells213 and could explain why HV3-derived iPS cell clones failed to generate 
beating bodies. Nonetheless, the two guided cardiac differentiation protocols 
optimised in Chapter 3 efficiently and reliably generated beating bodies from 
undifferentiated BP clones 5 and 26. Patient-specific derived cardiomyocytes shared 
all the characteristics of previously investigated cardiomyocytes derived from 
healthy control hES (H9) and iPS cell lines (34-D6). Spontaneous contractions, 
unaligned myofibrils, immature sarcomeres and a lack of t-tubule structures in the 
cell membrane are all evidence of an immature foetal-like phenotype. However, as 
observed in healthy stem cell (H9 and 34-D6) derived cardiomyocytes in Chapter 4, 
some cardiomyocytes showed a slightly more mature phenotype with greater 
myofibril density, alignment of Z-lines of neighbouring myofibrils as well as 
presence of I- and A-bands in sarcomeres. Greater myofibril density and alignment of 
Z-lines of neighbouring myofibrils was observed with immunocytochemistry as well 
as TEM while the ultrastructure of more developed sarcomeres were observed in few 
cells with TEM.  
 
Assessment of kinetics of intracellular calcium transients showed faster decay in BP 
iPS cell-derived cardiomyocytes compared to primary foetal cardiomyocytes. The 
minimally slower calcium decay compared to 34-D6 (healthy control iPS cell) 
derived cardiomyocytes was not significantly different and might be explained with 
differences in length of culture of the beating bodies prior to assessment. While 
calcium transients were measured in BP-derived beating bodies after 2 weeks in 
culture, beating bodies derived from 34-D6 were assessed after 5 weeks. This 
reduction of culture time by 3 weeks would have given the BP-derived beating 
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bodies less time to mature and could explain the slight shift of decay dynamics 
towards the foetal phenotype, as a 4 week difference in culture time has been shown 
to result in ultrastructural maturation. Overall, comparison of structure and 
intracellular calcium handling revealed no significant differences between 
cardiomyocytes derived from healthy control (H9, 34-D6) and patient-specific (BP) 
pluripotent stem cells. However, analysis of electrophysiological recordings revealed 
a 48.38% reduction of sodium current density in patient-derived compared to healthy 
control cardiomyocytes suggesting that the patient’s heterozygous mutation in 
SCN5A resulted in a complete loss of function in mutated channels. This was in 
accordance with electrophysiological studies carried out in HEK293 cells and 
Xenopus oocytes were expression of channels carrying the patient’s mutation 
(c.1100G>A) produced no measurable current74, 210. These results illustrate the ability 
of patient-specific iPS cell technology to model the abnormal functional phenotype 
of an inherited channelopathy that is independent of structural abnormalities and that 
the relative immaturity of iPS cell-derived cardiomyocytes does not prevent their use 
as an accurate model system for channelopathies affecting the cardiac sodium 
channel Nav1.5. This successful generation of a patient-specific iPS cell based model 
system for classical Brugada Syndrome allows for the first time to study a mutation 
in their native environment and holds the promise for further studies to investigate 
disease mechanisms of known and unknown mutations and to develop new therapies. 
 
In conclusion, fibroblasts from one patient with classical Brugada Syndrome and one 
healthy volunteer were successfully reprogrammed. Using techniques optimised in 
Chapter 3, the morphological and functional characteristics of newly generated iPS 
cell lines were shown to be comparable to control lines H9, 33-D9 and 34-D6 in all 
regards. Examination of structural and functional characteristics of Brugada 
Syndrome patient-specific cardiomyocytes, derived using guided differentiation 
protocols optimised in Chapter 4, showed they were indistinguishable from healthy 
control iPS cell line (34-D6) derived cardiomyocytes in every aspect except sodium 


















GENERAL DISCUSSION  
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Brugada Syndrome is a heterogeneous condition with an unpredictable clinical 
course. Understanding the cellular mechanisms that lead to the disease will help to 
provide clarity about differences in clinical outcome between patients and the role of 
modifier genes. However, with more than 400 genetic alterations known to cause 
Brugada Syndrome, this poses an enormous challenge. Complimentary in vitro and 
in vivo models have improved our understanding, however, some show contradictory 
results investigating the same mutation and they are all restricted to modelling cases 
in which the underlying genetic alteration is identified. Patient-specific iPS cells will 
help us to understand the consequences of different mutations that influence the 
clinical outcome for individual patients as well as help us to validate previous model 
systems and to overcome some of their limitations. The functional characterisation of 
cardiomyocytes derived from iPS cells bearing specific mutations have the potential 
to provide novel insight into the mechanisms and pathophysiology of this condition 
and may offer opportunities to improve the diagnosis and treatment of patients with 
Brugada Syndrome. 
 
The overall aim of this study was to develop such a model system for Brugada 
Syndrome by generating iPS cell-derived cardiomyocytes from a patient with 
classical symptoms and a mutation that had previously been studied in other model 
systems. This was to be achieved step by step by developing and optimising 
protocols for reprogramming, cardiac differentiation and characterisation of de novo 
patient and healthy control cell lines. 
 
In Chapter 3, comprehensive tests to assess pluripotency and differentiation potential 
of control pluripotent stem cells were established in order to subsequently validate 
patient-derived iPS cell lines. Additionally, cardiac differentiation protocols were 
systematically compared and optimised to establish a reliable, efficient and robust 
protocol to be adopted for patient-derived iPS cell lines. Cells from hES (H9) and 
iPS cell lines (33-D9 and 34-D6) exhibited typical stem cell morphology and 
expression of pluripotency markers Oct-4, Sox2, Nanog, c-Myc, SSEA-3, SSEA-4 
and Tra-1-60 which was shown at the RNA or protein level. All tested pluripotent 
stem cell lines were capable of forming the three germ layers confirming their 
181 
 
pluripotency. SNP analysis identified two microduplications in H9 in regions not 
associated with genes, and one microduplication in 33-D9 and 34-D6 each that has 
been associated with long-term cell culture. Subsequent systematic comparison of a 
variety of cardiac differentiation protocols revealed significant inter-line variability 
in terms of efficiency and found that guided differentiation protocols could be used 
to reliably and efficiently generate beating bodies.  
 
Healthy control hES and iPS cell lines fully validated in this chapter were used in 
subsequent chapters to generate healthy control cardiomyocytes for characterisation. 
Additionally, protocols optimised in this chapter were used at later stages to validate 
pluripotency of newly generated Brugada Syndrome patient-derived iPS cell lines 
and to efficiently generate beating bodies from them in order to characterise 
patient-specific cardiomyocytes.  
 
In Chapter 4, pluripotent stem cell-derived cardiomyocytes generated from 
previously validated control pluripotent stem cell lines were compared to isolated 
primary human adult and foetal cardiomyocytes to evaluate their maturity and 
functionality. Improving our knowledge about the maturity of stem cell-derived 
cardiomyocytes will be critical if these are to be employed for the assessment of 
cellular function in cardiac disease modelling. 
 
Cardiomyocytes were successfully isolated from foetal cardiac tissue while isolation 
of viable cells from adult tissue proved challenging. Morphological and structural 
comparisons demonstrated the respective classical phenotypes with adult 
cardiomyocytes displaying rod-shaped morphology and parallel aligned myofibrils 
with fully formed sarcomeres, while foetal cardiac cells exhibited less defined 
morphology, had fewer myofibrils that lacked parallel alignment and showed 
immature sarcomeres. Structural and functional characterisation of cardiomyocytes 
derived from a healthy hES (H9) and a healthy control iPS (34-D6) cell line showed 
varying degrees of maturity but overall more closely resembled foetal rather than 
adult cardiomyocytes. Spontaneous contraction was observed in stem cell-derived 
cardiomyocytes and immature human foetal but not adult cardiomyocytes. Stem 
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cell-derived cardiomyocytes also displayed organisation of myofibrils, ultrastructure, 
lack of t-tubules and intracellular calcium handling more similar to foetal than adult 
cardiomyocytes. In addition, they expressed functional voltage-activated sodium 
channels and exhibited action potential triggered CICR. 
 
The maturity of healthy pluripotent stem cell-derived cardiomyocytes was 
comparable to a foetal phenotype but functional cardiac sodium channels were 
detected.  Their functionality was confirmed and protocols optimised in this chapter 
were subsequently used to characterise newly derived patient-specific 
cardiomyocytes while the data gathered provides a platform for comparison against 
healthy control pluripotent stem cell-derived cardiomyocytes as well as adult and 
foetal controls.  
 
Protocols established in Chapter 3 were then employed to generate and validate 
iPS cell lines from a Brugada Syndrome patient and a sex and age matched healthy 
volunteer. Next, patient-specific cardiomyocytes were generated and characterised 
employing protocols optimised in Chapter 4.  
 
Fibroblasts from a Brugada Syndrome patient (BP) with classical symptoms and a 
mutation (c.1100G>A) in SCN5A and a healthy age- and sex-matched volunteer 
(HV3) were reprogrammed using episomal vectors carrying Oct-4, shp53, Sox2, 
Klf4, L-Myc and Lin28. Newly derived patient (n=5) and control iPS cell lines 
(n=3), did not differ significantly from the hES control line H9 characterised in 
Chapter 3 in terms of morphology and expression of pluripotency markers, with the 
exception of three clones (BP-C5, BP-C6, HV3-C28) that showed a significantly 
lower percentage of SSEA3 positive cells. Examination of structural and functional 
characteristics of Brugada Syndrome patient-specific cardiomyocytes, derived from 
two clones using guided differentiation, showed they were indistinguishable from 
healthy control iPS cell line (34-D6) derived cardiomyocytes in every aspect 
(morphology, myofibril organisation, sarcomere structure, t-tubule structures and 
kinetics of intracellular calcium transients). Importantly, sodium current density was 
reduced by 48.38% in Brugada Syndrome patient-derived cardiomyocytes. This 
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reduction in current density not only matches previous observations made in 
HEK293 cells and Xenopus oocytes, but for the first time demonstrates that classic 
Brugada Syndrome can successfully be modelled using patient-specific iPS cells. 
These results illustrate the ability of patient-specific iPS cell technology to model the 
abnormal functional phenotype of an inherited channelopathy that is independent of 
structural abnormalities and that the relative immaturity of iPS cell-derived 
cardiomyocytes does not prevent their use as an accurate model system for 
channelopathies affecting the cardiac sodium channel Nav1.5. This iPS cell based 
model system for classical Brugada Syndrome allows for the first time to study the 
mutation in its native environment and holds the promise for further studies to 




6.1 Limitations of this study 
Although this study was ultimately successful in achieving our aims and provides 
promising future opportunities, it has its limitations with regard to both iPS cell 
technology in general and the experimental set-up of this particular project. 
 
The iPS cell based model system has great strengths, but also limitations and should 
be considered to complement rather than replace other model systems. A major 
advantage of iPS cell technology is the generation of patient-specific iPS cells that 
not only carry the patient’s exact genetic background but also permit the generation 
of the specific cell type directly affected by the disease, i.e. cardiomyocytes in the 
case of Brugada Syndrome. However, generating relevant iPS cells requires ethical 
approval, patient consent and a tissue sample. In comparison to expression systems it 
is also very expensive and time consuming. As with other in vitro systems 
cardiomyocytes generated from iPS cells also lack the complexity of an organ, 
specifically the 3D in vivo structure and the presence of other cell types providing 
complex signalling networks. Although in vitro differentiation techniques yield 
beating clusters or sheets composed of ventricular, atrial and pacemaker cells214, they 
are not organised in layers of endo- and epicardium and are usually not pure 
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populations of ventricular or atrial cells. However, methods have been developed to 
direct differentiation towards a specific cardiac subtype by manipulating retinoid 
signals215. Identification of the cell surface marker VCAM1216 also made it possible 
to purify and reassemble iPS cell-derived cardiac cells in cardiac tissue sheets217. 
This might proof particularly challenging for modelling VT/VF in cases of Brugada 
Syndrome, since arrhythmias have been linked to transmural gradients across the 
ventricular wall involving cells of the endo- and ectoderm and abnormalities in the 
RVOT.  
 
A particular challenge remains the relative immaturity of the derived cardiomyocytes 
as evidenced by spontaneous contractions, immature ultra-structure and a lack of 
t-tubules. Further functional characteristics of pluripotent stem cell-derived 
cardiomyocytes have been reviewed in depth by Hoekstra et al218. Although no cells 
resembling adult cardiomyocytes have been derived from pluripotent stem cells yet, 
recent studies have shown that stem cell-derived cardiomyocytes slowly mature 
structurally and functionally when kept in long term in vitro culture219, 220 and when 
exposed to mechanical loading221.  
 
In addition to the general limitations of iPS cell based model systems, some technical 
difficulties and limitations specific to this project such as low efficiency or 
suboptimal controls have to be considered and leave room for improvement. 
Although systematic comparison of cardiac differentiation protocols identified a 
reliable protocol, the efficiency was comparatively low. The main contributor to low 
efficiency was the selection of protocols for the comparison study, which was 
influenced by a variety of criteria. Protocols were chosen based on the fact that they 
were technically comparatively simple, cost-effective, allowed for investigation into 
the effect of serum and made efficiency easily assessable. The last condition in 
particular was the determining factor to use protocols involving EB formation. At the 
same time, to simplify comparison of a multitude of factors at the same time, 
protocols with identical or similar timings for addition of supplements and medium 
changes were preferred. Without these restrictions for a comparison study efforts can 
be focused on a chemically defined, growth factor-free monolayer protocol222 that 
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was recently published and has proven reliable and efficient in our laboratory. 
 
A major limitation was the occasional lack of adult cardiomyocyte controls. This was 
partly due to the absence of suitable equipment, e.g. field-stimulator to induce 
contraction for calcium imaging, and partly a result of the fact that mature adult 
cardiomyocytes quickly de-differentiate in culture, making experiments such as 
membrane staining, calcium imaging and electrophysiology, which require cells to be 
attached to a culture surface, particularly challenging. However, based on the fact 
that results from foetal cardiomyocytes in this study were in accordance with 
previously published results and vastly different from the expected adult phenotype, 
comparison with data on adult cardiomyocytes available in literature was considered 
sufficient for this aspect of our study.  
 
Although age- and sex-matched control iPS cell lines were derived they did not give 
rise to beating bodies due to technical difficulties, i.e. persistent mycoplasma 
contamination, and could hence not be used as the appropriate control for 
patient-derived cardiomyocytes. Instead an iPS cell line previously derived from a 
healthy 35-year-old female was used as a control. Although Brugada Syndrome 
manifests differently in male and female patients carrying the same mutation this is 
thought to be caused by inherent differences in transient outward potassium current 
density and should hence have no effect on sodium current recordings66. It is also 
more likely to become evident when considering the whole heart rather than a single 
cell. The age of the tissue donor on the other hand was not expected to have any 
significant influence on functionality of derived cardiomyocytes not only because 
Brugada Syndrome is not a disease that manifests later in life but also because 
cardiomyocytes generated from different iPS cell lines are all equally immature, 







6.2 Future directions 
Having shown that classical Brugada Syndrome can successfully be modelled 
in vitro using patient-specific iPS cell-derived cardiomyocytes has both scientific as 
well as clinical implications and opens up exciting new opportunities. 
 
The immediate focus is on ongoing efforts to not only increase the number of 
electrophysiologically characterised control and patient-derived cells to decrease the 
error and to include cardiomyocytes from age- and sex-matched controls, but also to 
broaden the spectrum of parameters analysed. In addition to total sodium current, 
kinetics of activation and inactivation can be investigated. However, mutations that 
lead to a complete loss of function, observed as a reduction of sodium current to 50% 
of wild type current, are unlikely to alter channel kinetics83. Examining the mutated 
channel in its appropriate environment will allow us to determine the mechanism 
(e.g. disrupted cell-surface localisation, production of truncated proteins) by which it 
causes a complete loss of function. Identification of a mechanism that has thus far 
not been described may provide clues as to how better treat the patient. Additionally, 
patient-specific cardiomyocytes can provide a platform for screening of de novo 
drugs or those that are already in use to personalise treatment. 
 
Generally, investigating mutant Nav1.5 in their appropriate environment will help 
determine whether HEK293 cells or Xenopus oocytes more accurately represent the 
biophysical properties of mutant channels in cases where results are contradictory. In 
addition to being able to record action potentials, researchers can also investigate the 
effects of possible modulator proteins. This is particularly interesting in patients with 
clear Brugada Syndrome symptoms but no known mutation and symptom free 
individuals carrying the same mutation as their symptomatic siblings. The possibility 
to investigate Brugada Syndrome patients without known genetic cause and mutation 
carriers that show no symptoms is an advantage none of the other model systems 
have. On a larger scale it might even be conceivable to screen affected families in an 
attempt to understand the mechanisms of sudden cardiac disease. The iPS cell based 
model system also offers the most accurate and relevant setting for drug toxicity 
screening of all the model systems, which could help exclude potential drugs, based 
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on their toxic effects on cardiomyocytes, before they go into expensive trials. Lastly, 
since iPS cell lines are immortal and compared to other expression systems do not 
transiently express the mutant channel, they can be shared between groups, allowing 
for new collaborations and more in-depth characterisation. 
 
Although cardiomyocytes derived from iPS cells represent a mixture of immature 
and more mature cells, they all exhibit typical cardiac markers and have functional 
cardiac sodium channels. This model system may be utilised to investigate patients 
with and without known genetic mutations to provide a better understanding of the 
pathophysiology of inherited cardiac channelopathies and has great potential to 
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